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Abstract
We have designed and synthesized novel molecules capable of selectively killing
tumor cells that aberrantly express steroid hormone receptors. Many human breast
cancers express high levels of the estrogen receptor (ER), and most prostate cancers
express the androgen receptor (AR). We reasoned that the potential genotoxic effect of
DNA adducts would be increased in target cells if these adducts were camouflaged by
their association with receptor proteins. This association could shield the DNA adducts
from repair proteins and thus increase the toxicity towards a tumor cell. Furthermore,
these hormone receptors are transcription factors and an interaction between the protein
and the DNA adduct could disrupt cellular signaling events, thus leading to further
toxicity.
We have synthesized bifunctional agents that contain an aniline mustard linked to
ligands for tumor specific hormone receptors. To target ER(+) breast cancers, an aniline
mustard was linked to estradiol at the 7a position (E2-7a), and to target AR(+) prostate
cancer, the aniline mustard was linked to estradien-3-one at the 1113 position (11 3).
Competitive binding experiments show that E2-7a and 1 3 compete well with the natural
ligands for the ER and AR, respectively. Clonal survival studies have shown that
hormone receptor expressing malignant cell lines are more sensitive to our compounds
than a corresponding receptor deficient line.
[14C]-E2-7a and [14C]- 13 have been formulated in Cremophor-EL and exhibit
good bioavailability and stability when injected into mice intraperitoneally. E2-7a
inhibits the growth of ER(+) HeLa cells and 1 3 inhibits the growth of AR(+) LNCaP
cells, both in xenograft mouse models. The compounds are well tolerated by mice after
the therapeutic regimens. Stable DNA adducts have been isolated and detected by
electrospray mass spectrometry and accelerator mass spectrometry has provided us with a
means of quantifying the number of DNA adducts formed in vivo. E2-7a DNA adducts
are repaired, in part, by nucleotide excision repair but the adducts persist longer in ER(+)
cells than in ER(-) ones. Melphalan adducts, however, are repaired with equal rates in
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both cell lines. This result provides evidence in support of the repair shielding hypothesis
and suggests that it may be a contributing mechanism to the increased toxicity observed
for the ER(+) cell line in the clonal survival study.
Supervisor: John M. Essigmann
Title: Professor of Chemistry
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Chapter 1
Introduction
Cancer
Cancer is a multifaceted disease with approximately 100 subtypes, all
characterized by excessive, uncontrolled growth of abnormal cells that invade and
destroy other tissues. (Hanahan and Weinberg 2000). Cancer can develop in almost any
organ or tissue of the body and is the second leading cause of death in the U.S. (Cancer
Facts and Figures 2005) As a result of better treatment options, over 60% of Americans
with the disease live longer than five years. The exact causes of cancer are still unknown,
although epidemiological studies have implicated several risk factors including:
increased age, obesity, a high salt or fatty diet, and chronic exposure to carcinogens,
radiation, environmental or occupational chemicals, and tobacco smoke. Furthermore,
exposure to pathogens (certain viruses, bacteria, and parasites), hereditary factors
(genetic mutations in proto-oncogenes) and steroid hormones (especially prolonged
exposure to estrogen) has also been implicated. The five most common types of cancer
in the U.S. are prostate cancer (232,000/yr), breast cancer (212,000 new cases per year),
lung cancer (172,000/yr), colorectal cancer (144,000/yr), and lymphoma (64,000/yr)
(Cancer Facts and Figures 2005). (Note: Although there are over a million new cases of
skin cancer diagnosed each year, the 2005 Cancer Facts and Figures report does not
include nonmelanoma skin cancers. There will be an estimated 59,000 new cases of
melanoma in 2005.)
After decades of research, a complex body of work has been established revealing
cancer to be a disease involving dynamic changes in the genome. The foundation has
been set in the discovery of mutations that produce oncogenes with gain of function and
inactivate tumor suppressor genes with loss of function (Hanahan and Weinberg 2000).
Several lines of evidence indicate that tumorigenesis is a multistep process and that these
distinct steps reflect genetic alterations that drive the progression of normal cells to
malignant ones. Although the disease can afflict people of all ages, most types are
diagnosed with an age-dependent incidence implicating four to seven rate-limiting steps
(Renan 1993). Additionally, pathological analyses of a number of organ sites reveal
lesions that appear to represent the intermediate steps in a process through which normal
cells progressively evolve into malignant invasive cancers (Foulds 1954).
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Hanahan and Weinberg suggest that the vast array of cancer cell genotypes is a
manifestation of six essential alterations in cell physiology that collectively dictate
malignant growth:
1. Self-sufficiency in growth signals: Cancer cells show a reduced
dependence on exogenous growth signals for proliferation. The tumor cells
generate many of their own growth signals and reduce their dependence on
stimulation from the normal tissue microenvironment by overexpressing pro-
growth factor receptors, by becoming hyperresponsive to the growth factors, or by
altering the downstream cytoplasmic circuitry that responds to ligand activated
receptors (Aaronson et al. 1993; Di Fiore et al. 1987).
2. Insensitivity to antigrowth signals: Normal cells use antigrowth signals
to maintain cellular quiescence and tissue homeostasis. However, malignant cells
acquire insensitivity to the antigrowth signals most likely somewhere along the
retinoblastoma protein pathway, thought to be the main antiproliferative signaling
pathway (Weinberg 1995).
3. Ability to evade apoptosis: The apoptotic machinery includes sensors
which monitor the cellular environment for conditions that influence whether a
cell should live or die, and effectors that act on the signals from the sensors.
Resistance to apoptosis can be achieved by many mechanisms. Most notably, the
DNA damage sensor and proapoptotic regulator, p53, is mutated in more than
50% of human cancers (Harris 1996).
4. Limitless replicative potential: Independent of the cell-cell signaling
pathways described above, an intrinsic cellular program limits the ability of many,
if not all, cells to multiply. One way cancer cells overcome this limitation is by
expressing the protein telomerase, which adds hexanucleotide repeats onto the
ends of chromosomes thereby thwarting the cells' natural shortening of telomeres
(the ends of chromosomal DNA) (Bryan and Cech 1999). The (normal)
progressive shortening of telomeres with each successive replication results in the
inability of DNA polymerases to completely replicate the 3' ends of chromosomal
DNA during S phase of the cell cycle and eventually in end-to-end fusion of the
chromosomes resulting in karyotypic disarray and inevitably cell death.
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5. Sustained angiogenesis: Cells within aberrant proliferative lesions
initially lack angiogenic (new vascular growth) ability, but in order to further
progress, tumors must acquire angiogenic ability to obtain the nutrients and
oxygen crucial for cell function and survival (Hanahan and Folkman 1996).
Tumors appear to activate blood vessel formation by changing the balance
between angiogenesis inducers and repressors. For example, vascular endothelial
growth factor (VEGF) has been shown to be upregulated in many tumors and is
the target of several anticancer drugs including the recently FDA approved
Avastin.
6. Tissue invasion and metastasis: Eventually the primary tumor travels
through the blood stream or lymphatic system to settle in a distant site in the
body. These metastases are the cause of 90% of cancer deaths (Sporn 1996).
Often, alterations in cell-cell adhesion molecules (immunoglobulins and calcium-
dependent cadherin proteins) and disruption in cell-environment interactions (by
integrins) allow for tumor cells to break free from the extracellular environment
and invade normal tissue at distant sites. For example, E-cadherin function is lost
in many epithelial cancers by mechanisms involving mutational inactivation of
the E-cadherin or p-catenin genes, transcriptional repression, or proteolysis of the
extracellular cadherin domain (Christofori and Semb 1999). E-cadherin normally
makes intercellular contacts with [3-catenin to transmit antigrowth and other
signals.
The paths by which cells become malignant are highly variable. Mutations in certain
oncogenes and tumor suppressor genes can occur early in some tumor progression
pathways, but late in others. A specific genetic mutation may contribute only partially to
the acquisition of a single capability, whereas another genetic mutation may aid in the
simultaneous acquisition of several distinct capabilities. As a consequence, the
acquisition of the six biological alterations described above does not follow a linear
sequence, but rather the summation of these events eventually leads to invasive cancer
(Hanahan and Weinberg 2000).
Unfortunately for patients, there are few available screens that can readily detect
these acquired physiological alterations at the molecular level. However, some cancers
25
can be screened for specific markers or visual evidence. For example, prostate specific
antigen (PSA) is elevated in men with prostate cancer, mammography can visualize
breast cancer, and colonoscopy is used to detect polyps and colorectal cancer. Other
cancers that have ample space to grow, such as ovarian, are considered silent killers since
the tumor usually does not manifest until it is quite large. In many cases, patients only
present with cancer at later stages when the malignancies cause some sort of discomfort.
Therefore it is imperative that patients are monitored by physicians routinely, especially
as they age, and that they inform their physicians of any signs of lethargy or discomfort.
The earlier a patient is diagnosed with cancer, the better the prognostic outcome.
There are several options for treatment depending on the disease, but many cancers are at
least eradicated with surgical removal of the malignancy. In order to ensure the removal
of the entire primary cancer and all micrometastases, oncologists often follow up with
radiation therapy, chemotherapy, hormone therapy, and/or immunotherapy. Researchers
have shown that combinations of these therapies often results in the best outcome. For
example, the chemotherapeutic cisplatin successfully cures 95% of patients afflicted with
testicular cancer, typically in combination with etoposide and bleomycin (Feuer, Brown,
and Kaplan 1993; Kartalou and Essigmann 2001b). However, the cruel reality is that
cancer is a very lethal disease and despite the efforts of thousands of researchers and
millions of dollars, much work still needs to be completed in order to better treat cancer
patients. The work described here will focus on two novel anticancer agents that target
breast and prostate cancers.
Breast Cancer
Breast cancer is the most frequent malignancy among women in the US,
accounting for 30% of all cancers diagnosed, (Greenlee et al. 2000) with an incidence of
135 cases per 100,000 women and a death rate of 27.7 per 100,000 women (Weir et al.
2003). The increasing rate of breast cancer incidence and simultaneous decreasing rate in
mortality that has been reported in the 1990's can, in part, be attributed to increased
mammography screening (Edwards et al. 2002; Howe et al. 2001; Wingo et al. 1998).
Screening mammography is currently the best available tool for early detection and
reduces mortality rates by 16-30 percent (Kerlikowske 1997).
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Screening mammography is especially important in women with a family history
of breast cancer. About 10% of breast cancer patients have a familial form of the disease,
and of these, about half have inherited mutations in the breast cancer susceptibility genes
BRCA1 and BRCA2. BRCA1 and BRCA2 are involved in the repair of oxidative DNA
damage and DNA damage from ionizing radiation (Chen et al. 1999; Chen, Lee, and
Chew 1999). The remaining half of patients with the familial form of the disease are
thought to have mutations in the p53 tumor suppressor (Malkin et al. 1990), the
STK/LKB 1 protein kinase (Shen et al. 2002), the PTEN phosphatase (Nelen et al. 1996),
or other genes as yet undiscovered (Easton 1999). In addition to familial inheritance
through genetic mutations, other risk factors include increased hormone exposure with
early menarche or late menopause, alcohol consumption, postmenopausal obesity, and
hormonal replacement therapy. A decreased risk can be attributed to young age at first
pregnancy, prolonged lactation, and physical exercise (Baselga and Norton 2002).
Especially for those with a high risk of breast cancer, early detection of the disease is a
priority since cure rates are greater the earlier the clinical stage at diagnosis. Clinical
signs and symptoms of breast cancer depend largely on whether the disease has
metastasized. The most common sites of metastases include the skin, lymph nodes, bone,
lung, liver, and central nervous system. The evaluation of a patient at presentation of the
disease includes a pathological examination of the tumor and an evaluation of the extent
of the disease. The pathological examination includes assessment of histological type,
size, and grade of the tumor as well as estrogen receptor (ER) and human epidermal
growth factor receptor 2 (Her-2) status (Baselga and Norton 2002).
Her-2, also known as ErbB2, is a transmembrane tyrosine kinase receptor in the
epidermal growth factor receptor family and is an essential breast cancer oncogene.
Amplification of Her-2 occurs in 30% of early stage breast cancers, and a significant
correlation between Her-2 overexpression and reduced survival of breast cancer patients
has been found (Lohrisch and Piccart 2001). Her-2 overexpression correlates with a lack
of response to endocrine and chemotherapy (Bange, Zwick, and Ullrich 2001). In 1998,
the biotechnology company Genentech developed the monoclonal antibody Herceptin
(trastuzumab) as a therapy for the 15-30% of patients with metastatic breast cancer whose
tumors have gene amplification of Her-2. Herceptin inhibits tumor cell proliferation by
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downregulating Her-2 protein receptors upon attaching to the protein on the cell surface
and facilitates antibody-dependent cell-mediated cytotoxicity by attracting natural killer
cells to the Herceptin/Her-2 complex on the cell surface (Sliwkowski et al. 1999).
Additionally, Herceptin is used in combination with conventional chemotherapeutics,
especially paclitaxel, and has been shown to improve the duration of response and
median survival time by 25% compared to chemotherapy alone (Baselga 2001; Slamon et
al. 2001).
Despite the advances in genomics-based therapeutics, most women still undergo
surgery, either lumpectomy or mastectomy, followed by radiation as a result of the small
portion of the patient population that qualifies for therapies like Herceptin. Systemic
adjuvant therapies designed to eradicate clinically undetectable cancer cells that may
have spread from the primary tumor are necessary to decrease reoccurrences and improve
survival. Adjuvant therapies include endocrine therapy, usually tamoxifen or raloxifene,
or chemotherapy, most often as a combination of alkylating agents (e.g.
cyclophosphamide), anthracyclins (e.g. doxorubicin), antimetabolites, (e.g. 5-
flurouracil), and antimicrotubule agents (e.g. paclitaxel).
The decision to use chemotherapy or hormone therapy depends on the presence or
absence of the ER in the primary tumor. Approximately half of breast cancers
overexpress the ER (Ferno et al. 1990). The anti-estrogens, tamoxifen and raloxifene,
reduce the incidence of cancer relapse in ER-expressing tumors and can even delay or
prevent the development of breast cancer in women at high risk (Peto and Mack 2000).
These compounds antagonize the effects of estrogen and therefore put tumor cells into a
state of stasis, which can eventually lead to apoptosis (programmed cell death) (Lerner
and Jordan 1990; Obrero, Yu, and Shapiro 2002). Hormonal therapy can be extended
over long periods in which the ER+ tumors are often held in check. However, the long
term effectiveness of such therapies is complicated by the development of hormone
resistant breast cancer (HRBC) (Katzenellenbogen 1991) and possible carcinogenesis
(Jordan 1995; Osborne et al. 1996). Additionally, ovarian tumors that express the ER do
not respond well to endocrine therapy. Therefore, a need exists for more effective agents
to target ovarian tumors and HRBC.
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The current trend in pharmaceutical research is to target smaller patient
populations with very specific targets. Herceptin is one such example of a very effective
compound that targets only one third of those afflicted with breast cancer. The work
described here will discuss the design and efficacy of a compound targeting all breast and
ovarian cancers that express the ER.
Prostate Cancer
Prostate cancer is the most frequent cancer among males in the U.S. with an
incidence of 170.1 cases per 100,000 men and a death rate of 32.9 per 100,000 men (Weir
et al. 2003). Prostate cancer mortality has been declining since 1993 as the frequency of
serum testing for PSA has increased. PSA is a glycoprotein secreted into the blood by
prostatic epithelial cells and is elevated in most men with prostate cancer. The decline in
mortality correlates with the observed decrease in the incidence of late-stage prostate
cancer after 1992 and the introduction of PSA screening in a population which had little
or no screening (Hankey et al. 1999).
As in the case of breast cancer, early detection is often the best gauge for
prognostic outcome. PSA screenings often begin at the age of 40 to establish a baseline
level. By the age of 50, the American Cancer Association recommends digital rectal
exams and PSA testing annually in an effort to detect prostate cancer at its earliest stage
(Smith et al. 2001). Early-stage prostate cancer is often asymptomatic but occasionally
causes urethral obstruction leading to difficulty in urination, smaller stream, and frequent
and less forceful urination. Although preneoplastic lesions can be found in men in their
twenties and are frequent in men by their fifties (Sakr et al. 1993), clinically detectable
prostate cancer does not generally manifest until the age of 60 or 70. The morphological
changes associated with initiation are relatively common and occur early in life; however,
progression to invasive carcinoma is significantly less common and occurs in a more
limited population later in life (Abate-Shen and Shen 2000). Therefore, it is not
surprising that one of the major risk factors for prostate cancer is aging, although the
reason for this is not clearly understood (Sakr et al. 1993).
A positive family history of the disease is also among the strongest
epidemiological risk factors (Simard et al. 2003). To date, three familial susceptibility
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genes have been described: Escherichia coli elaC homolog (ELAC2) (Tavtigian et al.
2001), 2'-5'-oligoadenylate-dependent ribonuclease L (RNASEL) (Carpten et al. 2002),
and macrophage scavenger receptor 1 (MSR1) (Xu et al. 2002). Although more has been
learned about the function of ELAC2, RNASEL, and MSR1 in recent years, the
mechanism linking mutations in these genes to prostate carcinogenesis has yet to be
determined. It is also of interest that a significant percentage of men with early-onset
prostate cancer (< 55) harbor germline mutations in the BRCA2 gene (Edwards et al.
2003; Gayther et al. 2000). Oliveira and Lopes from the beautiful city of Porto, Portugal,
have shown that genetic polymorphisms in the androgen receptor (AR) and ER are
associated with disease progression and metastasis (Medeiros et al. 2003). While still
controversial, there is some evidence that dietary and environmental factors may exert a
role in prostate carcinogenesis as the incidence is much higher in the United States than
in most other countries, particularly those in Asia (Carter, Carter, and Isaacs 1990; Dhom
1983).
As research continues on the epidemiology and molecular biology of prostate
cancer, clinicians still struggle to treat some forms of the disease. In its initial stages,
prostate cancer is essentially curable by surgical intervention and/or radiation therapy. In
addition, most cases of prostate carcinoma are relatively indolent, such that the majority
of men diagnosed with the disease will die instead of other causes. However, if not
detected early, or in more aggressive forms of the disease, prostate cancer can advance to
stages characterized by local invasion of the seminal vesicles, followed by metastasis
primarily to the bone (Abate-Shen and Shen 2000). Metastasis to the lung, lymph nodes,
and liver are also common. The transition to metastatic disease is generally followed by
a shift from androgen dependence to androgen-independence, which is often provoked by
androgen-ablation therapy.
In 1941, Huggins and Hodges published a report in Cancer Research showing that
castration, over the short term, caused regression in androgen-dependent prostate cancer
(Huggins C and Hodges CV 1941). Since then, clinicians have used surgical castration or
chemical castration (lowering of testosterone by using compounds that lower testosterone
production and/or by using compounds that block androgens from entering prostate cells)
to lower testosterone levels and thereby treat androgen-dependent metastatic prostate
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cancer by temporarily arresting tumor growth for several months or even years.
Unfortunately, such treatments ultimately result in aggressive and metastatic androgen-
independent prostate cancers. This transition to androgen-independence is likely to occur
through selection for growth of androgen-independent cells that may already coexist with
an androgen-dependent population prior to androgen deprivation therapy (Gingrich et al.
1997; Isaacs and Coffey 1981).
Despite the success and prolonged survival of treating patients with prostatectomy
combined with radiation and/or androgen-ablation therapy, many patients eventually
progress to hormone-refractory prostate cancer (HRPC) with an increasing PSA level as
the only indication of disease. Oncologists adjust the therapeutic regimen by introducing
chemotherapeutics alone or in combination to try to stop metastases. Unfortunately,
chemotherapeutics are not very effective, in part because several anti-apoptotic factors
are present in malignant prostate cells (Lebedeva et al. 2000; Raffo et al. 1995; Vlietstra
et al. 1998). Some clinical oncologists debate that doing nothing at all may be the right
course of action as some HRPC prostate metastases are slow growing and the quality of
life of the patient outweighs the potential benefits of chemotherapy (Bhatnagar et al.
2004; Gulley and Dahut 2003).
Currently pre-clinical and clinical phase research concentrates on new modalities
of selectively targeting prostate cancer and its metastases including vaccines to stimulate
the body's own immune system to kill the cancer, anti-angiogenesis agents that will
suppress neovascular growth and starve off the tumor from necessary nutrients and
oxygen, antisense oligonucleotides and siRNA to down regulate specific genes necessary
for growth and survival, and novel chemotherapeutic agents and combinations of agents
to achieve better selectivity and efficacy. The work here will describe the development
of novel chemotherapeutics that selectively target AR expressing prostate cancer cells
while sparing non-cancerous cells.
31
Nuclear Hormone Receptors
Nuclear hormone receptors are ligand-activated transcription factors that regulate
gene expression by binding to specific sequences of DNA. This superfamily includes
receptors for hydrophobic molecules such as steroids, retinoic acids, thyroid hormones,
fatty acids, leukotrienes, prostaglandins and as yet undiscovered ligands. There are
currently over 100 nuclear hormone receptors identified and these can be divided into
three subfamilies: Class I - ligand dependent and will homodimerize upon ligand binding
(includes: ER, AR, progesterone receptor, mineralocorticoid receptor, glucocorticoid
receptor), Class II - ligand independent with the potential to homo- or heterodimerize
(includes: retinoic acid receptor, vitamin D receptor, thyroid receptor, and peroxisome
proliferators activated receptor), and Orphan - unknown ligand or only very recently
discovered ligand (includes: pregnane X receptor, constitutive androstane receptor, liver
X receptor, benzoate X receptor, and famesoid X receptor).
Nuclear hormone receptors consist of two domains - a ligand binding domain
(LBD) and a DNA binding domain (DBD). Ligand binding allows for the recruitment of
coactivator complexes and translocalization into the nucleus (if the unliganded form is in
the cytoplasm). The DBD binds DNA, generally as a dimer, with each monomer
recognizing a six base pair sequence of DNA known as the hormone response element.
The hormone response element lies upstream (5' flanking region) of the gene that will be
transcribed into ribonucleic acid (RNA). The binding of the nuclear hormone receptor to
the HRE is often in close proximity to the recognition sequences for other transcription
factors (TATA box) and interaction between these factors and the receptor play an
important role in the rate of transcription (Schule et al. 1988). Nuclear hormone
receptors bound to the HRE recruit chromatin remodeling proteins, histone acetylation
proteins, and RNA polymerase holoenzyme recruitment proteins to the promoter region
of a gene through two activation function areas on the C- and N- terminals known as
activation function -1 and -2 (AF-1 and AF-2). Finally, when all of these protein
complexes are present an RNA polymerase binds and transcribes a gene. Nuclear
hormone receptors regulate genes involved in reproduction, development, and
metabolism.
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Estrogen Receptor
The ER is a 67 kDa protein belonging to the class I nuclear hormone receptor
superfamily and is activated by estrogens (Evans 1988). In 1996, a second isoform of the
ER was discovered by a group in Sweden and was termed ERP (Kuiper et al. 1996).
Unlike most nuclear hormone receptors that translocalize from the cytoplasm to the
nucleus upon ligand binding, the ER is exclusively localized in the nucleus (King and
Greene 1984; Welshons, Krummel, and Gorski 1985). However, recent evidence
suggests that ERa also localizes to the plasma membrane where it functionally regulates
protein kinase cascades in response to estrogen (Razandi et al. 2003; Xu et al. 2004).
While ERa is found mainly in estrogen target tissues (uterus, vagina, and mammary
glands), ERP has been detected in a large variety of tissues (lung, hypothalamus, prostate,
and ovary) (Enmark et al. 1997). Interestingly, ERP is the predominant form in the
normal mammary gland, however, in breast cancer ERa predominates (Leclercq 2002).
Although encoded by different genes on different chromosomes, ERa and ERP
have >95% sequence homology in the DBD and >55% in the LBD and have similar
binding affinities for many estrogen ligands -- ERa binds estradiol with a Kd of 0.35 nM
whereas ERP3 binds it with a Kd of 0.6 nM (Kuiper et al. 1998). With such high sequence
homology in the DBD, the two receptors bind a largely overlapping set of HREs. They
differ, however, in their ligand binding and transcriptional activation regions (AF- 1 and
AF-2) (Barkhem et al. 1998). AF-1 is located in the N-terminus of the ER while AF-2 is
in the C-terminus. Although AF-2 function is dependent upon ligand binding, AF-1
functions independently of ligand binding but synergizes with AF-2 in the promotion of
ligand-dependent transcriptional activation (Tsai and O'Malley 1994). Alternatively, AF-
1 and -2 can function independently, depending on the cellular context (McInerney and
Katzenellenbogen 1996). Ligand binding produces a conformational change in AF-2 that
allows for the recruitment of transcriptional co-regulatory proteins. Since the amino acid
identity of ERa and P is relatively low in the AF region, it is not surprising that the same
ligand can and does have different levels of potency and efficacy towards the different
receptor subtypes. This allows for selective stimulation of diverse estrogen-regulated
genes (Makela et al. 1999).
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Upon ligand binding the ER undergoes conformational changes and is released
from inactive complexes containing heat shock proteins (hsp90, hsp70) and
immunophilins (Klinge et al. 1997; Ylikomi et al. 1998). The ER then dimerizes and
binds to its HRE in order to stimulate transcription. The consensus sequence for ERa and
ER[3 is a palindromic inverted repeat: (A/G)GGTCAnnnTGACC(T/C) (where n is any
nucleotide) (Klein-Hitpass et al. 1988; Sanchez et al. 2002). The ER contains a zinc
finger in the DBD that makes sequence specific contacts with DNA allowing for AF-1
and AF-2 to recruit the cellular transcription machinery. The ER may also regulate
transcription through protein-protein interactions in the absence of DNA and ligand. This
subject is the focus of several reviews (Katzenellenbogen and Katzenellenbogen 2000;
Klinge 2000; Sanchez et al. 2002).
In order for the ER to act as a transcription factor, it must first be activated. The
phosphorylation of a serine residue at position 118 (Serl 18) is required for full activity of
the ER. Serl 18 is phosphorylated by mitogen-activated protein kinase (MAPK) in the
Ras-MAPK signaling pathway (Kato et al. 1995). Recently, protein phosphatase 5 was
shown to inhibit the phosphorylation of Serl 18 and thereby act as a negative regulator of
transcription in vivo (Ikeda et al. 2004). Additional sites of phosphorylation include: Ser-
104, 106, 126, 167 and Tyrosine-537. They are phosphorylated by various protein
kinases and all seem to play a role in ER activation (Arnold et al. 1994; Arnold et al.
1995a; Arnold et al. 1995b; Auricchio et al. 1984; Le Goff et al. 1994). The ER is also
activated by glycosylation at Ser-10, Threonine-50 and -575 and these glycosylations,
particularly Thr-575, may help regulate transcription by inhibiting degradation (Cheng et
al. 2000; Cheng and Hart 2000; Jiang and Hart 1997; Rechsteiner and Rogers 1996).
Even though ligand binding is required for transcriptional activation, estradiol binding
actually induces the degradation of the ER by the ubiquitin-proteasome pathway (Nawaz
et al. 1999) and reduces its half-life from -5 days to 3-4 hours (Pakdel, Le Goff, and
Katzenellenbogen 1993). Therefore, the cell has evolved a clever way to respond to a
stimulus, activate a necessary response gene, and quickly degrade the activation signal so
as not to overcompensate for the initial stimulus.
The ER is expressed at low levels in normal breast epithelial cells, averaging only
10-20% of cells depending on the menstrual cycle (Ricketts et al. 1991). However, in
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early non-invasive breast cancer approximately 75% of cells express the ER (Harvey et
al. 1999; Karayiannakis et al. 1996) and 50% express the ER at high levels (Ferno et al.
1990; Pallis et al. 1992). Although there are two isoforms of the ER, it appears that ERa
is the predominate player in early breast cancer (Leclercq 2002). However, ERP was
more recently discovered and despite its low abundance in early breast cancer tissue,
could in fact play a very important role in disease progression. Additionally, it has been
estimated that about 75% of invasive breast cancers express ERa (Harvey et al. 1999) and
about 50% express ERP3 (Speirs et al. 1999). As in the case of early breast cancer, the
role of ER[3 in invasive breast cancer growth and progression is not clearly understood.
Since many breast cancers are initially positive for the ER, their growth is
stimulated by estrogens and inhibited by antiestrogens. This is evident in the fact that the
benefit from tamoxifen therapy (reduction in recurrence and mortality) was directly
related to ER expression levels in breast cancers (Rutqvist et al. 1989). However,
tamoxifen-sensitive tumors invariably become resistant after prolonged treatment.
Although ER expression is generally maintained during metastasis, other genetic and
nongenomic events must override hormone responsiveness and contribute to the
evolution of resistance to antiestrogen therapies. Alterations in ER expression, function,
and estrogen responsiveness could play a role in breast cancer progression. Therefore a
considerable effort has been devoted to the investigation of the ER in breast cancer
progression and in the transition to HRBC.
Gene mutations of the ER could be responsible for deviations from its normal
role. In fact, mutations in the ER gene have been shown to elicit changes in receptor
activation by conferring constitutive activity, presumably through conformational
changes, (Weis et al. 1996; Zhang et al. 1997) modulating ER activity due to abrogation
of phosphorylation sites, (Le Goff et al. 1994) interfering with cofactor binding, (Henttu,
Kalkhoven, and Parker 1997; Weis et al. 1996) and/or by modulating the
agonist/antagonist activity ratio of antiestrogens (Montano et al. 1996). For example, a
clinically observed tyrosine 537 to asparagine mutation affects a major site of
phosphorylation in the LBD and results in a constitutively active receptor (Karnik et al.
1994). Mutational analysis of this site has shown that alanine, serine, aspartic acid, and
glutamic acid can also cause the receptor to be constitutively active. However, these ER
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mutants are capable of binding the co-activator, steroid receptor coactivator 1 (SRC-1),
even in the absence of ligand. This illustrates that the mechanisms above are non-
mutually exclusive. Although missense mutations have been estimated to be present in
only 1% of primary breast cancers, (Roodi et al. 1995) the frequency may be higher in
metastatic malignancies (Karnik et al. 1994; Zhang et al. 1997). Mutations in the ER
may affect any one of the various functions of the ER - recruitment of
coactivators/repressors, ligand binding, DNA binding, etc.
Either through mutations or some other unknown mechanism, the ER in a
cancerous cell may be a more (or less) active form of the protein. In a normal cell, the
ER regulates many genes necessary for growth and survival. The overexpression of the
ER in malignant cells, therefore, induces the proliferation of many proto-oncogenes and
growth factors that promote tumor survival. For example, the nuclear proto-oncogenes,
c-fos, c-jun, and c-myc, are regulated by the ER. An increase in ER expression could
lead to tumor progression. Likewise, key factors necessary for the development of new
blood vessels to provide nutrients to the growing tumor, such as VEGF, are regulated by
the ER. VEGF is induced by both estrogen and the antiestrogen tamoxifen. Continued
ER expression may promote new vessel formation and contribute to the early phases of
tumor growth and metastatic dispersal into the vasculature (Hyder et al. 2000; Ruohola et
al. 1999).
Although the ER is known to be involved in breast caner initiation, progression,
and possibly the transition to HRBC, its exact role in the proliferation and survival of
malignant cells is still unknown. Since the ER is involved in cellular proliferation, stress
response, and signaling pathways, an alteration in the expression or function of the
protein has a drastic effect on the fate of a cell. Evidence has shown that genetic
mutations in the ER can lead to increased transcriptional activation. Although not
discussed here, a recent review presents evidence from tissue culture, animal, and clinical
studies supporting the hypothesis that corepressors are crucial regulators of ERa-
mediated action, and that their loss could promote breast cancer development and
resistance to antiestrogen therapy (Dobrzycka et al. 2003). Thus, the role of the ER in
breast cancer is complex and further research is needed to better elucidate its actions.
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The most likely scenario is that there is no one mechanism by which the ER
initiates breast cancer or aids in its progression. While many researchers focus on the
biochemical aspects of this problem, the fact remains that current therapies do not
effectively cure most breast cancer cases. Therefore, new therapies are required to
combat the different stages of the disease. The work here will describe novel genotoxins
that take advantage of the overexpression of the ER in breast cancers and other
malignancies, such as epithelial ovarian tumors, to achieve selective killing of malignant
cells.
Androgen Receptor
The androgen receptor is a 110 kDa protein that acts as a transcription factor in
response to androgen binding and plays a major role in sexual development and sexual
function in males. It is a member of the Class I nuclear receptor superfamily and will
usually homodimerize upon ligand binding. The AR has high affinity for both
testosterone and 5a-dihydrotestosterone with a Kd of 1 nM and 0.1 nM, respectively.
The tissue specific actions of testosterone and dihydrotestosterone mediated by the same
receptor suggest ligand specific recruitment of transcription intermediary factors
(Brinkmann 2001). However, no such experimental evidence has been provided. The
AR has two variable-length amino acid repeats in the N-terminal domain that result from
trinucletotide repeats in the AR gene: polyglutamine (CAG) and polyglycine (GGN).
Several reports have shown that shorter repeats (for example, < 19 versus >25
polyglutamines) correlate with a higher transactivational function or expression level of
AR, which is associated with an increased risk of prostate cancer (Giovannucci et al.
1999). Although trinucleotide repeat expansion has been implicated in prostate cancer
disease progression, there are conflicting reports on their actual involvement
(Montgomery, Price, and Figg 2001).
Most of the unliganded AR is localized in the cytoplasm (Tyagi et al. 2000),
where it is sequestered as a multiprotein complex with heat shock proteins (Hsp90) and
immunophilins (DeFranco 1999). Upon ligand binding, the AR dissociates from the heat
shock proteins, dimerizes, and translocates into the nucleus. Dimerization allows for a
conformational change in the protein exposing a nuclear localization signal. The exposed
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nuclear localization signal is then capable of binding to importins, which serve as
chaperones for the transport of the ligand-activated AR into the nucleus. Once in the
nucleus, the AR recognizes and binds to its HRE, typically in the promoter region of
target genes, through sequence specific contacts between DNA and zinc fingers in the
protein. The consensus DNA binding sequence for the AR is comprised of two imperfect
palindromic 6-base pair elements separated by a three base pair spacer,
GG(A/T)ACAnnnTGTTCT (where n is three nucleotides) (Roche, Hoare, and Parker
1992), although more specific AR response element sequences have been identified
(Claessens et al. 1996; Rundlett and Miesfeld 1995). Upon binding to the HRE, the AR
signals for the cellular transcription machinery to express a gene through its activation
functions.
The AR contains two amino-terminal activation functions AF-1 (ligand
dependent) and AF-5 (ligand independent), and one carboxy-terminal activation function,
AF-2 (ligand dependent). Since AF-5 is ligand independent, the AR has transcriptional
activity even in the absence of ligand binding. Mutations in the AF-2 region result in a
decrease in activation function without affecting the ligand-binding capability despite the
close proximity to the LBD. This indicates that the amino acid residues in the AF-2
region are not directly involved in ligand binding, but rather, determine the interaction
surface (Berrevoets et al. 1998; Feng et al. 1998). The interaction between AF-2 and
either of the activation functions in the amino-terminus reduces the dissociation rate of
the bound androgen and stabilizes the receptor (He et al. 2001). The interaction of the
activation functions aids in the recruitment of coactivator and/or corepressor proteins for
the transcription of an AR response gene.
Like the ER, the AR is activated by post-translational modifications including
phosphorylation, acetylation, and sumoylation. The phosphorylation occurs within
minutes after translation and results in a shift from a 110 kDa band on a sodium dodecyl
sulfate (SDS) - polyacrylamide gel to a 112 kDa band indicative of a phosphoisoform of
the AR (Jenster et al. 1994). Several phosphorylation sites have been identified,
including: Ser-81, -94, -515, -650, and -662, (Blok, de Ruiter, and Brinkmann 1998;
Jenster et al. 1994; Zhou, Kemppainen, and Wilson 1995) although as many as 21
potential phosphorylation sites have been identified (Kuiper et al. 1993). Ser-650 seems
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to be a key phosphorylation site since mutating the AR by substituting an alanine for the
serine reduced AR activity by 30% (substitution for the other serines showed no
difference in activity). (Zhou, Kemppainen, and Wilson 1995) A third isoform has been
identified with a molecular weight of 114 kDa and is thought to involve an addition and
redistribution of phosphorylation sites, but only after ligand binding (Jenster et al. 1994;
Kuiper et al. 1993; Zhou, Kemppainen, and Wilson 1995). The ligand-bound AR is
acetylated at lysines (K) within the 630-633 region (KxKK) (Fu et al. 2003; Fu et al.
2000). Recently, work from the Pestell group showed that the acetylation of the AR
regulates coactivator complex binding and, therefore, the expression of genes that are
transcriptionally activated by the AR. Furthermore, AR acetylation promoted cell
survival and growth of prostate cancer cells in soft agar and in nude mice suggesting that
acetylation alters the expression of specific growth control genes (cyclin D1, cyclin E,
and cyclin A) and may promote aberrant cellular growth in prostate cancer (Fu et al.
2003). Finally, the AR is modified in an androgen-dependent factor by sumoylation at
Lys-386 and -520. The sumoylated lysine residues enhance transcriptional activity of the
AR and it has been suggested that reversible sumoylation is a mechanism for regulation
of the steroid receptor function (Poukka et al. 2000).
Ligand binding of the AR induces a conformational change that exposes a nuclear
localization signal, which leads to the translocation of the AR from the cytoplasm into the
nucleus. Not only does the AR require ligand binding to translocate into the nucleus, but
ligand binding seems essential for its retention in the nucleus. This is evidenced by the
fact that after its androgen-mediated nuclear import, androgen withdrawal (by
transferring cells to a DHT-free medium) results in the export of the receptor back into
the cytoplasm. In fact, the AR has been reported to undergo up to four rounds of cycling
into and back out of the nucleus (Roy et al. 2001). The ability of one molecule of AR to
undergo multiple rounds of signaling indicates that, unlike the ER which is tagged for
degradation upon ligand binding, ligand dissociation and/or inactivation may play a more
critical role in the termination of androgen signaling.
Although androgen binding stabilizes the AR, the receptor is eventually degraded
by the ubiquitin-proteasome pathway. Initial evidence stemmed from the fact that a
highly conserved proline-, glutamate-, serine-, threonine-rich sequence in the AR which
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is thought to target proteins for ubiquitination and proteasomal degradation was found.
Additionally, AR protein levels were elevated under proteasome inhibitor treatment
(Sheflin et al. 2000). More recently a group from the University of Rochester
demonstrated that Akt and Mdm2 formed a complex with the AR and promoted
phosphorylation-dependent AR ubiquitination and subsequent degradation by the
proteasome (Lin et al. 2002).
The AR is expressed in both androgen-dependent and -independent cancers at
both the primary and metastatic sites and in HRPC (Hobisch et al. 1995; Marcelli and
Cunningham 1999). Most patients with prostate cancer initially respond to androgen
ablation therapy, but the recurrence of the cancer with its hormone independent status
makes it difficult to treat. Thus the progression from androgen-dependence to -
independence is a critical step in the development of prostate cancer, although the
molecular mechanisms are poorly understood. Loss of androgen sensitivity is generally
considered to have four causes: selection of cancer clones, adaptation of cells to an
environment without androgen, an alternative pathway of signal transduction, and
involvement of the AR (Suzuki et al. 2003).
There are three central mechanisms that describe the role of the AR in tumor
progression: mutations, activation and upregualtion of receptor activity by androgens, and
ligand-independent activation. The AR is frequently mutated within the LBD in both cell
lines and primary tumors, rendering the AR permissive for binding of other steroid
hormones (Elo et al. 1995; Gaddipati et al. 1994; Trapman et al. 1990). AR mutations
have also been found in other regions of the protein including the coding region (Taplin
et al. 1995; Tilley et al. 1996) and in the polyglutamine and polyglycine repeats
(Montgomery, Price, and Figg 2001) which may increase the risk of cancer.
Through these mutations or other unknown mechanisms, AR function may
become highly sensitized to low levels of residual androgens. The AR in normal prostate
and in prostate cancer is involved in cellular proliferation, apoptosis, and angiogenic
events. Androgens enhance the expression of cyclin-dependent kinases 2 and 4 (cdk-2/-
4), as well as induce the down regulation of the cell cycle inhibitor p16 in cells
expressing the AR, whereas in androgen-independent cells, there is no difference in
expression of these proteins upon androgen stimulation (Lu, Tsai, and Tsai 1997).
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Therefore in cells expressing the AR, there is an overall increase in Cdk activity and
stimulation of the cells to enter S phase of the cell cycle and thus an enhancement of
cellular proliferation. Androgens also upregulate the anti-apoptotic factor, p21,
suggesting that androgens may induce anti-apoptotic activity (Lu et al. 1999). Data has
shown that patients with advanced prostate cancer do in fact have increased p21
expression (Aaltomaa et al. 1999). Therefore, upregulation or increased activity of the
AR could lead to increased cell proliferation and cancer progression. In fact, most
prostate cancers express the AR and a high proportion of HRPC overexpress it (Hobisch
et al. 1995).
The AR can also be activated in a steroid-independent manner by various growth
factors, cytokines, Her-2, peptide hormones, and neurotransmitters (Craft et al. 1999;
Culig et al. 1994; Hobisch et al. 1998; Nazareth and Weigel 1996). For example, insulin
growth factor 1 and keratinocyte growth factor are able to promote AR transcriptional
activity in vitro in the absence of androgens (Culig et al. 1994). The plasma
concentration of the cytokine, interleukin 6 (IL-6), is elevated in patients with HPRC and
seems to correlate with increased PSA level (Adler et al. 1999). IL-6 can enhance AR
transactivation via the STAT3 or MAPK pathways and can suppress transactivation via
the PI3K/Akt pathway (Yang et al. 2003). However, the mechanism of IL-6 induction of
AR transactivation is still unknown; as is the physiological role each of these pathways
play in the promotion of AR induced transcription.
These data suggest that the AR plays an important role in the progression of
prostate cancer. Since the AR is overexpressed in many prostate cancers, it provides an
obvious target for therapeutics (Hobisch et al. 1995; Marcelli and Cunningham 1999).
However, current androgen ablation therapies are limited in scope by the transition from
androgen-dependent to -independent status (Gingrich et al. 1997; Isaacs and Coffey
1981). Therefore, a need exists to treat prostate cancer before and after it becomes
refractory to androgen ablation therapy. The work described here will discuss novel
DNA damaging agents that take advantage of the expression of the AR in order to
achieve selective killing of prostate malignancies.
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Design of Novel Anticancer Agents
Current therapy for most cancers includes the surgical removal of the tumor
followed by adjuvant therapy to rid the body of any micrometastases or cancerous cells
not removed by the surgeon. The adjuvant therapy often includes hormones, radiation,
and chemotherapeutics either alone or in combination. The drawback of current
chemotherapies is the severe toxic side effects experienced by non-cancerous tissues
resulting in a painful and arduous course for the patient. Moreover, these treatments
usually do not fully cure the cancer, but rather only prolong the patient's life expectancy
by placing the tumor into a temporary state of stasis. Cisplatin is somewhat unusual in
this regard as it is extremely effective against testicular tumors and is capable of curing
95% of men with the disease (Feuer, Brown, and Kaplan 1993). Although the exact
biological mechanism of cisplatin is unknown, it is well-established that the cellular
toxicity derives from processes triggered by its reaction with DNA. From the lessons
learned about the mechanism of action of cisplatin, we have rationally designed
chemotherapeutics that produce DNA damage and exploit molecular changes in tumor
cells.
Lessons Learned from Cisplatin
cis-Diamminedichloroplatinum (II) (cisplatin) (Fig 1.1A), typically in
combination with etoposide and bleomycin, displays significant antitumor activity against
cancers of the testis, ovary, head, neck, and lung (Masters and Koberle 2003). Once
cisplatin enters a cell, its chloride ligands are displaced by water molecules generating a
positively charged species that is capable of reacting with nucleophilic sites on DNA,
RNA and proteins. Despite the chemical feasibility of cisplatin to form adducts with
RNA and proteins, the level of adduction to these macromolecules are too low to be
physiologically relevant (Akaboshi et al. 1992; Pascoe and Roberts 1974). All evidence
points to the interaction of cisplatin with DNA as the key step underlying its toxicity:
Escherichia coli and eukaryotic cells deficient in DNA repair enzymes are more sensitive
to cisplatin than the corresponding wild type cells; there is an inverse correlation between
DNA adduct levels and cell survival in culture; and there is a direct correlation between
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cisplatin adduct levels in blood cells of cancer patients and clinical response (Kartalou
and Essigmann 2001a; Kartalou and Essigmann 2001b).
Cisplatin is injected intravenously and remains coordinated to its chloride ligands
while circulating in the blood where the chloride concentration is high (100 mM). Upon
entering the cell where the chloride concentration is low (4 mM), the chloride ligands are
rapidly substituted by water molecules (tl/2 = 2 hr. for substitution of the first chloride
ligand with water) (Bancroft, Lepre, and Lippard 1990; Johnson, Hoeschele, and Rahn
1980). The aquated species of cisplatin is capable of reacting with nucleophilic sites on
the various macromolecules in the cell, such as DNA, RNA, and proteins. The water
molecule of the singly aquated species is far more easily displaced than the chloride
ligand, and is
susceptible to nucleophilic attack by the N7 position of guanine (or by adenine) forming a
monofunctional DNA adduct (tl/ 2 = 0.1 hr) (Bancroft, Lepre, and Lippard 1990). If there
is another potentially reactive site nearby, the monofunctional adduct can react further to
form an inter- or intra-strand crosslink (t1/2 = 2.1 hr) (Bancroft, Lepre, and Lippard 1990).
Cisplatin reacts with DNA to form approximately 65% 1,2-d(GpG), 25% 1,2-d(ApG),
and 5-10% 1,3-d(GpNpG) intrastrand crosslinks and only a small percentage of
monoadducts and interstrand crosslinks (Kartalou and Essigmann 2001b). These adducts
result in the bending of DNA towards the major groove and an unwinding in the helical
nature of DNA (reviewed in (Kartalou and Essigmann 2001 a)). Cisplatin treatment
results in inhibition of DNA replication (Ciccarelli et al. 1985; Uchida et al. 1986),
inhibition of RNA transcription (Mello, Lippard, and Essigmann 1995), arrest at the G2
phase of the cell cycle and/or programmed cell death (Sorenson and Eastman 1988a;
Sorenson and Eastman 1988b). The molecular mechanisms that link these physiological
events with the initial formation of DNA adducts are not entirely understood.
One possible link between the physiological toxicity and DNA adduct formation
may stem from the fact that certain proteins bind to cisplatin-DNA adducts (Pil and
Lippard 1992; Toney et al. 1989). Partially through work in the Essigmann laboratory,
several nuclear proteins, most containing a high mobility group (HMG) domain, have
been identified with very high affinity for the therapeutically active cisplatin DNA
adducts (Brown, Kellett, and Lippard 1993; Bruhn et al. 1992; Donahue et al. 1990; Pil
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and Lippard 1992; Toney et al. 1989). On the surface, this may not be surprising as the
structure of cisplatin DNA adducts is very similar to the structure of HMG box proteins
bound to DNA - upon binding, HMG proteins bend and unwind DNA to a degree similar
to that of a cisplatin adduct. However, other proteins, such as the ER, also bend DNA
upon binding to its response element, but the affinity of the ER is lost when cisplatin is
adducted to a base within this region (Massaad-Massade et al. 2000). Therefore, the
interaction between the HMG proteins and the cisplatin adducts is specific. The stability
of the unnatural bent DNA structure is further enhanced by the intercalation of an amino
acid side chain (from HMG) into the duplex at the site of the bend (Kartalou and
Essigmann 2001 a).
Several models have been proposed to explain the involvement of HMG proteins
in the cellular toxicity of cisplatin (Fig 1.2). One model suggests that the binding of these
proteins to the cisplatin-DNA adduct is so tight that repair enzymes are inhibited from
accessing the lesion (Fig 1.2A). Evidence has illustrated that HMG proteins sensitize
cells to cisplatin toxicity by shielding DNA adducts from repair (Brown, Kellett, and
Lippard 1993; Huang et al. 1994; McA'Nulty and Lippard 1996). A second model (Fig
1.2B) stems from the discovery that human upstream binding factor (hUBF), a
transcription factor that plays a key role in the regulation of ribosomal RNA synthesis,
binds to cisplatin adducts with a similar affinity to its cognate promoter sequence (Kd =
60 pM and 18 pM, respectively) (Treiber et al. 1994). Since hUBF is essential for
proliferating cells, cisplatin adducts may hijack the transcription factor and deplete the
cells of a necessary resource to grow (Treiber et al. 1994). The "repair shielding" and
"transcription factor hijacking" mechanisms, although not mutually exclusive, may help
explain the unusual effectiveness of cisplatin against malignant cells (Kartalou and
Essigmann 2001 a). The main drawback of cisplatin is its relatively limited applicability
to only a small handful of cancers.
Applying the Lessons Learned from Cisplatin to Novel Anticancer Agents
The toxicity of cisplatin can, in part, be attributed to the repair shielding and
transcription factor hijacking mechanisms. The work here describes the use of synthetic
chemistry to create de novo molecules that are capable of killing malignant cells through
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these two mechanisms. In order to achieve this goal, the new compound must be capable
of adducting DNA and attracting specific proteins present only (or predominantly) in
cancer cells. The salient features of the compounds that were designed and their intended
mechanism of action are shown in Figure 1.3. The compounds are bifunctional
molecules containing a DNA reactive warhead and a protein recognition domain capable
of attracting tumor specific proteins. In normal cells where the repair blocking protein is
absent (or at concentrations too low to be physiologically relevant), the adduct is
unshielded and hence more readily accessible to repair enzymes (Fig 1.3 lower left).
However, in cancerous cells where the protein is aberrantly expressed, the protein would
be attracted to the DNA lesion. A tight interaction between the tumor specific protein
and the drug's protein recognition domain would inhibit repair enzymes from accessing
the lesion (Fig 1.3 lower right). The adduct would persist and thus cause the cell to enter
the apoptotic cascade. Additionally, if the tumor specific protein were a transcription
factor, the DNA adduct could hijack the protein and disrupt necessary cellular
transcriptional events. Moreover, if the protein was overexpressed in tumor cells, those
cells would be selectively more sensitive than normal cells, resulting in a favorable
therapeutic index.
Examples of the types of molecules we have studied are shown in Figure 1.1 B-D.
Aromatic nitrogen mustards were chosen as the DNA damaging warhead because they
react slowly (they have comparatively low toxicity when compared to more reactive alkyl
mustards), and they form DNA adducts that are readily repaired. Furthermore, repair
deficient cell lines are more sensitive to mustard compounds (De Silva et al. 2000;
Frankfurt 1991). We therefore reasoned that inhibiting the repair of these DNA adducts
in tumor cells should increase lethality. The nitrogen mustard, which is based on the
FDA approved drugs chlorambucil and melphalan, was linked to a protein recognition
domain. The ER was a logical protein to target since it is both a transcription factor and
is overexpressed in approximately 50% of all breast cancers (Ferno et al. 1990; Pallis et
al. 1992). Initial studies were conducted with a phenyl-indole linked to a nitrogen
mustard and served as a relatively uncomplicated synthetic molecule that could be used
to test the overall strategy (Fig 1.1 B). The phenyl-indole moiety was later substituted for
estradiol linked at the 7a position (Fig 1.1 C) to provide a molecule with increased affinity
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for the ER. Lastly, this platform has been expanded to treat prostate cancers by tethering
a testosterone-like moiety to the nitrogen mustard (Fig 1. D). As in the case of breast
cancer, many prostate cancers also overexpress the AR and the AR is also a transcription
factor (Hobisch et al. 1995; Marcelli and Cunningham 1999).
Although seemingly functionally silent in the repair shielding and transcription
factor hijacking mechanisms, great care went into devising the region linking the
warhead to the protein recognition domain. The linker was optimized based on several
factors: 1. ease and simplicity of chemical synthesis, 2. stability from enzymatic
degradation, 3. enhanced solubility of the overall compound, 4. binding to the tumor
specific protein, 5. formation of DNA adducts. Several iterations were synthesized
before proceeding with the compounds shown in Fig 1.1 B-D. This will be discussed in
brief below.
2-Phenyl-indole-C6NC2-mustard - A Rationally Designed Drug Candidate
The main drawback of conventional chemotherapeutics is the toxic side effects
suffered by non-target tissues. Using the lessons learned from cisplatin, the Essigmann
laboratory initially sought out to improve the therapeutic index of chemotherapeutics
targeting breast and ovarian cancers that aberrantly expressed the ER (Rink et al. 1996).
The rationale was to form DNA adducts that were capable of attracting tumor specific
proteins, such as the ER. If the ER is attracted to DNA adducts, the adduct-protein
complex could inhibit repair enzymes from accessing the lesion and rendering it
nontoxic. The lesion would persist and the cell would enter into apoptosis.
Alternatively, a malignant cell could also enter programmed cell death if the DNA adduct
disrupts necessary transcriptional events by hijacking the ER from its response element.
As a proof of concept 2-(4'-hydroxyphenyl)-3-methyl-5-hydroxy-indole was linked to 4-
(3-aminopropyl)-N,N-(2-chloroethyl)-aniline (Fig 1.4). The former is a molecule that
interacts well with the ER in competitive binding experiments with estradiol and the
latter is the DNA reactive warhead (von Angerer, Prekajac, and Strohmeier 1984).
Rink et al. synthesized a series of bifunctional alkylating agents capable of
damaging DNA and attracting the ER. The linkage between the warhead and the protein
recognition domain was designed to permit DNA damage while preserving the ability of
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the phenylindole group to interact with the ER. Therefore, the number of carbon atoms
between the phenylindole and the secondary amine and between the secondary amine and
the carbamate was systematically varied to optimize both DNA adduction and protein
binding (Fig 1.4). A fourth compound, 2PI(OH)-C6NC2, was synthesized as a control
compound that has poor affinity for the ER as a result of only a monohydroxylation of the
phenylindole (von Angerer, Prekajac, and Strohmeier 1984). A carbamate was chosen to
join the two halves of the molecules together because it is resistant to enzymatic
degradation in vivo (Cho et al. 1993), and it provides a stable synthetic handle.
Additionally, a secondary amino group was incorporated into the linker to enhance
solubility. Since the pKa of the secondary amino group is -10, these compounds are
anticipated to have a positive charge which may promote association with DNA.
The relative binding affinities (RBA) of the four molecules illustrated that the
2PI-C6NC2 mustard interacted the best with the ER (Fig 1.4). An RBA of 7.1 indicates
that 2PI-C6NC2 binds to the ER with an affinity that is 7.1% of that for estradiol, the
natural ligand for the ER. As expected, the monohydroxylated 2PI(OH)-C6NC2-mustard
showed poor binding to the ER. The C3NC3 and C5NC3 linkers also displayed
relatively disappointing binding affinities to the ER. The solving of the ER crystal
structure in 1997 now sheds light as to why the C6NC2 linker had the highest affinity for
the ER (Brzozowski et al. 1997). Due to the depth of the ligand binding pocket, a six
carbon chain is necessary to provide optimal binding and minimize steric clashes from
the secondary amine. Figure 1.5 depicts a molecular docking model of a second
generation nitrogen mustard (E2-7a) DNA adduct with the ER-LBD. This model
illustrates two points: 1. although not easily seen in the figure shown, a six carbon chain
is optimal for efficient binding of the ER to the nitrogen mustard, and 2. the linker is of
sufficient overall length to allow for the binding of the mustard even when adducted to
DNA. The second point is of particular importance since the compounds were designed
to hijack transcription factors and shield DNA adducts from repair enzymes. These two
mechanisms can only be effective if the ER has a high affinity for the drug-DNA adducts
and not just for the compounds alone.
The compounds in Figure 1.4 were allowed to react with a 16-mer
oligonucleotide. The overall reactivity of the compounds tested was 2PI-C3NC3 > 2PI-
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5NC3 > 2PI-C6NC2 > chlorambucil > 2PI(OH)-C6NC2. Based upon chemical
fragmentation analysis of the alkylated products, guanine was the primary base alkylated
by these compounds, followed by adenine. It is likely that the adducts were mainly at the
N7 position of guanine (Lawley 1966; Singer 1975) and the N3 position of the adenine
residues (Pieper, Futscher, and Erickson 1989). Additionally, the DNA adducts of the
2PI-C6NC2-mustard were able to compete with estradiol for the ER ligand binding site
(RBA - 0.5). Furthermore, this result provides experimental evidence for the molecular
docking model indicating that 2PI-C6NC2-mustard DNA adducts can act as a molecular
decoy binding site for the ER.
Finally, Rink et al. evaluated the phenylindole mustard compounds for their
selective toxicity towards ER expressing cells, MCF-7, versus ER deficient cells, MDA-
MB23 1. Both cell lines were treated for a brief, 2 hr period to minimize ER antagonistic
effects in a clonogenic survival assay. Figure 1.6 illustrates the survival curves for the
MCF-7 and MDA-MB231 cells treated with the mustard compounds. The overall
toxicity of the compounds tested in either cell line were consistent with their abilities to
adduct DNA in vitro -- 2PI-C3NC3 > 2PI-5NC3 > 2P1-C6NC2 > 2PI(OH)-C6NC2 >
chlorambucil. However, the two compounds that interacted best with the ER, 2PI-
C5NC3- and 2PI-C6NC2-mustard, were more toxic to the ER(+) MCF-7 cells than they
were to the ER(-) MDA-MB231 cells (Fig 1.6 C and D). Chlorambucil, 2PI-C3NC3-
mustard, and 2PI(OH)-C6NC2-mustard did not exhibit selective toxicity toward either
cell line (Fig 1.6 A and B). The results with the control compounds made it unlikely that
the selective toxicity towards the MCF-7 cells by 2PI-C5NC2-mustard and 2PI-C6NC2-
mustard were due to cell line specific variation in the detoxification of the mustards or in
their DNA repair capability. Instead, these results suggest that the difference in
sensitivity between the two cell lines is due, in part, to their ER status.
These data illustrate that the compounds that interact the best with the ER, both
alone and as DNA adducts, are more toxic to ER(+) MCF-7 cells than to ER(-) MDA-
MB231 cells. Several mechanisms could explain the selective toxicity including ER
antagonism, selective delivery to ER(+) cells, or the repair shielding/transcription factor
hijacking models. Since the cells were treated for a very short period (2 hr), it is unlikely
that the primary source of toxicity of the phenylindole mustards resulted from ER
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antagonism. As a control experiment, 2PI-C6NC2-mustard was inactivated by
hydrolyzing the bis-chloroethyl arms of the nitrogen mustard. Only after extended
periods of exposure to cells (when the inactivated 2PI-C6NC2-mustard was continuously
present in the cell growth medium) were some signs of toxicity evident. A 2 hr exposure
to the inactivated drug showed minimal effect on survival - approximately a 10%
reduction in survival. This ruled out the possibility that the toxicity of the phenylindole
mustards was due strictly to ER antagonism. Furthermore, it is unlikely that the mustards
were selectively delivered to the ER(+) cells based on the fact that the levels of
interstrand crosslinks of 2PI-C6NC2-mustard in the ER(+) MCF-7 and ER(-) MDA-
MB231 cells are identical shortly after dosing. This is compounded by the fact that Rink
et al. calculated that 20-25% of the DNA adducts formed by 2PI-C6NC2-mustard are
likely to be associated with the ER (Rink et al. 1996). Therefore it is quite possible that
the repair shielding and transcription factor hijacking mechanisms are responsible for the
selective toxicity.
Based on the initial findings linking the repair shielding and transcription factor
hijacking mechanisms with the selective toxicity of these compounds, future iterations
have continued to use many of the key features from the preliminary work of Rink et al.
The work described here will focus on two new molecules with higher specificity for
their respective nuclear hormone receptors. In the case of breast cancer, a new agent
incorporates into its design the warhead and the linker of the 2PI-C6NC2-mustard
molecule, but has substituted the phenylindole moiety with 1 7f-estradiol to increase the
affinity for the ER. In the case of prostate cancer, the same warhead and linker have been
tethered to a testosterone-like moiety. In the subsequent chapters, I have treated these
two molecules separately since they target different cancers and seem to have slightly
different mechanisms of action. The next 4 chapters will focus on work with the
compounds that we have used to target ER(+) breast cancer. Chapters 6-8 will focus on
the work I have completed with a molecule that targets prostate cancer. For both
compounds, I will initially discuss the results from various in vitro experiments which
illustrate their potential as chemotherapeutic agents - ability to form DNA adducts, bind
to their respective receptors, and selectively destroy receptor expressing cancer cell lines.
I will then discuss the results of in vivo experiments, including pharmacokinetics, toxicity
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and efficacy against xenograft tumor models. I will conclude by hypothesizing on the
mechanism of action of these compounds. Although I will focus on the experiments that
I have done during my graduate career, I will occasionally introduce work from my
colleagues, as it makes for a much more interesting and complete story.
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Fig 1.2 The cellular toxicity of cisplatin may be explained by the extremely tight
interaction between DNA adducts and cellular proteins, such as HMG and hUBF. A.
The interaction between a cisplatin-DNA adduct and a cellular protein may inhibit
repair enzymes from accessing the damaged base, resulting in persistence of the
adduct and thus toxicity to the cell. This has been coined the "repair shielding"
mechanism. B. hUBF, a cellular transcription factor, binds to cisplatin adducts with a
similar affinity to its cognate promoter sequence (Kd = 60 pM and 18 pM
respectively). Therefore, a cisplatin-DNA adduct could hijack a transcription factor
from expressing an essential gene and result in cell death. This has been coined the
"transcription factor hijacking" mechanism.
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hexanyl linkage is of sufficient length to transcend the
The 7a-
hydrophobic binding pocket of the ER-LBD and the reactive
aniline mustard is capable of forming an adduct with DNA when
(based on Pike et al. 2001 Structure 9, 145-153.)bound to the ER-LBD.
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Fig 1.6 Survival curves for ER (+) MCF-7 (solid line) and ER (-) MDA-
MB231 (dashed line) cells treated with various compounds. 2PI-C3NC3
(A), chlorambucil (A), and the monohydroxylated 2PI(OH)-C6NC2 (B),
which does not interact well with the ER, were equally toxic to both ER
cell lines. Only the compounds that had the greatest affinity for the ER-
LBD (those with the highest RBA in Fig 4), 2PI-C5NC3 (C) and 2PI-
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Chapter 2
Biophysical Properties of a Series of Compounds
Designed to Selectively Target Estrogen Receptor
Expressing Cancers
The work discussed in this chapter pertains to my contribution to the following
publications:
1. Mitra K, Marquis JC, Hillier SM, Rye PT, Zayas B, Lee AS, Essigmann JM, Croy RG.
A rationally designed genotoxin that selectively destroys estrogen receptor-positive breast cancer
cells. J Am. Chem. Soc. 2002 Mar 6;124(9):1862-3.
2. Sharma U, Marquis JC, Nicole Dinaut A, Hillier SM, Fedeles B, Rye PT, Essigmann JM,
Croy RG. Design, synthesis, and evaluation of estradiol-linked genotoxicants as anti-cancer
agents. Bioorg. Med. Chem. Lett. 2004 Jul 16;14(14):3829-3833.
Although these publications contain work by several people, I shall focus on the
experiments that I conducted. The results of others will be discussed (and referenced
accordingly) to provide a complete story. The work from these two publications has
established a ground work from which my subsequent experiments have been designed.
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Introduction
Many antitumor agents produce their cytotoxic effect by covalently modifying
DNA (Hurley 2002; Teicher 1997). The persistence of DNA damage produced by
alkylating agents has lethal consequences for malignant cells. DNA repair enzymes that
remove these lesions restore the integrity of the genome but limit the effectiveness of
these drugs. Therefore, inhibition of the DNA repair machinery specifically in cancer
cells is an attractive strategy to potentiate the therapeutic effects of alkylating
chemotherapeutics (Barret and Hill 1998; Dolan 1997). Early work in the Essigmann
laboratory has helped to illustrate this principle through studies on the effectiveness of
the chemotherapeutic cisplatin.
cis-Diamminedichloroplatinum (II) (cisplatin) is a strikingly effective treatment
for testicular and ovarian malignancies. It has a high cure rate of 95% in men treated for
testicular cancer and is an effective initial treatment for ovarian cancer but is typically not
curative. Investigations in our laboratory and others demonstrate that cisplatin forms
DNA adducts that attract certain nuclear proteins and bind them with very high affinity
(Kd values in the 60 pM range have been observed) (Donahue et al. 1990; Pil and
Lippard 1992). These protein-adduct complexes are so tight that DNA repair enzymes
are unable to gain access to the lesion for repair (Huang et al. 1994), leading to retention
of the cytotoxic adducts and increased lethality. A second, non-mutually exclusive
mechanism stems from the observation that the proteins that bind the most tightly to
cisplatin adducts are often critical transcription factors. We have proposed (and found in
one case) that the regulation of the genes controlled by these transcription factors is
disrupted in the presence of cisplatin adducts (Treiber et al. 1994; Zhai et al. 1998).
These two mechanisms, DNA adduct repair shielding and transcription factor hijacking,
may explain the unusual effectiveness of cisplatin against germ cell malignancies
(Kartalou and Essigmann 2001).
The repair shielding and transcription factor hijacking mechanisms discovered for
cisplatin have become the basis for our design of novel anticancer agents targeted against
breast and prostate cancers. Our drug design strategy takes advantage of the fact that
these tumors selectively express certain proteins. For example, over half of human breast
cancers express the estrogen receptor (ER) (Ferno et al. 1990), and most prostate cancers
express the androgen receptor (AR) (Hobisch et al. 1995; Marcelli and Cunningham
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1999) and progesterone receptor (PR)(Bonkhoff et al. 2001). We reasoned that if these
abundant tumor specific proteins could be attracted to the sites of DNA adducts, then
increased toxicity could be achieved in tumor cells by the repair shielding mechanism. In
addition, since all three of these hormone receptors are transcription factors, their
association with DNA lesions could disrupt the genes critical for growth and survival as
is the case with current antihormonal therapies for breast and prostate malignancies
(Bruckheimer, Gjertsen, and McDonnell 1999; Kozlowski, Ellis, and Grayhack 1991;
Kreis 1995; Peto and Mack 2000; Santen 1992).
As a proof of concept and in an effort to design novel anticancer agents rationally,
a series of compounds containing a protein recognition domain that could attract tumor
specific proteins was linked to a DNA damaging warhead that could covalently modify
DNA. These compounds initially consisted of N,N-bis-chloroethylaniline connected to a
2-phenylindole group by alkyl-amino-carbamate linkers of various lengths (Rink et al.
1996). 2-Phenylindole was chosen for the protein recognition domain of the molecule
because studies have shown it interacts well with the ER in competitive binding
experiments with estradiol (von Angerer, Prekajac, and Strohmeier 1984). N,N-bis-
Chloroethylaniline is a nitrogen mustard that is capable of covalently modifying DNA,
most commonly at the N7 position of guanine. Investigations with these derivatives
identified several molecular characteristics of the linker that were important for the
compound to react with DNA and bind to the ER. These features were discussed in
Chapter 1.
Of all the compounds tested by Rink, et al., 2PI-C6NC2-mustard was determined
to have an optimal balance of properties suitable for an agent designed to shield adducts
from repair and to hijack the ER from its role as a transcription factor, these being
affinity for the ER both alone and when covalently adducted to DNA, reactivity with
DNA, lethality towards breast cancer cell lines, and selective toxicity in favor of ER(+)
cell lines over ER(-). 2PI-C6NC2-mustard served as a proof of concept that it is possible
to rationally design an agent that could form DNA adducts and that these adducts could
serve as molecular decoys capable of hijacking the ER from its natural targets. The
results implicated the transcription factor hijacking and repair shielding mechanisms as
possible explanations for the observed selective toxicity (Rink et al. 1996).
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Despite the promising results with these initial findings, we reasoned that an agent
with a higher affinity for the ER may be more potent in selectively killing ER(+) breast
cancer. In this effort, the 2-phenylindole group was replaced by 1713-estradiol at the 7a
position. The site of substitution of estradiol in E2-7a was based on reports that
relatively large alkyl groups can be attached at the 7a position with retention of high
affinity for the ER (Bowler et al. 1989; Bucourt, Vignau, and Torelli 1978; DaSilva and
van Lier 1990). The work by Mitra, et al., utilized the same C6NC2 linker as by Rink, et
al., described in Chapter 1. However, Sharma, et al. systematically studied the linker by
substituting C6NC2 with seven other novel linkers. The modified linkers retain the six
carbon chain that appears to be essential for the attached ligand to fit into the estradiol
binding pocket of the ER (Brzozowski et al. 1997; Rink et al. 1996). Amino, amido, and
guanidino groups were incorporated into the region connecting the hexanyl-substituted
estradiol and the aniline mustard. These changes were designed to probe linker variations
that could provide a less complex synthesis, improved DNA adduction, enhanced ER
binding, increased water solubility, and/or increased selective toxicity towards ER(+)
breast cancer cells.
The work described in this chapter will focus on E2-7a and its derivatives. The
synthesis of these molecules will not be covered as their syntheses have been previously
documented (Mitra et al. 2002; Sharma et al. 2004). However, the reactivity of E2-7a
with DNA and the identification of these DNA adducts by mass spectrometry will be
given considerable attention. The kinetics of DNA adduction by E2-7a over time will
also be described.
Additionally, the partition coefficient (log P) for E2-7a and its derivatives will be
discussed in some detail. The log P can be predictive of aqueous solubility, absorption,
and permeability (Hansch and Fujita 1964; Leo, Hansch, and Elkins 1971). Octanol is
used to mimic the phospholipid cellular membrane and water is used to mimic the
cytosol. Therefore, the amount of drug that partitions between the two solvents helps
describe the potential of a drug to enter a cell. Lipinski, in 1997, coined the "rule of five"
to describe a compounds "drugability" (Lipinski et al. 1997). Lipinski claimed an ideal
drug has the following properties: a log P < 5, the # of H bond acceptors < 10, the # of H
bond donors < 5, and a molecular weight < 500. Additionally, the log P of a compound
can provide an estimate of how the drug will be excreted and what routes of
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administration would most likely be used: log P < 0: injectable, log P 0-3: oral, log P 3-
4: transdermal, log P 4-7: not ideal because of a toxic buildup in fatty tissues.
There are several ways to measure a log P, the most common of which is the
shake-flask method. In this method, the drug of interest is placed in a mixture of octanol
and water, and this mixture is quickly shaken. The concentration of drug in the octanol
phase and in the aqueous phase is measured. The Log P value is calculated by taking the
log of the ratio of the concentration of drug in the octanol phase divided by the
concentration in the aqueous phase. Alternative means of calculating a log P are by
computer simulation, slow stir-flask, generator column, and HPLC. I shall discuss my
results with several of these methods and some of their limitations. The log D, the log P
at physiological pH of 7.4, was then calculated based on the experimentally determined
log P (Donovan and Pescatore 2002).
Finally, I will provide reference to the remaining experiments in Mitra, et al. and
Sharma, et al. (Mitra et al. 2002; Sharma et al. 2004). Specifically, I shall discuss the
RBA, the amount of DNA adduction as assessed by piperidine cleavage, the ability of
DNA adducts to interact with the ER-LBD, and the selective toxicity towards ER(+) cell
lines for E2-7a and its derivatives. Although I did not directly conduct these
experiments, I believe it is important to discuss them in brief as they have provided the
groundwork for the remainder of my research.
Materials and Methods
Synthesis. The complete chemical synthesis of all estradiol-linked genotoxicants has
been conducted by various members of the Essigmann laboratory. The work was
described in Mitra, et al.(Mitra et al. 2002) and Sharma, et al. (Sharma et al. 2004).
Covalent Modification of DNA by E2-7a. pGEM-7fz plasmid DNA (150 tg, Promega)
was dissolved in 270 gL of 10mM Tris-HCl/1 mM EDTA (pH 8). [14C]-E2-7a (specific
activity 53 mCi/mmol, dissolved in DMSO) was added to this solution to obtain a final
concentration of 100 pM E2-7a, 10% DMSO by volume. This mixture was incubated at
37°C and 50 jtL aliquots were removed at 0, 0.5, 1, 2, 4, 6, and 24 hours. Non-covalently
bound E2-7a was removed by extraction with phenol:chloroform:isoamyl alcohol
(25:24:1) and subsequent ethanol precipitation. The DNA was dried in vacuo and
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redissolved in 100 tL of 10 mM Tris-HCl/1 mM EDTA (pH 8). DNA concentration was
determined by absorbance at 260 nm and radioactivity was measured by scintillation
counting.
Mass Spectrometric Analysis of E2-7a DNA Adducts. Reaction of DNA with E2-7a
was performed on a larger scale to obtain sufficient material for structural analysis of
covalent products. Salmon testes DNA (20 mg, Sigma-Aldrich) was dissolved in 20 mL
of 5 mM sodium cacodylate, 25% N,N-dimethlyformamide. To the DNA solution was
added 100 [tL of 10 mM E2-7a in DMSO, and the final concentration of E2-7a was 50
[tM. After incubation for 16 hours at 37 °C, unbound E2-7a was removed by extraction
with phenol:chloroform:isoamyl alcohol (25:24:1) and subsequent ethanol precipitation.
The DNA was then reconstituted in water and subsequently hydrolyzed in 0.1 N HCl for
30 min at 70°C. The solution was then neutralized with 1N NaOH and adjusted to 20
mM Tris-HCl (pH 7.4), 10% methanol. The hydrolyzed DNA was loaded onto a C 18
Sep-Pak (Waters Co.) column and eluted sequentially with 10 mL of 10% and 50%
aqueous methanol solutions and finally with 100% methanol. The 100% methanol
fraction was reduced in vacuo and analyzed by HPLC and mass spectrometry. HPLC
analyses were performed using a Beckman ODS 4.6 x 250 mm Ultrasphere column
eluted at 1 mL/min with a 20 min linear gradient of 50% 0.1 M ammonium acetate/10%
acetonitrile, 50% methanol to 100% methanol. Aliquots of samples obtained from HPLC
fractionation were analyzed by electrospray ionization mass spectrometry (ESI-MS)
using flow injection (0.2 mL/min) in methanol:water:acetontrile (50:45:5) in positive ion
mode. The mass spectrometric analysis was conducted with the help of John Wishnok
and Beatrice Zayas.
Determination of the Partition Coefficient (log P):
Computer Simulation: The structure of various reference compounds and the E2-7a
derivatives were entered into the following web sites: 1. www.logp.com and 2.
www.molinspiration.com. The log P of the reference compounds determined by the
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computer simulations were compared to experimentally derived log P values found in the
literature to test the accuracy of these simulations.
HPLC: The log P of all compounds was determined by the HPLC method of Donovan
and Pescatore. (Donovan and Pescatore 2002) Briefly, 1 mg of the test compound was
dissolved in 1 mL internal standard solution, which consisted of 2 mL toluene and 20 mg
triphenylene dissolved in 200 mL of methanol. The compound/internal standard solution
(2 tL) was injected into a Rainin HPLC with an octadecyl poly(vinyl alcohol) (ODP-50)
20x4 mm, 5 tm, 250 A pore size column (Supelco), 10-100% 0.01 M sodium
phosphate(pH 7)/methanol gradient over 9.4 min, and a flow rate of 1.5 mL. The
compounds were detected at 260 nm by a Dynamax UV- 1 detector. The log P of the test
compound is calculated by Equation 2.1. The log D at physiological pH was calculated
based on the equation derived by Horvath, Equation 2.2 (Horvfith, Melfnder, and Molnar
1977).
Results
E2-7a Modifies DNA Covalently. In order to achieve selective toxicity towards ER(+)
cancer cells, E2-7a must be capable of forming DNA adducts and attracting tumor
specific proteins. 14C-E2-7a was incubated with pGEM-7fz plasmid and aliquots were
removed at various intervals to test the ability of E2-7a to form stable DNA adducts. E2-
7a covalently modifies DNA at a rate of 13.1 DNA adducts per plasmid per hour during
the first 6 hours (Fig 2. 1A). This rate of adduction eventually diminishes, as evident by
Figure 2.1 B. Between 6 and 24 hours E2-7a covalently modifies DNA at a much slower
rate of 3.4 adducts per plasmid per hour.
E2-7a Forms DNA Adducts with Guanine Residues. The reaction of E2-7a with DNA
was then performed on a larger scale in order to analyze the nature of the covalently
modified DNA. Full scan ESI-MS analysis of the material that eluted at 14.5 min by
HPLC (Fig 2.2A) revealed a prominent signal at m/z 813.5 (Fig 2.2B). A separate high
resolution mass spectrometric analysis (not shown) provided an m/z of 813.5051
(812.4949 calculated). Collision induced decay (CID) on the 813.5 molecular ion yielded
prominent fragment ions at m/z 662.3 and 372.1 (Fig 2.3). The 813.5 mass and the
resulting CID are consistent with a chemical structure in which one ethylene arm of the
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mustard of E2-7a is attached to guanine and the other has a substituted hydroxyl group
for the chlorine atom (Fig 2.4, left panel). As shown in Figure 2.4 (left), these ions are
consistent with the loss of the guanine fragment from the adduct (m/z 662.3) and from the
fragmentation of the proposed structure at the secondary amino group in the linker (m/z
372.1). Confirmation of these structures and of the 813.5 molecular ion resulting from an
E2-7a-Guanine adduct was provided by analysis of covalent products from a
tetradeuterated analog of E2-7a (d4-E2-7a). HPLC and ESI-MS analysis of the
hydrolysis products of d4-E2-7a under identical conditions identified a compound that
formed a molecular ion of 817.5 (a separate high resolution mass spectrometric analysis,
not shown, provided an m/z of 817.4120, 816.5200 calculated) with the same retention
time as the compound that produced the m/z 813.5 ion. This result is consistent with a
d4-E2-7a-Guanine adduct (Figure 2.4, right panel). CID on the 817.5 molecular ion
yielded fragment ions of m/z 666.5 and 372.1, indicating that the m/z 666.5 ion contained
the deuterated portion of the molecule while the m/z 372.1 did not (Fig 2.5). These
results support the proposed structure for the E2-7a-Guanine adduct and the proposed
fragmentation pattern.
The Log P of the E2-7a Derivatives Encompass a Wide Range of Values. The log P
of a compound can be predictive of aqueous solubility, absorption, and permeability
(Lipinski et al. 1997). The lipophilicity of E2-7a and its derivatives were assessed by the
HPLC method of Donovan and Pescatore (Donovan and Pescatore 2002). Prior to
settling on the HPLC methodology, computer simulations were employed in an effort to
narrow the potential log P range of our series of compounds so a suitable methodology
could be used. The structures of a series of reference compounds (including estradiol,
testosterone, progesterone, chlorambucil, and decachlorobiphenyl) (Fig 2.6) and the E2-
7a homologues (Fig 2.7) were entered into two websites, www.logP.com and
www.molinspiration.com. The reference compounds were chosen because they are
structurally related to our compounds - estradiol is the protein recognition domain and
chlorambucil is a nitrogen mustard similar to the warhead of our compounds.
Decachlorobiphenyl has the highest experimentally determined log P and was used as an
upper limit on hydrophobicity. Unfortunately, the values obtained from the websites did
not correlate well with the values published in the literature (Table 2.1) (De Bruijn et al.
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1989; Donovan and Pescatore 2002; Greig et al. 1990). In fact, the computer simulations
seemed to overestimate the log P in nearly every case.
Nonetheless, these results suggested that our compounds were relatively lipophilic
and therefore the best methodology of determining the log P of our series of compounds
was to use HPLC. The reference compounds (mentioned above) were first used to test
the HPLC methodology of Donovan and Pescatore (Donovan and Pescatore 2002). As
seen in Table 2.2 the HPLC derived log P values of the reference compounds correlated
very well with the values found in the literature. This gave confidence in the HPLC
methodology, so the log P of the neutral form of E2-7a and its derivatives were
determined using this approach. A representative HPLC chromatogram is shown in
Figure 2.8. E2-7a (11.52 min) is bracketed by toluene (8.53 min) and triphenylene
(12.72 min). The log D at pH 7.4 was estimated using an equation derived by Horvath et
al (Horvith, Meldnder, and Molndr 1977). Table 2.3 displays the log P and log D values
of the 8 compounds. In all cases the computer simulations grossly overestimated the log
P values obtained by HPLC. The log D values in Table 2.3 indicate that the aqueous
solubility of the eight compounds span approximately a 2500-fold range under
physiological conditions.
Discussion
Covalent Modification of DNA by E2-7a and Identification of Adducts by Mass
Spectrometric Analysis. The ability of E2-7a to modify DNA covalently was
investigated by incubating the compound with pGEM-7zf plasmid and removing aliquots
at various time intervals. The amount of radioactivity bound to DNA increased at an
apparent zero order rate of 13.1 adducts/plasmid/hour for the first 6 hours, indicative of
the formation of covalently bound E2-7a DNA adducts. However, between 6 and 24
hours, the rate of DNA adduction dramatically decreased to 3.4 adducts/plasmid/hour
indicating a pseudo-first order rate as the reactant, E2-7a, was consumed. This perhaps is
not surprising as the effective concentration of E2-7a would diminish over time as a
result of DNA adduct formation and decomposition (through hydrolysis) of the reactive
aniline mustard.
The clinically used nitrogen mustard, chlorambucil, has a half-life of only 18
minutes in a non-nucleophilic 0.2 M cacodylic acid solution at 37°C. The predominant
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decomposition product is the inactivation of the N,N-bis(2-chloroethyl) arms of the
mustard through hydrolysis yielding an N,N-bis(2-hydroxyethyl) substituted product
(Haapala et al. 2001). The rapid decomposition of chlorambucil is a result of an
intramolecular, rate-determining attack of the deprotonated nitrogen atom to form an
aziridinium ion intermediate followed by attack of an external nucleophile (such as
water) (Chatterji, Yeager, and Gallelli 1982; Kundu, Schullek, and Wilson 1994; Owen
and Stewart 1979). Hence, chlorambucil (and other nitrogen mustards) is a reactive
compound that decomposes rapidly in aqueous solutions and forms covalent bonds with
other nucleophiles. When chlorambucil does react with DNA, the most common stable
end product is at the N7 position of guanine (Haapala et al. 2001). It has been well-
documented in the literature that alkylating agents typically form covalent adducts with
the N7 position of guanine (and the N3 position of adenine) because of the highly
nucleophilic nature of the nitrogen atom (Roberts 1978; Singer and Grunberger 1983;
Singer and Kusmierek 1982).
Since we had shown that E2-7a is capable of adducting DNA, we investigated
whether it would act analogously to chlorambucil and predominantly adduct the N7
position of guanine. E2-7a was incubated with DNA to form covalent adducts. These
adducts were isolated and analyzed by ESI-MS. A molecular ion of 813.5 m/z was
obtained which is consistent with one arm of the nitrogen mustard adducted to guanine
and the other arm being hydroxylated. Furthermore d4-E2-7a yielded a molecular ion of
817.5 m/z with the same retention time as the 813.5 m/z and the CID of both molecules
are identical with the exception that the tetradeuterated molecule had one breakdown
product with a + 4 m/z. These ESI-MS results illustrate that E2-7a forms DNA adducts
with guanine in a similar manner as to what has previously been reported with
chlorambucil (Haapala et al. 2001).
The Partition Coefficient (log P): In an effort to predict the toxicological and
pharmacokinetic properties of a substance, Hansch and Fujita implemented a method for
correlating the lipophilicity of a molecule with biological activity (Hansch et al. 1962;
Hansch and Fujita 1964). They used a simple biphasic solution consisting of equal parts
octanol and water. A test compound is added to the solution and briefly shaken; hence
the procedure is termed the "shake-flask" method. The log P is calculated as the log of
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the ratio of the concentration of compound in the octanol phase divided by the
concentration in the aqueous phase. Octanol is now the most widely accepted reference
system because of its high correlation of physicochemical properties with biomembranes
(Leo, Hansch, and Elkins 1971; Walter, Brooks, and Fisher 1985). Despite the foresight
of Hansch and Fujita, their methodology has a major drawback: the log P of the test
compound is only accurate if it is < 5. Therefore, alternative means of determining the
partition coefficient have been established.
In an effort to estimate the log P of our compounds and focus on an experimental
methodology, computer simulation was initially incorporated to provide an initial, albeit
crude, value. Two websites were used: www.logp.com and www.molinspiration.com.
Reference compounds were chosen because they resemble the E2-7a derivatives and
have experimentally determined values: chlorambucil is a nitrogen mustard similar to the
warhead in E2-7a, estradiol is the protein recognition domain of E2-7a, progesterone and
testosterone are other steroids similar in structure to estradiol, and decachlorobiphenyl
has the highest experimentally determined log P. These compounds give a range of log P
values and are very representative of our series of compounds. Unfortunately, the
calculations for the reference compounds did not correlate very well with their
experimentally derived values (De Bruijn et al. 1989; Donovan and Pescatore 2002)
(Table 2.1). In all cases, the computer simulations resulted in higher log P values than
those determined experimentally (note the good correlation found between the literature
values and the HPLC methodology that was eventually employed, as seen in Table 2.2).
Calculated Log P values are typically estimated by the hydrophobic fragment approach of
Rekker (Rekker 1976) or by the approach of Leo and Hansch (Leo 1993; Leo et al. 1975).
Significant deviations between predicted and experimental log P values occur when the
pattern of connectivity and non-bonded intramolecular interactions are unfamiliar to the
database upon which these methodologies rely (Bodor, Gabanyi, and Wong 1989).
Neither www.molinspiration.com nor www.logp.com provided information on which
methodology they use (although molinspiration.com did indicate that their calculations
were likely to be less accurate than the CLogP program available through ACD Labs).
Despite the inherent error found in the computer calculated log P values for the
reference compounds, E2-7a and its derivatives were still entered into the websites in an
effort to provide a crude estimate of their log P. This data was then used to decide upon
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an experimental methodology. The log P of E2-7a and its derivatives were estimated to
be between 5 and 9 with the majority of the derivatives > 8 (Table 2.1). Starting with
such lipophilic compounds ruled out the traditional shake-flask method of Hansch and
Fujita. However, the slow-stir flask method was initially considered as an option. The
slow-stir method has been used to experimentally determine the log P of
decachlorobiphenyl (8.23) (De Bruijn et al. 1989). This methodology uses a small
volume of octanol (i.e. 1-50 mL) and a much larger volume of water (i.e. 950-999 mL)
buffered with 0.1 M sodium phosphate and pH adjusted to 7.4 (similar salt concentration
and pH as found in human blood). The solutions are pre-saturated in order to account for
the small mutual miscibility of the two solvents. The compound is added to the octanol
and the biphasic solution is stirred for several hours (or days) with aliquots removed until
equilibrium is reached (for highly lipophilic compounds often 3-7 days later). The log P
is calculated based on the concentration in each layer. Although this method was initially
tested, it was soon proved to be inadequate due to the large volumes that would have
been necessary to obtain a valid log P value. Additionally, it is very time consuming and
would have required extremely precise measurements of test compound concentrations.
Therefore, the HPLC method of Donovan and Pescatore was tested. The main
advantages of this method are speed, simplicity, and theoretically any log P value can be
obtained. Methanol is used as the organic mobile phase, instead of acetonitrile, because
of its hydrogen bonding capability and better correlations to traditional log P
methodologies (Cimpan et al. 1998; Cole, Dorsey, and Dill 1992). Vallat et al. have
shown that the ODP-50 columns measure the log P with good accuracy (Vallat et al.
1992) and these columns can accommodate a wide range of pH buffers (2-13). The
internal standards allowed for corrections in the subtle differences in flow-rate and
percent composition from run to run. Additionally, toluene and triphenylene are easily
monitored at 260 nm.
As shown in Table 2.2, this HPLC methodology provides accurate analysis of the
log P of a wide variety of compounds. The results in Table 2.3 illustrate the range of log
D values of the E2-7a derivatives. Three compounds, the diamide, amide, and
carbamate, have log D values of 4.85, 5.07 and 5.61 respectively. With such high log D
values it is unlikely these molecules would make good drug candidates as a result of the
likely toxicity to fat tissue and poor bioavailability. However, the diamine, E2-7a (amine
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carbamate), guanidine, amine, and amine guanidine had log D of 2.22, 2.22, 2.52, 2.87,
and 3.12, respectively, all of which could potentially be formulated for oral
administration and have favorable bioavailability.
Despite the favorable log D values obtained for many of the E2-7a derivatives,
further research is required prior to claiming to have a successful drug candidate. Our
series of molecules has been designed with two key features in mind: (1) the ability to
covalently modify DNA and (2) the ability to interact with the ER in order to inhibit the
repair of DNA adducts and to titrate the ER from its necessary cellular role as a
transcription factor. A successful drug candidate would have the ability to accomplish
both of these feats in order to achieve selective toxicity in ER expressing cells or tumors.
I have shown that E2-7a covalently modifies DNA, but, as of yet, I have not mentioned
its ability to interact with the ER. Below I shall briefly summarize the experiments
conducted by several members of the Essigmann laboratory who have shown the extent
to which the E2-7a derivatives can modify DNA, bind to the ER both free in solution and
when adducted to DNA, and achieve selective toxicity in favor of ER expressing cells. I
shall not discuss experimental detail as it can be found in Mitra, et al. and Sharma, et al.
(Mitra et al. 2002; Sharma et al. 2004). I shall however, provide a summary of the
findings, their implications and the relationship with the log D values I have determined.
Covalent modification of DNA by the E2-7a derivatives. The reactivity of each
compound with DNA was assessed by its ability to produce piperidine-labile sites in the
self complimentary deoxyoligonucleotide 5'-d(AATATTGGCCAATATT) by Bogdan
Fedeles. The results in Table 2.4, column 3 (% DNA Adduction) indicate the percent of
the oligonucleotide that was cleaved by piperidine. The diamine produced the greatest
number of DNA adducts, with 79% of the oligonucleotide cleaved by piperidine, whereas
the carbamate produced the least number of adducts with only 3% of the oligonucleotide
cleaved. Modification of the carbamate to an amido resulted in a 5-fold increase in
adduction to 14%. The presence of a cationic species within the linker tended to increase
the formation of DNA adducts, for example, adding an amine to the carbamate linker
increased the adduction by over 10-fold (carbamate 3%, amine carbamate 45%).
Additionally, the amine (44%), guanidine (58%), and the amine guanidine (29%), which
would all be cationic under experimental conditions, illustrated significant levels of
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adduction. It is likely that the presence of a cationic species within the linker would
localize the reactive alkylating group in the vicinity of nucleophilic atoms within
(anionic) DNA. A similar result has been reported for a conjugate of chlorambucil with
the polyamine spermidine (Holley et al. 1992).
Affinity of the E2-7a derivatives for the estrogen receptor. The affinity of our
compounds for the ER was assessed both when free in solution and when adducted to
DNA. Nicole Dinaut used a radiometric competitive binding assay (Pike et al. 2001)
with rabbit uterine ER to determine the RBA of each compound for the ER as compared
with estradiol (by definition the RBA of estradiol = 100%). (See Figure 2.9 for RBA
curve of E2-7a). Each of the 8 derivatives has some affinity for the ER as illustrated in
Table 2.4, column 4. The amine carbamate (E2-7a) has the highest RBA of 46 (this
means that E2-7a binds to the ER 46% as tightly as estradiol), whereas the carbamate has
the lowest (6). The amine, guanidine, diamine, and diamide also had RBA's > 28 which
is a considerable feat considering the amount of extraneous mass that is connected to the
estradiol moiety in our derivatives. Previous work by Rink, et al. implied a 6 carbon
chain was necessary to pass through the hydrophobic binding pocket of the ER active site
(Rink et al. 1996). The explanation of this result has been made clearer through work in
the Carlquist laboratory (Brzozowski et al. 1997; Pike et al. 2001; Rink et al. 1996). A
co-crystal structure using a 7a-undecylamide estradiol analog (ICI 164,384) reveals that
the positioning and orientation of the estradiol moiety of ICI 164,384 within the
hydrophobic binding cavity of the ER is directed by its 7a side chain which protrudes out
of a hydrophobic channel extending from the binding pocket. At the surface of the ER-
LBD, a 90° flexion of the undecyl chain enables the remainder of the linker to track
closely with the surface contours of the LBD (Pike et al. 2001). The low RBAs of the
amine guanidine, amide, and carbamate may result from surface interactions adopted by
the linkers in these molecules that do not permit optimal alignment of the estradiol
moiety within the binding cavity.
Using an electrophoretic gel mobility shift assay (Mitra et al. 2002), Kaushik
Mitra, Bogdan Fedeles, and Peter Rye observed that covalent DNA adducts of the amine
carbamate, amine, diamine, amine guanidine, and guanidine form complexes with the
ER-LBD (Table 2.4, column 5). The extent of complex formation generally correlated
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with the RBAs of the unreacted compounds. The exception was the amine guanidine
where virtually all of the modified oligonucleotide formed a slowly moving band, despite
its relatively low RBA of 10. We do not know the basis for this unexpected finding (see
Fig 2.10A for the gel shift produced by E2-7a). (Note: Figure 2.10A also illustrates some
control compounds, which are truncated versions of E2-7a that lack the steroid binding
domain. None of these control compounds result in a band shift indicating that the shift
observed with E2-7a is specific.)
Bob Croy confirmed the specificity of the interaction between the ER and the E2-
7ca derivatives by adding the competitor, estradiol. Under conditions that allowed
complex formation, addition of the ER to the modified oligomer resulted in the
appearance of a slowly migrating band that was eliminated by addition of excess
competitor, estradiol. Fig. 2.10 OB illustrates the competition between estradiol and an E2-
7a modified oligonucleotide. Increasing concentrations of estradiol diminishes the ability
of the E2-7a adducted oligomer to interact with the ER and result in a band shift. This
result, as well as the result with the control compounds in Fig 2.1 OA, indicates that the
interaction between the ER and our series of molecules is specific to the ability of the
molecule to interact with the ER and is not the results of other, nonspecific interactions.
Differential Toxicity towards estrogen receptor expressing cells. The lethal effects of
the E2-7a derivatives were investigated in the ER(+) MCF-7 and ER(-) MDA-MB231
breast cancer cell lines. John Marquis dosed the cells for two hours and assessed the
toxicity by a colony forming assay. Table 2.4 columns 6 and 7 indicate that many of the
modifications in the linker resulted in decreased toxicity toward both cell lines. Despite
showing reactivity toward DNA in vitro, the guanidine and amine guanidine compounds
did not show any significant toxicity at the highest dose of 20 jtM. The low toxicity of
the guanidinium-containing linkers may be related to either poor uptake by cells or their
rapid excretion once absorbed (Brown and Heim 1973). Lack of uptake by the cells may
also be responsible for the low toxicity of the carbamate, diamide, and amide compounds
that have high log D values indicative of poor absorption (Lipinski et al. 1997). Further
work is warranted in order to definitively determine if cellular uptake is indeed limiting
for these compounds.
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Future Work
The results described in this chapter have illustrated the importance of the linker
moiety of our compounds. Slight modifications in the linker, such as the addition of a
secondary amine (i.e., amine carbamate vs. carbamate), result in drastically different
biochemical properties and toxicological profiles. E2-7a was found to have an optimal
balance of properties which enabled it to have the greatest differential toxicity in favor of
ER(+) cells. Therefore, all future work targeting ER expressing cancers was conducted
with the E2-7a molecule. With the help of a great many individuals, these studies have
provided the foundation of my work.
In the next chapter, I will test the results I obtained in determining the log P and
log D values by injecting E2-7a into mice and observing the bioavailability, distribution
in tissues, acute toxicity, and ability of E2-7a to remain intact and form DNA adducts in
vivo. The subsequent chapter will address the efficacy of E2-7a as an anti-cancer agent
by treating human xenografts that have been implanted into nude mice. Finally, I will
address current evidence for the mechanism of action of E2-7a in support of the repair
shielding and transcription factor hijacking hypothesis. (Singer and Kusmierek 1982;
Tsai and O'Malley 1994)
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As previously reported, E2-7a was significantly more toxic toward MCF-7 cells
than MDA-MB231 cells (Mitra et al. 2002). The amine and diamine compounds also
showed toxicity similar to that of E2-7a (amine-carbamate) and were selectively more
toxic to the ER expressing MCF-7 cells. This result was consistent with our intended
mechanism in that these two compounds, like E2-7a, had low log D values, high RBA's,
and high reactivity with DNA. The compound with the greatest differential toxicity, E2-
7a, also had DNA adducts with the greatest affinity for the ER-LBD as assessed by the
electrophoretic gel mobility shift assay. A balance between reactivity with DNA, affinity
for the ER, and solubility seemed to confer to E2-7a optimal properties as a selectively
cytotoxic agent.
Conclusion
We have rationally designed and synthesized a series of bifunctional molecules
capable of attracting the ER and adducting DNA. Previously, we have reported on the
synthesis of a series of compounds using 2-phenyl-indole as the protein recognition
domain of our molecules (Rink et al. 1996). Using the lessons learned from those studies
we have maintained the 7a-hexanyl linker to ensure optimal binding to the ER and
transitioning out of the hydrophobic binding pocket. The work described here illustrates
the use of structure-activity relationships to further modify the linker and achieve
selective toxicity towards ER expressing cell lines. Interestingly, the parent compound,
E2-7a, seemed to contain an optimal balance of properties as it had the greatest
differential toxicity towards the ER(+) MCF-7 cells as compared to the ER(-) MDA-
MB231 cells. E2-7a ranked first in RBA, first in ability to interact with the ER when
covalently adducted to DNA, third in ability to covalently modify DNA, and had the
lowest log D which would indicate it should have good absorption. Likewise, the only
two other compounds that illustrated differential toxicity, the amine and diamine, were
also among the highest ranking compounds in each of these categories. Although no one
biochemical property clearly indicated therapeutic effectiveness, a combination and good
overall balance of them did.
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Equations used to Calculate
the Log P and Log D
log Punk = (log Ptol - log Ptriph)*tunk + ttol*log Ptriph - ttriph*log Ptol
ttol - ttriph
Equation 2.1. t is the retention time as determined by HPLC
(tol = toluene, triph = triphenylene, unk = unknown). The log P
of toluene and triphenylene were 2.61 and 6.27 respectively as
previously reported.
log D = log (P * 1 0pKa + Pi * 10PH) - og(10p Ka + 10P H)
Equation 2.2. P is the partition coefficient for the neutral
molecule (as determined by HPLC), Pi is the partition coefficient
for the ion (not measured but assumed the log Pi was 3.15 less
than the log P of the neutral molecule), Ka is the equilibrium
constant for acids.
Calculated Log P Values of Reference
Compounds and E2-7a Derivatives
Reference Compounds
Decachlorbiphenyl
Chlorambucil
Progesterone
Testosterone
Estradiol
E2-7a Derivatives
amine guanidine
monoamine
guanidine
carbamate
E2-7a (amine carbamate)
diamine
amide
diamide
molinspiration.com logP.com
9.89 8.44
3.05 3.36
4.30 3.74
3.77 3.24
4.50 3.50
molinspiration.com
8.60
9.25
8.93
8.96
9.06
8.50
9.19
9.24
Lit. IogP
8.23
-0.66
3.56
2.79-3.29
3.34-4.01
IogP.com
4.84
8.79
4.92
6.82
7.26
8.80
7.66
6.08
'Table 2.1 Comparison of the log P values obtained from the
two free website. The values obtained for the reference
compounds did not agree very well with previously published
literature values.
Note: The literature value obtained for chlorambucil was calculated by the
method of Leo and Hansch for the ionized molecule. The values for the other
reference compounds were obtained experimentally. (Leo, Hansch, and Elkins;
De Bruijn et al.;Donovan and Pescatore;Greig et al.)
-I
I
II
A Comparison of the Log P of the
Reference Compounds by Different
Methodologies
Compound
Decachlorobiphenyl
Chlorambucil
Progesterone
Testosterone
Estradiol
HPLC
LogP
7.35
1.44
3.69
2.61
3.53
Literature molinspiration.com logP.com
LogP LogP LogP
8.23 9.89 8.44
-0.66 3.05 3.36
3.56 4.30 3.24
2.79-3.29 3.77 3.24
3.34-4.01 4.50 3.50
Table 2.2 A comparison of the HPLC derived log P values with
the computer simulation and literature values. The HPLC
values corresponded to the literature values better than the
computer simulations.
I
A Comparison of the Log P of the E2-7a
Derivatives Obtained by Different
Methodologies
Compound
amine guanidine
amine
guanidine
carbamate
E2-7a (amine carbamate)
diamine
amide
diamide
HPLC IogP
6.27
5.96
5.67
5.61
5.32
5.32
5.07
4.85
HPLC IogD Molinspiration logP.com
pH 7.4 IogP logP
3.12 8.6 4.84
2.87 9.25 8.79
2.52 8.93 4.92
5.61 8.96 6.82
2.22 9.06 7.26
2.22 8.5 8.8
5.07 9.19 7.66
4.85 9.24 6.08
Table 2.3 The log P and log D values obtained for the E2-7a
derivatives. The log D values of the series span a range of
approximately 2500-fold in lipophilicity. Since blood is at the
physiological pH of 7.4, the log D values best estimate the fate
of the compounds in vivo.
-
Physical Properties of the E2-7a
Derivatives
Linker
Amine-Carbamate
Amine
Diamine
Diamide
Guanidine
Amide
Amine-Guanidine
Carbamate
Log D
2.22
2.87
3.17
4.85
2.52
5.07
3.12
5.61
% DNA
Adduction
45
44
79
39
58
14
29
3
RBA
46
40
29
29
28
13
10
6
0/ % Oligo
Shifted
93
67
38
n.d.
38
n.d.
93
n.d.
EC30 (M)
MDA-MB231 MCF-7
9.6 5.1
8.6 5.1
7.9 5.1
>20 >20
>20 >20
>20 >20
>20 >20
>20 >20
Table 2.4 Summary of the results obtained for the E2-7a
derivatives. The log D, % DNA adduction, RBA, % oligo shifted,
and the EC30 for each compound is shown.
E2-7a Forms Adducts in DNA with
Apparent Zero-Order Kinetics
0 1 2 3 4 5 6 7
Reaction Time (hr)
Fig 2.1A E2-7a forms 13.1 DNA adducts per plasmid per hour
in a seemingly linear manner.
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Fig 2.1B The rate of adduction of DNA by E2-7a slows over
time. An initial rate of 13.4 adducts per plasmid per hour over
the first 6 hours decreases to 3.4 adducts per plasmid per hour
between 6 and 24 hours.
The Identification of E2-7a DNA
Adducts
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Fig 2.2 A. HPLC chromatogram of the hydrolysis products after
E2-7a reacted with DNA. B. The ESI-MS chromatogram of the
14.5 min peak isolated by HPLC. The 813.5 m/z ion
corresponds to an E2-7a guanine monoadduct where the
second arm of the nitrogen mustard has become hydroxylated.
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Characterization of E2-7a DNA Adducts
by Collision Induced Decay Mass
Spectrometry
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Fig 2.3 A. ESI-MS analysis of the 14.5 min peak on HPLC
produces a molecular ion of 813.5 m/z. B. CID of the 813.5 m/z
ion produces two daughter ions of 372.2 m/z and 662.4 m/z.
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Structures of E2-7a Fragmentation
Pattern after Collision Induced Decay
Mass Spectrometry
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Fig 2.4 CID of the 813.5 m/z ion produced by the reaction of
E2-7a with DNA (left). d4-E2-7a was reacted with DNA and
produced a similar CID fragmentation pattern (right). The
notable difference is in the 662.4 / 666.4 m/z molecular ion in
which the latter contains the tetradeuterated linker. This result
supports the structure and fragmentation pattern proposed for
the undeuterated compound.
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Fig 2.5 A. ESI-MS analysis of the 14.5 min peak on HPLC
(after d4-E2-7a was allowed to react with DNA ) produces a
molecular ion of 817.5 m/z. B. CID of the 813.5 m/z ion
produces two daughter ions of 372.2 m/z and 666.4 m/z.
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Chemical Structures of Log P
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Fig 2.6 The chemical structures of the reference compounds
used to validate the log P values obtained by computer
simulation.
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Fig 2.7 The chemical structures for the E2-7a derivatives.
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Fig 2.8 HPLC Chromatogram of E2-7a co-injected with the Log
P standard. The peak at 8.53 min. is toluene, 11.52 min. is E2-
7a, and at 12.72 min. is triphenylene.
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Chapter 3
Probing the Biochemical Mechanisms of
E2-7a in Vivo:
Pharmacokinetics, Toxicity, and Adduct Identification
Introduction
Cytotoxic alkylating agents have been used for decades to treat cancer. While
they usually cause an initial antitumor response, they cure cancers with only modest
success. These agents, such as chlorambucil and melphalan, react with DNA in all cells,
but the majority of the adducts are readily repaired. Persistent DNA damage by
alkylating agents has lethal consequences for malignant cells (Dolan 1997; Frankfurt
1991; Hurley 2002; Teicher 1997). Therefore, inhibition of the DNA repair machinery,
specifically in cancer cells, is an attractive strategy to potentiate the therapeutic effects of
alkylating chemotherapeutics (Barret and Hill 1998; Dolan 1997). In line with this goal,
we have described the rational design of compounds capable of covalently modifying
DNA and attracting tumor specific proteins to the site of the modification (Mitra et al.
2002; Rink et al. 1996; Sharma et al. 2004).
As a proof of concept, Rink et al. linked an aniline mustard with a 2-phenylindole
moiety, which is capable of attracting the estrogen receptor (ER). The ER is an attractive
target because approximately 50% of breast cancers overexpress this protein (Ferno et al.
1990). Rink et al., were able to show that the newly synthesized molecules were capable
of forming adducts with DNA that attract the ER with modest binding affinity (Rink et al.
1996). Therefore, it is possible that in a malignant cell in which the ER is overexpressed,
a drug-DNA adduct complex could be inhibited from repair if the ER were bound tightly
to the adducted site and it shielded the repair enzymes from accessing the lesion. If the
ER were attracted to the site of adduction, an interaction between the ER and the DNA
adduct could disrupt necessary cellular signaling events since the ER is also a
transcription factor.
Subsequent synthetic work in the Essigmann Laboratory has improved the lead
compound by substituting an estradiol moiety for the 2-phenylindole, while maintaining
the key molecular characteristics of the linker that were important for the compound to
react with DNA and bind to the ER. The new compound, E2-7a, was a dramatically
improved version of 2PI since the RBA for E2-7a was 7-fold higher. In an effort to
improve E2-7a further, a series of derivatives were synthesized and evaluated as potential
new drug candidates. The results were discussed in Chapter 2. The compounds had a
varied range in affinity for the ER and differential toxicity towards ER-expressing cells.
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No new derivative was a significant improvement over E2-7a so subsequent studies were
conducted with E2-7a.
The results discussed in Chapter 2 gave us confidence in E2-7a as a potential drug
candidate because of its high RBA (46), ability to form adducts with DNA, low log D
(2.22), and differential toxicity in favor of killing the ER(+) MCF-7 cell line over the
ER(-) MDA-MB231 line. We therefore believed it was necessary to take the compound
forward by injecting it into animals and studying its pharmacological properties. E2-7a
was initially formulated in DMSO and injected intravenously (IV), but a Cremophor-EL
(CR-EL) formulation injected intraperitoneally (IP) was later shown to be superior.
(Note: CR-EL is currently part of the formulation for the clinically used Taxol
(paclitaxel) in the therapy of ovarian cancer, breast cancer, Kaposi 's sarcoma, and non-
small cell lung cancer.) The distribution in mice injected with E2-7a by either of these
vehicles will be discussed as will the pharmacokinetic parameters derived from these
studies.
Additionally, a dose range finding study was performed to address the acute
toxicity of E2-7a dissolved in the CR-EL vehicle administered IP. Blood chemistry and
hematology reports provided a means of addressing organ specific toxicity. This
information is critical in deciding upon a therapeutic dose when initiating a tumor
ablation study and in more focused monitoring of the side-effect profile of the treated
mice (to be discussed in Chapter 4). I shall also discuss the identification of E2-7a DNA
adducts isolated from tissue in vivo. These results parallel the in vitro work discussed in
Chapter 2.
Materials and Methods
Animals. Four to six week old NIH Swiss Webster mice were purchased from Charles
River Laboratories, Wilmington, MA. NIH Swiss nu/nu athymic mice (female, 25 g)
were purchased from the National Cancer Institute-Frederick Cancer Center (NCI),
(Frederick, MD). The mice were housed under standard conditions in MIT approved
facilities with 12 hour light/dark cycles and food and water ad libitum. All protocols
were performed in compliance with the regulations of the Animal Care Committee at
MIT.
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Bio-Distribution. E2-7a (25 mg/kg) spiked with 5 CCi of 14 C-E2-7a were dissolved in
50 giL of DMSO and injected IV into 25 g male NIH Swiss Webster Mice or in 50 uL of
a CR-EL based solution (43% CR-EL, 30% saline, 27% ethanol) and injected either IP or
IV. Mice were sacrificed by carbon dioxide asphyxiation at 0.25, 1, 2, 4, 6, and 24 hours
post injection. Blood was obtained by cardiac puncture. The following internal organs
were removed surgically: lung, liver, spleen, kidney, GI, feces, and in some instances
adipose, heart, and skeletal muscle. Approximately 100 mg of each tissue (10 L of
whole blood) were isolated for liquid scintillation counting. To each tissue sample was
added lmL of Solvable (Packard Biosciences, Meriden, CT) and heated to 65°C for 3
hours or until the tissue was completely dissolved. Two 100 [iL aliquots of 30%
hydrogen peroxide were added to the cooled off solution to decolorize. Approximately
15 mL of Hionic Flour scintillation fluid (Packard Biosciences, Meriden, CT), which is
compatible with Solvable, was added and counted in a Beckman LS 1801 Liquid
Scintillation Counter. The data is calculated as % injected dose per gram of tissue (%
ID/g).
Pharmacokinetic Analysis. Pharmacokinetic parameters after administration of E2-7a
were calculated by standard noncompartmental methods with GraphPad Prism version
3.00 for Windows (GraphPad Software, San Diego California USA). The area under the
blood concentration Vs time curve (AUC) was calculated by the linear trapezoidal rule.
The systemic clearance (CL) was calculated by dividing the dose by the AUC. The
volume of distribution (Vd) was calculated by dividing the dose by the extrapolated
concentration of drug in the blood at time equals zero hour. Since the drug concentration
(post-peak) declined nearly exponentially, the half-life (tl/2) was determined by nonlinear
regression analysis using a single phase exponential decay model. Cax and tax were
read directly from the data.
Plasma Analysis. Whole blood was collected by cardiac puncture from the mice after
14C-E2-7a injection. The plasma was isolated by adding two volumes of acetonitrile to
one volume of whole blood to precipitate the red blood cells and plasma proteins. The
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colloidal suspension was centrifuged for 5 min at 13,000 x G and the supernatant was
collected and dried using a speed-vac. The dried residue was reconstituted with 100 IL
of acetonitrile and injected onto a Rainin HPLC with a Rainin UV-1 UV Detector
monitored at 260 nm and an in-line Packard Flow Scintillation Analyzer Model 150TR.
The analyses were performed using a Beckman ODS 4.6 x 250 mm Ultrasphere column
eluted at 1 mL/min with a 20 min linear gradient of 50% 0.1 M ammonium acetate/10%
acetonitrile, 50% methanol to 100% methanol. Only the radioactive 14C-E2-7a parent
peak was used to determine the concentration of the compound in plasma. A 14C-E2-7a
standard was counted on a Beckman LS 1801 Liquid Scintillation Counter prior to
injection onto the HPLC. It was determined that an area under the curve (AUC) of
432,000 corresponded to 13,300 CPM.
Acute Toxicity. Groups of 3-4 NIH Swiss nu/nu athymic mice from the NCI were
injected IP with 25 - 200 mg/kg of E2-7a formulated in a CR-EL solution (43% CR-EL,
30% saline, 27% ethanol). Additionally, 4 mice were injected with the vehicle only and 4
others were left untreated as controls. The mice were sacrificed by carbon dioxide
asphyxiation 24 hours after the injection. Blood was obtained by cardiac puncture and
sent to IDEXX (formerly Tufts Veterinary Diagnostic Laboratory, North Grafton, MA)
for hematology and blood chemistry analysis.
Isolation of E2-7a DNA Adducts in Vivo. E2-7a (25 mg/kg, not radiolabeled) was
injected into NIH Swiss Webster mice by IP injection. The mice were sacrificed after 4
hours by carbon dioxide asphyxiation. The liver was removed surgically, snap frozen on
dry ice, and stored at -80°C until it could be worked up. The liver sample was thawed
and homogenized in a Dounce homogenizer on wet ice with 15 mL of cold (4°C) 0.01 M
Tris (pH 6.9), 0.25M sucrose, 2 mM calcium chloride buffer. The homogenate was
filtered through coarse and then a fine nylon mesh to remove all connective tissue. To
this solution was added 25% Triton X-100 to make a final concentration of 5%. The
solution was briefly vortexed and then centrifuged at 1000 x G in a Sorvall RC-2B
Centrifuge with a GSA rotor at 4°C for 20 min The supematant was removed by
aspiration and the nuclear pellet was resuspended in 2.5 mL of buffer. To this solution
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was added 5% sodium dodecyl sulfate (SDS) and 5 M sodium chloride (NaCl) to make a
solution with a final concentration of 1% SDS and 1 M NaCl. An equal volume of
chloroform:isoamyl alcohol (24:1) was then added and the biphasic mixture was shaken
vigorously for 15 min The mixture was then centrifuged at 7000 x G for 15 min at 4°C.
The aqueous phase was collected and re-extracted with another volume of
chloroform:isoamyl alcohol, shaken, and centrifuged. The aqueous phase was then
collected and the nucleic acids were precipitated with 3 volumes of ice cold ethanol and
chilled at -20°C for 20-30 min and subsequently pelleted by centrifugation at 7000 x G
for 15 min at 4°C. The nucleic acids were washed 2 times with cold ethanol and then
dried in vacuo. The dried pellet was reconstituted with 2 mL of 0.05 M Tris (pH 7.5), 0.1
M NaCl on ice. In order to remove any contaminating RNA, 0.5 mg of RNAse A was
added and incubated at 37°C for 10 min The reaction was stopped by cooling on ice, the
NaCl concentration was adjusted to 0.9 M, and the DNA was extracted by subsequent
additions of chloroform:isoamyl alcohol as indicated above. The aqueous phase from the
second extraction was isolated and the DNA was precipitated with 3 volumes of ice cold
ethanol, centrifuged, and washed 2 times as above. The DNA was finally hydrolyzed in
0.1 N HCl for 30 min at 70°C. The solution was then neutralized with N NaOH and
adjusted to 20 mM Tris-HCl (pH 7.4), 10% methanol. The hydrolyzed DNA was loaded
onto a C 18 Sep-Pak (Waters Co. Milford, MA) column and eluted sequentially with 10
mL of 10% and 50% aqueous methanol solutions and finally with 100% methanol. The
100% methanol fraction was reduced in vacuo and analyzed by HPLC and mass
spectrometry. HPLC analyses were performed using a Beckman ODS 4.6 x 250 mm
Ultrasphere column eluted at 1 mL/min with a 20 min linear gradient of 50% 0.1 M
ammonium acetate/10% acetonitrile, 50% methanol to 100% methanol. Aliquots of
samples obtained from HPLC fractionation were analyzed by electrospray ionization
mass spectrometry (ESI-MS) using flow injection (0.2 mL/min) in
methanol:water:acetontrile (50:45:5) in positive ion mode.
Results
Bio-Distribution and Pharmacokinetics. E2-7a was injected into mice by different
routes of administration and vehicles in an effort to obtain pharmacologically relevant
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information about the compound. Initial studies incorporated DMSO as the delivery
vehicle and the solution was administered IV. The results of the DMSO IV
administration are summarized in Table 3.1 and are reported as percent injected dose per
gram (% ID/g). The concentration of E2-7a in whole blood is illustrated in Figure 3.1
and has a peak concentration of 7.8 gtM at 15 min. E2-7a accumulated predominantly in
the lungs but also in the liver, kidneys, and spleen at the earliest time points. However,
at the 2 and 4 hour time points the majority of the drug was found in the feces, indicating
the liver as the primary metabolic route with excretion through the feces. The
significantly higher accumulation of E2-7a in the lungs over all other tissues was a matter
of concern especially considering the lungs were not the desired target organ. Therefore,
a new vehicle was investigated.
The new vehicle was formulated with 43% Cremophor-EL (CR-EL), 30% saline,
and 27% ethanol. Due to the high viscosity of the solution, a pilot experiment was
conducted to compare and contrast an IP and an IV administration. Mice were injected
by either route and sacrificed at 2 and 4 hours. The results of the pilot bio-distribution
experiment are summarized in Figure 3.2 with the quantitative results shown in Table 3.2.
The concentration of E2-7a in the lungs was significantly diminished in both the IP and
IV routes of administration. At two hours the lungs accumulated 21% ID/g with the
DMSO vehicle. In the CR-EL based vehicle, only 4% of the injected dose per gram of
tissue distributed to the lungs for the IV administration and only 1% ID/g for the IP
administration. E2-7a formulated in the CR-EL based vehicle, when injected IP or IV,
distributed to the remaining organs to a similar extent as in the DMSO based vehicle.
There were, however, some noticeable differences between the IP and IV routes
of administration with the CR-EL based vehicle. E2-7a seemed to be excreted more
rapidly when administered IV as evident by the higher concentrations found in the feces
at both the 2 and 4 hour time points. The feces contained - 15% of the ID/g tissue at
both the 2 and 4 hour time point when administered IV; however, only 3% ID/g at 2
hours and 8% ID/g at 4 hours were in the feces when E2-7a was administered IP. Not
surprisingly the GI tissue had a higher uptake with the IP administration. Interestingly,
the concentration found in the blood by either route was essentially the same.
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The similarity between the IP and IV routes did not provide an obvious optimal
means of administration. However, the addition of CR-EL to the vehicle did cause the
solution to be much more viscous; therefore, IP administration was deemed to be better
as it could be more easily incorporated into future tumor therapy experiments when the
compound would have to be administered daily. Additionally, when administered IV,
E2-7a seemed to be excreted more rapidly through the feces than when injected IP.
Since we want the drug to remain active in the body for long periods of time, the IP
administration was again considered to be slightly more favorable. A full bio-distribution
experiment was therefore performed in order to obtain more detailed pharmacological
information.
E2-7a was formulated in the CR-EL based vehicle and administered IP. The
results of this experiment are summarized in Table 3.3. The results follow a typical IP
administration profile - the organs accumulate compound over time until it is eventually
excreted. The organs with the most incorporation of E2-7a include: the liver, spleen, GI,
and kidneys. Additionally E2-7a accumulates in the feces to reach a peak concentration
of 10 - 1 1% between 4 and 6 hours. By 24 hours the majority of the compound has been
excreted. The concentration of E2-7a in whole blood and in plasma are shown in Figure
3.3A and B, respectively. The peak concentration is 39 gM in whole blood and 36 [M in
plasma, both at the 1 hour time point.
The concentration of E2-7a in whole blood was determined by liquid scintillation
counting. However, the concentration of E2-7a in plasma was conducted by precipitating
the red blood cells and proteins from the plasma and analyzing the serum only by HPLC.
The concentration of E2-7a in plasma was derived from the integration of the AUC of the
24 min peak on the HPLC. The 15 min, 1 hour, and 2 hour time points are shown in
Figure 3.4 A-C. In the 15 min and 1 hour time points the only radioactive peak that is
present corresponds to intact E2-7a. However, the 2 hour time point has a second
radioactive peak at 13 min which is likely a metabolic breakdown product. Only the
AUC of the 24 min peak was used to calculate the plasma curve shown in Figure 3.3B.
The discrepancy between the whole blood curve and the plasma curve is likely due to
protein binding, incorporation of E2-7a into erythrocytes, and metabolic products
containing the '4C atom in the vasculature.
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The pharmacological parameters of E2-7a by IV (DMSO) and by IP (CR-EL
based vehicle) administration were also calculated. Table 3.4 compares the following
pharmacological parameters by both routes of administration: AUC: area under the blood
concentration-Vs-time curve; t1/2: half-life; CL: clearance; Vd: volume of distribution;
Cmax: maximum concentration in blood; tma: time at which Cmax was achieved. As
expected the two different routes of administration and vehicles yield very different
results. Interestingly the Cmax and AUC of the IP administration is greater than that of the
IV administration.
Acute Toxicity. The acute toxicity of E2-7a was determined by injecting 3-4 NIH
Swiss Nude mice with 0-200 mg/kg of E2-7a IP. The mice were sacrificed 24 hours
post-injection and their blood was obtained for hematology and blood chemistry analysis.
The results of these findings are summarized in Table 3.5 and Table 3.6, respectively.
Values that are abnormally high or low are shown in bold and all values are expressed in
terms of measurable units with the exception of neutrophils, lymphocytes, monocytes,
and eosinophils, which are expressed in relative terms as percent of total white blood
cells. The most notable observation is that at the 200 mg/kg dose liver toxicity is evident
with elevated levels of aspartate aminotransferase (AST), alanine aminotransferase
(ALT), amylase, and lipase. Additionally the ratio of neutrophils to lymphocytes is
dramatically increased with the 200 mg/kg dose and is also somewhat evident in the 150
mg/kg dose. The dose at which 50% of the mice die (LD50) was unfortunately not
reached. Therefore the LD50 is estimated to be >> 200 mg/kg.
E2-7a Forms DNA Adducts with Guanine Residues in Vivo. E2-7a (25 mg/kg) was
injected IP into mice. The liver was harvested and homogenized in order to isolate E2-7a
DNA adducts that had formed in vivo. The DNA was isolated, hydrolyzed, and injected
onto an ESI-MS. Figure 3.5 shows the main molecular ion at 813.5 m/z. This is the
same mass as the ion observed when E2-7a was reacted with DNA in vitro as discussed
in Chapter 2. CID of the 813.5 m/z peak resulted in the same 662.4 m/z and 372.2 m/z
fragmentation as observed previously (data not shown). This gave us confidence that the
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813.5 m/z molecular ion was indeed an E2-7a-guanine adduct in which one arm had been
hydrolyzed.
Discussion
E2-7a was dissolved in DMSO and injected IV in an initial attempt to gain insight
into the pharmacological properties of the compound. The liver, kidney, and spleen
accumulated a significant fraction of the compound at the earliest time points. E2-7a
seemed to be excreted rapidly through the feces since the 2 and 4 hour time points had
significant accumulation (27 and 16% ID/g, respectively). Surprisingly, the lungs also
accumulated a significant fraction of the dose. In fact, 4-fold more E2-7a was found in
the lungs at every time point than in any other tissue (the only exception is the feces from
2-6 hours as the compound was being excreted). The reason for the high lung uptake is
was not established but warrants speculation. It is possible that the DMSO was taken up
by the blood extremely rapidly, thus causing E2-7a to aggregate and form a micelle
suspension. From the tail vein the blood is transported into the lungs for oxygenation,
and therefore E2-7a aggregates could potentially get trapped in the blood vessels
surrounding the alveoli. In general, all IV bloodborne particles >7-8 microns are
preferentially trapped in the pulmonary capillary bed. (Illum and Davis 1982; Rapp and
Bivins 1983) Another possibility is E2-7a may have partitioned into the surfactant
material (composed of mostly dipalmitoyl phosphatidyl choline and a smaller amount of
phosphatidyl glycerol and various proteins) that coats the lungs when administered in
DMSO.
Based on the undesirable effect of high accumulation of E2-7a in lung tissue, we
modified the vehicle to include 43% CR-EL, 30% saline, and 27 %ethanol. An initial
pilot experiment was performed in which we compared the IP and IV routes of
administration of E2-7a in the CR-EL formulation. Both routes of administration
displayed adequate distribution into tissues. However, one concern with the IV
administration is the rapid clearance into the feces. At the 2 and 4 hour time points, the
concentration of E2-7a in the feces was 5-fold and 2-fold higher than when administered
by the IV route. The high concentration of E2-7a in the feces and the need to move
forward with tumor ablation studies suggested the IP route of administration as being
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better. Most anticancer agents are administered IV; however, work from the Sparreboom
laboratory in Rotterdam has shown that the anticancer agent paclitaxel, when formulated
with CR-EL, has improved pharmacokinetics in patients when administered IP rather
than IV (Gelderblom et al. 2002).
E2-7a was therefore formulated in the CR-EL based vehicle and injected into
mice in order to observe a complete pharmacokinetic profile with this new vehicle. E2-
7a was distributed throughout the major internal organs with the highest accumulations in
the liver, intestines, and spleen. The accumulation in the lungs was significantly lower
than when E2-7a was formulated in DMSO (10- to 50-fold reduction at the earliest time
points). Additionally, the excretion from the feces was also reduced - from 26 to 3%
ID/g at 2 hours and 16 to 10% ID/g at 4 hours. The longer E2-7a remains in vivo, the
more likely the compound could deleteriously affect the health of a tumor.
The differences in the concentration of E2-7a in blood between the two vehicles
are also dramatically different. E2-7a reached a peak concentration (Cmax) of 8 pM at 15
min when dissolved in DMSO and injected IV. The Cmax of E2-7a when administered IP
in CR-EL was nearly 5-times greater (39 jtM) than when it was injected IV in DMSO.
Furthermore, the Cmax achieved with the CR-EL based vehicle when injected IP is 4-times
higher than the 10 tM dose necessary to kill the ER(+) MCF-7 cells in vitro (Mitra et al.
2002). The itma was at the one hour time point, implying a slow release from the CR-EL
solution. The release of E2-7a from the CR-EL solution was slow enough to produce a
> 10 M concentration in plasma for 2 hours.
The total exposure of E2-7a, as assessed by the AUC, was 7.5-fold greater when
administered using CR-EL IP. The large volume of distribution in both cases indicates
that the hydrophobicity of E2-7a results in rapid penetration into extravascular
compartments with favorable tissue kinetics. Additionally, the removal of E2-7a from
the body was 2.5-fold slower, as measured by the CL, and the tl/2 was nearly 2-times
greater when the compound was administered using the CR-EL vehicle. The increased
systemic E2-7a exposure and decreased clearance in the IP administration is likely a
result of the inclusion of CR-EL in the vehicle formulation. Paclitaxel, when formulated
with CR-EL, has a greater systemic exposure and reduced clearance when it is
administered IP versus IV. Kinetic experiments revealed that this effect is primarily
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caused by reduced cellular uptake of the drug from large spherical micellar-like structures
with a highly hydrophobic interior, which act as the principal carrier of circulating drug
(ten Tije et al. 2003). This may help explain the dramatic difference in systemic
exposure and clearance between the CR-EL and DMSO vehicles. The pharmacokinetic
parameters suggest that the CR-EL based vehicle would likely result in better tumor
ablation because the systemic exposure is much greater than that of E2-7a formulated in
DMSO and injected IV and the clearance is much less.
Additional evidence that the CR-EL formulation administered IP may be
therapeutic for the treatment of tumors stems from work on chlorambucil.
Pharmacokinetic data from Newell et al, show the t/2 of chlorambucil is 2.4 hours and
the Cma, is 40 pM when a therapeutic dose of 10 mg/kg was administered sub-
cutaneously in rats. Both the ti/2 and the Cmax are very similar to what was observed with
a 25 mg/kg dose of E2-7a (A 10 mg/kg dose of chlorambucil is 33 jimol/kg and a 25
mg/kg dose of E2-7a is 35 pmol/kg. Therefore, the dose to an animal on a mole basis is
essentially equivalent and a comparison between the compounds is straightforward).
Furthermore, the total exposure of drug is greater for E2-7a than for chlorambucil (302
Vs 22 [lg x Hr/mL) (Newell, Shepherd, and Harrap 1981). The exposure necessary for
E2-7a to be therapeutically active could be much less than what is needed for
chlorambucil if the repair shielding and transcription factor hijacking hypothesis are
valid. In either case, E2-7a would be selectively retained in tumor tissue, and therefore
potentially fewer DNA adducts would be required for tumor lethality. Additionally, the
validity of the repair shielding and transcription factor hijacking mechanisms would
suggest a greater therapeutic index for E2-7a as compared to chlorambucil, thus resulting
in a less arduous course of treatment for a patient.
Blood chemistry and hematological analyses were performed in order to assess
the acute toxicity to mice injected with increasing doses of E2-7a. No toxicity was
evident at doses below 150 mg/kg. At the 150 mg/kg dose, a slight alteration in the ratio
of lymphocytes to neutrophils was observed, such that the ratio of neutrophils increased.
Furthermore, at the 200 mg/kg dose a notable increase in the percentage of neutrophils
compared to the percentage of lymphocytes was observed. At the 200 mg/kg dose 72%
of the white blood cells were neutrophils while 25% were lymphocytes, whereas in the
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control group 80% of the white blood cells were lymphocytes and only 18% were
neutrophils. Higher neutrophil and lower lymphocyte levels indicate an active infection
(or in this case possible sensitivity to E2-7a). Despite the alteration in the ratio of
lymphocytes to neutrophils, the total number of leukocytes remained very much
unaffected. This fact is fortunate but rather surprising as many anticancer agents,
including chlorambucil, induce myelosuppression. The dose limiting toxicity of
chlorambucil is, in fact, neutropenia, or a decrease in neutrophils (Blumenreich et al.
1988). E2-7a not only does not induce myelosuppression but either stimulates
neutrophils or inhibits the proliferation of lymphocytes in order to alter their respective
ratios.
Like the hematology report, the blood chemistry profile of an acute dose of E2-7a
is largely unaffected. Again, only at the 200 mg/kg dose is any toxicity evident: ALT,
AST, amylase, and lipase are all elevated. These enzymes are all involved in liver
function and therefore an increase in the levels of these enzymes signifies hepatotoxicity.
Furthermore, blood urea nitrogen, BUN, is decreased as compared to the control mice,
again indicative of hepatotoxicity (or possibly renal toxicity). Amino acids are
catabolized by the liver to produce ammonia. The ammonia is combined to form urea,
which is transported to the kidneys for excretion. Therefore, a decreased BUN is
indicative of renal toxicity as a result of decreased urea metabolism in the liver.
Hepatotoxicity has also been documented in patients treated with chlorambucil
(Blumenreich et al. 1988).
The LD50 of E2-7a could not be determined with this experiment. All mice
survived when given an acute dose ranging from 25 to 200 mg/kg. Therefore the LD 5o is
estimated to be >> 200 mg/kg. Based on other evidence not yet discussed, I estimate the
LD5o of E2-7a after an acute dose to be approximately 300 mg/kg. (NOTE: This
evidence stems from the fact that 11 13, our compound used to target prostate cancer, is
approximately 2.5 times more toxic than E2-7a. The LD50 of 11 3 has been estimated to
be between 100 and 150 mg/kg. These data will be forthcoming in the following
chapters.)
In Chapter 2, the identification of E2-7a DNA adducts formed in vitro was
discussed. Using ESI-MS techniques, we illustrated that E2-7a covalently modified
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guanine, most likely at the N7 position. The identification of these adducts was
remarkable considering the related nitrogen mustard, chlorambucil, has a relatively short
half-life of only 18 minutes in a non-nucleophilic 0.2 M cacodylic acid solution (pH 6.8)
at 37°C (Haapala et al. 2001). The rapid decomposition of chlorambucil is a result of an
intramolecular, rate-determining attack of the unprotonated nitrogen atom to form an
aziridinium ion intermediate followed by attack of an external nucleophile (such as
water) (Chatterji, Yeager, and Gallelli 1982; Kundu, Schullek, and Wilson 1994; Owen
and Stewart 1979). Hence, chlorambucil (and other nitrogen mustards) is a reactive
compound that decomposes rapidly in aqueous solutions and forms covalent bonds with
other nucleophiles.
In blood, where the chloride ion concentration approximates 100 mM,
chlorambucil has a much longer half-life of 2.4 hours (Newell, Shepherd, and Harrap
1981). Since chlorambucil still had somewhat of a short half-life in blood, we chose the
four hour time point to look for E2-7a DNA adducts to maximize the number of adducts
that could form. We believed that 4 hours would be ample time for E2-7a to react with
DNA and hopefully it would not be entirely metabolized. The pharmacokinetic analysis
revealed that the highest amount of drug accumulated in the liver, approximately 5% ID/g
between 2 and 6 hours. Therefore, liver tissue was analyzed for the presence of DNA
adducts.
As in Chapter 2, a molecular ion with a mass of 813.5 m/z was found. This is
consistent with one arm of the nitrogen mustard adducted to guanine whereas the second
arm had been hydrolyzed. Unfortunately, there is no way of telling when the second,
non-reacting arm of the nitrogen mustard warhead underwent hydrolysis. It is possible
that the second arm remained chlorinated in vivo and only in the procedure used to isolate
the DNA adducts did the chloroethyl arm convert to hydroxyethyl. However, this may be
an unlikely scenario as the half-life of the related nitrogen mustards, chlorambucil and
melphalan, were found to be 2.4 hours and 1.5 hours, respectively, in plasma (Honess et
al. 1985; Newell, Shepherd, and Harrap 1981). Currently, we do not have any data on the
hydrolysis rate of E2-7a.
The identification of E2-7a DNA adducts in vivo is extremely encouraging even
though the adducts were found in non-target tissue. This data illustrates that E2-7a can
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be injected into a mouse, distribute throughout the body, and form DNA adducts while
remaining intact. The repair shielding and transcription factor hijacking hypotheses
require E2-7a to form DNA adducts in target tissues and attract tumor specific proteins.
In non-target tissues, we expect the adducts to be repaired since the tissue would lack the
tumor specific protein for which the molecule was designed to attract. Therefore, the
formation of DNA adducts in non-target tissues is expected and in this case it serves as an
illustration of the robustness of the molecule: E2-7a was administered to mice,
distributed throughout the body, remained intact, and covalently modified DNA.
Conclusion
E2-7a has previously been shown to contain properties favorable to our intended
mechanisms of action: it has a high RBA (46) for the ER, it is capable of covalently
modifying DNA, its log D (2.22) indicates it should have favorable pharmacokinetics,
and it displays differential toxicity in favor of killing the ER(+) MCF-7 cell line over
ER(-) MDA-MB231 line (Mitra et al. 2002; Sharma et al. 2004). These results have been
described in Chapter 2. Based on its log D and other properties making it an attractive
chemotherapeutic agent, we have continued to investigate the compound by monitoring
its in vivo pharmacokinetics, acute toxicity, and ability to adduct DNA and remain intact.
E2-7a, when formulated with a CR-EL based vehicle and injected IP, illustrates
good overall distribution into tissues. At 25 mg/kg, the peak plasma concentration was
39 ptM (4-fold higher than what was necessary to kill ER(+) MCF-7 cells in culture) and
remained greater than 10 [tM for 2 hours. The AUC, Cma,,, CL, and tl/2 with the CR-EL
vehicle are more favorable as compared to the DMSO based vehicle injected IV. The
DMSO vehicle suffered from drawbacks such as high lung uptake, quicker clearance and
lower systemic exposure. Therefore, the CR-EL based vehicle was used for addressing
the acute toxicity of E2-7a. Very little toxicity was evident until the dose reached 200
mg/kg. At this dose, moderate liver toxicity was evident as was an elevated level of
neutrophils as compared to lymphocytes. The LD 50 was not established as all mice
survived the 24 hour period after the injection. Finally, E2-7a was shown to be capable
of remaining intact and forming DNA adducts in liver tissue. The DNA adducts
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identified were the same as those found in vitro and described in Chapter 2: a mono-
guanine adduct with the other arm of the nitrogen mustard having undergone hydrolysis.
In summary, these results further support the notion of E2-7a as a potential drug
candidate. Following the encouraging pharmacokinetic results, we have continued to use
the CR-EL based vehicle for tumor ablation studies. Chapter 4 will describe the
effectiveness of E2-7a as an anticancer agent using xenograft animal models. I shall also
quantify the penetrance of E2-7a into xenograft tumor tissue and describe the toxicity to
mice after a therapeutic dose of E2-7a.
Future Work
CR-EL has provided us with a means of administering E2-7a into mice.
However, it is by no means an ideal delivery vehicle. The literature is inundated with
reports on the toxic side effects of CR-EL. A number of studies have reported that CR-
EL induced side effects such as hypersensitivity, neurotoxicity, nephrotoxicity, and the
extraction of plasticizers from intravenous infusion lines (Cheon et al. 2003; Gregory and
DeLisa 1993; Mazzo et al. 1997; Onetto et al. 1993). Nonetheless, the anticancer agent
Taxol (paclitaxel) continues to use a vehicle containing CR-EL, although the side effects
are now diminished with various pretreatments. Despite the continued use of Taxol with
CR-EL in the treatment of patients with cancer, the scientific community realizes that a
need exists to eliminate CR-EL from the current formulation. This is the subject of many
articles and reviews (Gelderblom et al. 2002; Singla, Garg, and Aggarwal 2002; ten Tije
et al. 2003).
We also acknowledge the limitations of CR-EL, especially with such a high
concentration (43%) in our vehicle. In this effort we have begun a collaboration with the
Sasisekharan Laboratory at MIT in an effort to formulate E2-7a using liposomes. We
have conducted a pilot experiment in which we injected a liposomal solution of our other
compound, 11 3, into two mice. Blood was taken for several hours and worked up to
show that the liposomes circulate in plasma for a considerable period of time. In fact, as
much as 80% of the drug was still circulating in blood 24 hours later. Unfortunately, a
full bio-distribution experiment was not able to confirm these results. The most likely
reason was the lipids had oxidized and the liposomes were unstable at injection and
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unable to transport our molecule effectively. However, this joint effort is ongoing and we
anticipate promising results in the near future. If a suitable alternative delivery agent
cannot be found, it is possible to continue the use with CR-EL since Taxol is formulated
as a concentrated solution of 6 mg per mL of CR-EL:dehydrated ethanol (1:1 v/v) which
must be further diluted 5 to 20-fold with saline prior to IV administration (Goldspiel
1994).
Any new delivery agent would have to undergo the same rigorous experiments,
described in this chapter, as the current vehicle: bio-distribution, pharmacokinetic
analysis, and acute toxicity. However, the work here sets a foundation for which
alternative delivery agents can be judged.
Even though the LD50 of E2-7a using the CR-EL based vehicle was not reached, I
believe it to be in the best interest of this researcher to delay repeating these experiments
until such a time as a more clinically relevant vehicle can be used. For now, the best
guess is that E2-7a will have an LD50 of approximately 300 mg/kg.
Finally, Charles Morton and I have begun work using human liver microsomes to
address the metabolic fate of E2-7a. Initial experiments have not provided much useful
information; however, a recent search of the literature indicates that we may have been
using too much drug for the assay and thus saturated the system. We are confident that in
the near future we will be able to identify the metabolites of E2-7a and also the P450s
likely responsible for its breakdown.
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Distribution of E2-7a in Mouse
Tissue with a DMSO Based Vehicle
Tissue 0.25 hr 1 hr 2 hr 4 hr 6 hr 24 hr
Blood 0.90 ± 0.22
Lung 43.3 + 13.2
Liver 11.8 1.3
Spleen 2.71 ± 0.9
Kidney 3.84 ± 1.06
GI 0.82 0.41
Feces 0.69 0.43
Adipose 0.31 ± 0.09
0.83 0 0.19+0.12
53.8 0 21.9 15.9
14.3+0 5.79+2.1
3.21 0 1.41 0.24
5.4+0 2.27± 0.78
0.38 0 0.58 0.06
1.16+0 26.5+22.7
0.18 ± 0 0.2 ± 0.11
0.46 ± 0.22
14.26 ± 0.2
4.24 ± 0.47
1.70 ± 0.20
2.06 ± 0.39
0.99 ± 0.13
16.2 ± 0.9
0.19 0.05
0.31 0.26
4.31 0.99
0.58 ± 0.08
0.20 0.07
0.44 ± 0.16
0.17 0.06
2.68 + 0.33
0.15 +0.00
0.41 0.16
2.63 ± 0.32
1.19 ± 0.02
0.75 ± 0.03
0.18 + 0.04
0.52 0.14
0.04 0 0.10 0.02
Mice were
dissolved in DMSO.
injected IV with 5 pCi of 14 C-E2-7a
They were sacrificed at 0.25, 1, 2,
4, 6, or 24 hours after the injection. The results are
reported as the mean percent injected dose per gram (of
each organ) + standard deviation.
Table 3.1
Pilot Bio-Distribution of E2-7a using a
New Cremophor Based Vehicle
Tissue 2 Hr. IV 2 Hr. IP 4 Hr. IV 4 Hr. IP
0.6 ± 0.1
1.29 0.48
4.17 + 0.74
5.51 1.23
1.91 + 0.22
3.78 0.86
1.41 + 0.62
15.97 6.22
0.58 ± 0.1
0.4 ± 0.18
0.31 ± 0.07
1.07 ± 0.32
3.3 ± 0.11
2.84 + 0.72
1.44 ± 0.25
4.25 + 0.42
2.7 ± 2.23
0.4 ± 0.19
0.34 ± 0.03
0.42 ± 0.23
2.59 ± 0.98
2.45 ± 0.42
0.89 ± 0.27
1.92 + 0.7
0.98 ± 0.39
14.82 8.68
0.44 + 0.4
0.19 0
0.34 ± 0.12
1.35 ± 0.46
2.95 ± 0.97
2.46 + 0.3
1.55 ± 0.43
4.23 + 2.59
8.02 + 0.36
0.19 1
Table 3.2 Mice were injected either IP or IV with 5 Ci
of 1 4 C-E2-7a dissolved in 43% CR-EL, 30% saline, 27%
ethanol. They were sacrificed at either 2 or 4 hours after
the injection. The results are reported as the mean
percent injected dose per gram (of each organ) +
standard deviation.
Blood
Heart
Lung
Liver
Spleen
Kidney
GI
Feces
Muscle
Bio-Distribution of E2-7a in Mouse
Tissue using a Cremophor Based
Vehicle
Tissue 0.25 hr 1 hr 2 hr 4 hr 6 hr 24 hr
1.48 ± 0
0.28 + 0.08
1.06 ± 0.24
3.99 ± 0.39
3.91 + 0.82
1.36 + 0.09
2.44 ± 0.7
0.79 + 0.48
0.29 ± 0.14
0.82+0
0.68 ± 0.17
1.79 ± 0.31
5.84 ± 1.06
4.77 + 1.11
2.01 ± 0.12
5.22 ± 1.31
2.6 + 0.64
0.25 ± 0.14
0.86 +0
0.48 ± 0.09
1.74 + 0.55
4.93 + 0.9
4.42 ± 0.23
2.49 + 0.19
4.06 ± 0.99
9.87 ± 1.16
0.17 ± 0.05
0.89 ± +0
0.51
1.99
4.03
3.93
2.39
4.45
11.4
0.16
± 0.17
± 0.35
+ 1.33
± 0.29
+ 0.89
±+ 1.51
+ 3.28
± 0.04
0.3± +0
0.29 ± 0.21
1.58 ± 0.39
1.86 ± 0.13
2.16 ± 0.3
0.97 ± 0.17
2.03 ± 0.62
1.75 ± 0.31
0.09 + 0.01
Table 3.3 Mice were injected IP with 5 pCi of 1 4C-E2-7a
dissolved in 43 % CR-EL, 30 % saline, 27 % ethanol.
They were sacrificed at 0.25,1, 2, 4, 6, or 24 hours after
the injection. The results are reported as the mean
percent injected dose per gram (of each organ) +
standard deviation.
Blood
Heart
Lung
Liver
Spleen
Kidney
GI
Feces
Muscle
0.6± +0
0.11+0
0.36 ± 0
2.4± 0
1.2 0
0.48 ± 0
2.05 ± 0
1.02 ± 0
0.22 ± 0
E2-7a has Better Pharmacokinetics
when Formulated with CR-EL
Parameter DMSO IV CR-EL IP
AUCa
t1/2b (hr)
CLC (mL/hr)
Vdd (L/kg)
C
t
max (pM)
maxf (hr)
40
2.4
15.6
4.4
7.9
0.25
302
4.4
6.2
2.7
38.7
1
Pharmacokinetic parameters following the
administration of E2-7a by two different routes of
administration: IV with DMSO as the vehicle or IP with a
CR-EL based vehicle. a area under the blood
concentration-Vs-time curve, b half-life, clearance,
d volume of distribution, e maximum concentration in
blood, f time at which Cmax was achieved.
(pg x hr/mL)
Table 3.4
Acute Toxicity of E2-7a:
Hematology
Control Vehicle 25 mg/kg 50 mg/kg 75 mg/kg 100 mg/kg 150 mg/kg 200 mg/kg Taconic
Test N=4 N=3 N=3 N=4 N=4 N=4 N=4 N=4 Nude
WBC (xmm3 ) 7.3 6.1 9.5 4.8 5.3 5.2 5.9 6.6 4.3-13.5
RBC (x 106 mm 3) 10.1 10.2 9.8 9.2 9.6 9.9 10.1 8.5 6.9-8.52
Hgb (g/dL) 15.2 15.4 15.1 14.2 14.5 14.5 14.6 12.9 7.5-15.2
HCT (%) 55.1 56.0 52.1 49.4 51.4 53.8 53.8 48.1 39.4-43.5
Neutrophils (%) 17.5 27.3 17.7 32.5 25.3 26.3 46.8 71.5 7.0-39
Lymphs (%) 80.0 70.3 78.7 64.8 71.0 71.3 51.5 25.0 56-92
Monos (%) 1.0 2.3 3.0 1.3 1.3 1.7 2.0 2.0 0-7
Eos (%) 1.0 0.7 1.5 1.0 1.0 1.0 1.0 0-4
Platelets(103/pL) 1138.3 1257.3 977.3 963.3 1037.8 1126.7 875.0 948.8 790-1014
MCV (fL) 54.8 55.0 53.1 53.5 46.8 54.6 53.1 56.4 51.1-53.4
MCH (pg) 15.1 15.1 15.5 15.4 15.2 14.8 14.5 15.2 17.6-19.1
MCHC (g/dL) 27.7 27.4 29.0 28.9 28.4 27.1 27.2 27.2 34.3-36.1
Table 3.5 Hematology report for mice injected with E2-
7a. Values in bold represent abnormally elevated or
suppressed levels. Only the ratio of neutrophils to
lymphocytes is altered at the highest dose of 200 mg/kg.
(Note: Since the test groups contained relatively few mice, the abnormal levels are
deviations from the normal range and do not necessarily reflect statistical
significance.)
Acute Toxicity of E2-7a:
Blood Chemistry
Control Vehicle 25 mg/kg 50 mg/kg 75 mg/kg 100 mg/kg 150 mg/kg 200 mg/kg Taconic
Test N = 4 N = 3 N = 3 N = 4 N = 4 N = 4 N = 4 N = 4 Nude
Alk. Phosphatase (IU/L) 136 137 140 134 122 113 102 97 96-117
ALT (SGPT) (IU/L) 45 57 65 34 35 54 52 1011
AST (SGOT) (IU/L) 186 136 126 96 117 110 167 1337 61-119
CK (IU/L) 814 527 412 323 493 279 681 313
GGT (IU/L) 0.3 0.0 0.0 0.0 0.8 0.5 0.0 0.0
Albumin (g/dL) 3.4 3.6 3.5 3.4 3.3 3.4 3.4 3.1 3.44.1
Total Protein (g/dL) 5.3 5.5 5.6 5.5 5.4 5.5 5.6 4.9 4.8-5.6
Globulin (g/dL) 1.9 1.9 2.1 2.1 2.1 2.1 2.3 1.8 1.1-1.6
Total Bilirubin (mg/dL) 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.2 0.3-0.8
Direct Bilirubin (mg/dL) 0.1 0.1 0.0 0.0 0.0 0.1 0.1 0.1
BUN (mg/dL) 23.5 26.7 26.7 25.3 25.5 22.0 23.8 14.0 30-37
Creatinine (mg/dL) 0.2 0.3 0.3 0.4 0.3 0.3 0.3 0.2 0.5-0.7
Cholesterol (mg/dL) 143 141 133 121 125 132 127 127.0 116-155
Glucose (mg/dL) 237 314 278 267 187 212 197 167.7 173-288
Calcium (mg/dL) 10.6 11.7 11.5 11.3 10.7 10.9 11.2 11.1 10.0-12.0
Phosphorous (mg/dL) 10.4 11.9 11.4 10.6 9.4 11.2 10.7 11.6 12.3-16.1
Bicarbonate (m Eq/L) 28.8 24.7 26.7 28.3 29.3 30.5 28.3 40.0
Chloride (mEq/L) 106 103 106 106 109 108 107 100.3 118-124
Potassium (mEq/L) 9.7 11.7 10.7 10.3 8.3 10.1 9.9 7.8 13.8-16.7
Sodium (mEq/L) 153 154 153 152 155 152 153 154.7 157-163
A/G Ratio 1.8 1.9 1.6 1.7 1.6 1.6 1.5 1.8
B/C Ratio 103.4 68.3 87.8 72.2 80.0 80.0
Indirect Bilirubin (mg/dL) 0.0 0.0 0.1 0.2 0.1 0.1 0.1 0.1
Na/K Ratio 16.3 13.0 15.0 15.0 18.5 15.0 16.3 19.7
Anion Gap (mEq/L) 27.8 33.5 31.3 28.0 24.8 23.8 28.3 22.0
Amylase (IU/L) 1283 1518 1303 1357 1203 1287 1682 7275
Lipase (IU/L) 79 80 106 140 107 191 490 2977
Table 3.6 Blood Chemistry report for mice injected with
E2-7a. Values in bold represent abnormally elevated or
suppressed levels. Slight evidence of liver toxicity is
observed with elevated levels of liver enzymes,
including: ALT, AST, amylase, and lipase.
(Note: Since the test groups contained relatively few mice, the abnormal levels are
deviations from the normal range and do not necessarily reflect statistical
significance.)
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Fig 3.1 Concentration of E2-7a in whole blood after an
IV administration of the compound dissolved in DMSO.
The peak concentration is 7.8 pM.
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Clearance of E2-7a from Blood and
Plasma after Administration with
Cremophor-EL Based Vehicle
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Fig 3.3 Clearance of E2-7a from Blood (A) and Plasma
(B). E2-7a was administered to mice and the
concentration in whole blood and plasma was
determined. The peak concentration is 39 pM in whole
blood and 36 pM in plasma, both at one hour.
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Intact E2-7a is the Major Radioactive
Product in Mouse Plasma
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Fig 3.4 HPLC traces of intact E2-7a in plasma A. 15 min B. 1
hour C. 2 hour. Plasma was isolated from whole blood,
precipitated with acetonitrile and injected onto HPLC. The peak
at 24 min is intact E2-7a. The peak at 13 min in 3C is probably
a metabolic breakdown product.
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E2-7a Forms DNA Adducts in
Mouse Liver Tissue
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E2-7a DNA adduct isolated from the liver of a
The same 813.5 m/z molecular ion is evident as
was seen in the in vitro adduction experiments discussed
in Chapter 2.
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Chapter 4
Probing the Biochemical Mechanisms of
E2-7a in Vivo:
Efficacy against ER(+) Tumors, DNA Adduct Levels
and Chronic Toxicity
Introduction
Breast cancer is the most frequently diagnosed malignancy among women in the
US, accounting for 30% of all cancers diagnosed, (Greenlee et al. 2000) with an
incidence of 135 cases per 100,000 women and a death rate of 27.7 per 100,000 women
(Weir et al. 2003). Despite increased mammography screening and new genomics-based
drugs, such as Herceptin, an estimated 40,000 women will have died from breast cancer
in 2004 (according to the American Cancer Society's statistics for 2003-2004). Most
women are treated with a combination of surgery and an adjuvant therapy such as
radiation, hormone therapy, or chemotherapy. The decision to use chemotherapy or
hormone therapy depends on the presence or absence of the estrogen receptor (ER) in the
primary tumor. Approximately half of breast cancers overexpress the ER (Ferno et al.
1990). The anti-estrogens, tamoxifen and raloxifene, reduce the incidence of cancer
relapse in ER expressing tumors and can even delay or prevent the development of breast
cancer in women at high risk (Peto and Mack 2000). These compounds antagonize the
effects of estrogen and therefore put tumor cells into a state of stasis, which can
eventually lead to apoptosis (Lerner and Jordan 1990; Obrero, Yu, and Shapiro 2002).
Hormonal therapy can be extended over long periods in which the ER(+) tumors are often
held in check. However, the long term effectiveness of such therapies is complicated by
the development of hormone resistant breast cancer (HRBC) (Katzenellenbogen 1991)
and possible secondary carcinogenesis (Jordan 1995; Osborne et al. 1996). Additionally,
ovarian tumors that express the ER do not respond well to endocrine therapy. Therefore,
a need exists for more effective agents to target ovarian tumors and HRBC.
Clinicians have used a combination of agents that act by different biological
mechanisms in order to overcome the resistance to front-line agents used to treat breast
cancer. Hundreds of clinical trials have illustrated the additional therapeutic benefit of
treating patients with combinations of drugs, instead of a single agent, for breast cancer
treatment (Hortobagyi 1998). Another strategy is the design of a chemotherapeutic with
additional built-in mechanisms to disrupt cellular signaling and transcriptional events
necessary for growth and proliferation. We have reported on the design, synthesis, and
biological properties of novel molecules that are capable of attacking a cancer cell by
several mechanisms. These molecules consist of a DNA damaging warhead that can
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covalently adduct DNA, as many conventional alkylating chemotherapeutics, and a
ligand binding domain that can attract proteins found predominantly in a cancer cell. We
have utilized the overexpression of the ER in many breast cancers (and in HRBC), by
designing an agent that links a DNA damaging agent to an estradiol moiety capable of
attracting the ER to the site of DNA damage. A DNA-adduct-ER complex could
potentially inhibit repair enzymes from accessing the lesion, resulting in persistence of
the adduct and eventually cell death. Furthermore, the ER is a transcription factor and a
high binding affinity to the DNA-adduct could titrate the ER from necessary cellular
transcriptional events, again resulting in cell death. These two mechanisms, DNA repair
shielding and transcription factor hijacking, would produce lethal results for a cancer cell.
In Chapter 2, described the biological properties of our current lead compound,
E2-7a. E2-7a has a high RBA for the ER (46), is capable of forming DNA adducts with
a high affinity for the ER, has a low log D (2.22), and displays differential toxicity in
favor of killing the ER(+) MCF-7 cell line over the ER (-) MDA-MB23 1 line (Mitra et al.
2002; Sharma et al. 2004). In Chapter 3, I described the pharmacokinetics of E2-7a in
two different vehicles, one of which was shown to be superior. Furthermore, the acute
toxicity of E2-7a in the cremophor-EL (CR-EL) based vehicle was shown to be very
moderate, and the identification of E2-7a DNA adducts isolated from liver tissue
indicated that the compound could remain intact and alkylate DNA.
The results from these experiments have given us confidence in our compound
and the methodology used to administer the compound to mice. This chapter will
therefore describe the efficacy of E2-7a as a treatment for ER(+) HeLa xenografts
implanted into mice. Furthermore, the toxicity to mice following the tumor therapy study
will also be discussed. Finally, the results of studies focusing on quantifying the number
of DNA adducts formed after a therapeutic dose of E2-7a in tumor tissue will also be
discussed.
Through a collaboration with the Tannenbaum laboratory at MIT, I have
employed the use of accelerator mass spectrometry (AMS) to quantify the number of
DNA adducts found in tissue samples following administration of E2-7a into mice.
Since this methodology is relatively new and only 200 articles were found on the topic in
a recent PubMed search (half of which pertained to biological applications), I believe this
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methodology requires a brief introduction. AMS has been used for the last 30 years but
predominantly for radiocarbon dating of archaeological samples based on their 14 C: 2C or
14C:13C ratios. However, more recently its use has been expanded to the biomedical
arena where it can detect many isotopes at the attomole level (Vogel et al. 1995; Vogel et
al. 2001; Williams et al. 2002). This level of sensitivity can be achieved by measuring
long-lived, rare isotopes of low natural abundance: 3 H, 0°Be, 14C, 2 6A1, 36C1, 4 1 Ca, and 129I
(Turteltaub and Vogel 2000).
For biological applications, the most commonly used isotope is 14C since drugs
are often radiolabeled for metabolic and disposition analysis. The main advantage of
AMS over scintillation counting is the extremely high sensitivity - radioactivity as low as
0.0001 dpm (decays per minute) have been reported (Garner 2000) (this contrasts to 100
decays per minute by traditional scintillation counting). This sensitivity is achieved
through the use of mass spectrometers rather than the detection of individual radioactive
decay events as current scintillation counting technology utilizes. Quantification of 14C
in a sample generally involves the conversion of the sample to graphite prior to the
introduction into the ion source. However, the AMS in the Tannenbaum lab uses a
slightly different technology in which the sample is combusted using a laser as a heat
source and copper oxide as an accelerant. See Figure 4.1. One of the advantages of this
approach is that the step of converting the sample to graphite in a slow and time
consuming manner is eliminated. Furthermore, this approach theoretically can be linked
to an HPLC for in-line analysis of metabolites in blood samples and, since the sample
loading only requires the pipetting of the sample onto a disc, this process could be easily
automated (Liberman et al. 2004).
The sample is volatilized by the laser and converted to atomic species that are
then introduced into a negative ion mass analyzer. See Figure 4.2. The negative ion
source removes 14N as a contaminant. A low energy mass analyzer isolates masses of 14
amu, and a Van de Graf accelerator with a foil stripper converts the negatively charged
ions to positively charged species. A second mass analyzer then isolates molecular ions
with a mass of 14 amu and a charge of +2, i.e. 14C2+.
Figure 4.3 depicts a representative data trace of a sample subject to AMS analysis.
In this case '4C-E2-7a was administered to a mouse and its liver was isolated,
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homogenized, and then analyzed by AMS. The homogenate was diluted 500-, 2,000-, or
10,000-fold in an effort to determine the lower detection limit. 14 C-BSA of a known
specific activity was used as a standard. The samples were loaded onto a disc that rotates
clockwise in the sample chamber, and each sample is spotted in duplicate or triplicate
with approximately 5° of rotational separation between each sample; therefore, a peak is
observed every time 14C from the sample is detected. The area under each peak
correlates to the amount of 14C in each sample. The results illustrate that the AMS is
capable of detecting the 60 counts per minute (CPM) in the homogenate even when the
sample is diluted 10,000-fold. By contrast, a traditional liquid scintillation counter has a
limit of detection near 60 CPM. The AMS is, therefore, at least 10,000 times more
sensitive than traditional liquid scintillation counting. A high concentration of 2C
content in a sample interferes with the detection of 4C and consequently the sensitivity of
AMS can be much greater than what was seen here with a crude liver homogenate
sample.
The power of AMS is only now being recognized and the technique is finding its
way into a diverse array of biological applications. Studies have been published using the
technology for the quantification of drug in blood samples using levels of radioactivity
that are lower than what is mandated by law to report. AMS technology has also been
used in the detection of covalently modified protein or DNA samples by drugs or their
reactive metabolites (Turteltaub and Dingley 1998). Furthermore, AMS technology can
be used to image ligand binding in tissue samples and isotopes other than 14C, such as
41Ca and 26A1, can be used in biological tracing studies. Further information on the
applications of AMS to biochemistry, pharmacology, toxicology, and nutritional sciences
can be found in several reviews (Garner 2000; Ross et al. 2004; Turteltaub and Vogel
2000; White and Brown 2004).
Materials and Methods
Animals. Four to six week old NIH Swiss nu/nu athymic mice (25g) were purchased
from the National Cancer Institute-Frederick Cancer Center (NCI), (Frederick, MD). The
mice were housed under standard conditions in MIT approved facilities with 12 hour
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light/dark cycles and food and water ad libitum. All protocols were performed in
compliance with the regulations of the Animal Care Committee at MIT.
Cell Culture. The human cervical cancer cell line, HeLa, was obtained from the
American Type Culture Collection (Rockville, MD). The cell line was maintained in
DMEM with glutamax (Gibco) supplemented with 10% fetal bovine serum in a
humidified C0 2/air atmosphere at 37°C. HeLa cells were stably transfected with the
human ER-ligand binding domain (ER-LBD) by John Marquis and Peter Rye using the
Becton Dickinson Biosciences (Clontech) Tet-Off gene expression system. When the
cells were used for injection into mice, the cells were grown in a P-150 plate to 50-70%
confluence. The cells were trypsinized, washed, and pelleted.
Tumor Therapy. ER-LBD (+) HeLa cells were collected and suspended in 50% saline,
50% Matrigel (Becton Dickinson, Franklin Lakes, NJ) and diluted to a concentration of
10 X 106 cells/mL. A 0.25 mL aliquot of the cell suspension was injected into the right
hind flank of each mouse. Therapy commenced when a palpable tumor of approximately
5 x 5 mm formed (5-7 days for HeLa cells). E2-7a was formulated in 43% CR-EL, 30%
saline, and 27% ethanol and administered either IP at a dose of 75 mg/kg or sub-
cutaneously (Sub-Q) at a dose of 25 mg/kg. Sub-Q doses were injected adjacent to the
tumor and not directly into the tissue. Chlorambucil was also formulated in 43% CR-EL,
30% saline, and 27% ethanol but injected at a dose of 15 mg/kg. The vehicle controls
consisted of only 43% CR-EL, 30% saline, and 27% ethanol Tumor dimensions were
measured five times per week with vernier calipers. Tumor volumes were calculated
using the formula of an ellipse: a/6 x (smaller diameter)2 x larger diameter. Statistical
analyses were performed using a paired t-test. The mice were treated with 3 cycles of 5
days on and 2 days off.
Assessment of Chronic Exposure of E2-7a. At the end of the HeLa tumor therapy
study, mice were euthanized by CO2 asphyxiation. Blood was obtained by cardiac
puncture and sent to IDEXX (formerly Tufts Veterinary Diagnostic Laboratory, North
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Grafton, MA) for hematology and blood chemistry analysis in order to assess the chronic
toxicity to the mice.
Quantification of DNA Adducts in Tissue. Approximately 400,000 counts per minute
(CPM) of 1 4C-E2-7a were injected into NIH Swiss nu/nu mice with HeLa xenografts by
either IP or Sub-Q injection. The mice injected IP were given a dose of 75 mg/kg and the
Sub-Q group was injected with a 25 mg/kg dose (these doses are the same as what was
used for the tumor therapy study). The mice were sacrificed after 4 hours by carbon
dioxide asphyxiation. The liver was surgically removed, snap frozen on dry ice, and
stored at -80°C until it could be processed further. The liver and tumor samples were
thawed and homogenized in a Dounce homogenizer on wet ice with 15 mL of cold (4°C)
0.01M Tris (pH 6.9), 0.25M sucrose, 2 mM calcium chloride buffer. The homogenate
was filtered through coarse and then a fine nylon mesh to remove all connective tissue.
25% Triton X-100 was added to make a final concentration of 5%. The solution was
briefly vortexed and then centrifuged at 1 OOOG in a Sorvall RC-2B Centrifuge with a
GSA rotor at 4°C for 20 min. The supernatant was removed by aspiration and the nuclear
pellet was resuspended in 2.5 mL of buffer. To this solution was added 5% sodium
dodecyl sulfate (SDS) and 5 M sodium chloride (NaCl) to make a solution with a final
concentration of 1% SDS and 1 M NaC1. An equal volume of chloroform:isoamyl
alcohol (24:1) was then added and the biphasic mixture was shaken vigorously for 15
min. The mixture was centrifuged at 7000G for 15 min at 4°C, and the aqueous phase
was collected, re-extracted with another volume of chloroform:isoamyl alcohol, shaken,
and centrifuged. The aqueous phase was then collected and the nucleic acids were
precipitated with 3 volumes of ice cold ethanol and chilled at -20°C for 20-30 min and
subsequently pelleted by centrifugation at 7000G for 15 min at 4°C. The nucleic acids
were washed 2 times with cold ethanol and then dried in vacuo. The dried pellet was
reconstituted with 2 mL of 0.05 M Tris (pH 7.5), 0.1 M NaCl on ice. In order to remove
any contaminating RNA, 0.5 mg of RNAse A was added and incubated at 37°C for 10
min. The reaction was stopped by cooling on ice, the NaCl concentration was adjusted to
0.9 M, and the DNA was extracted by subsequent additions of chloroform:isoamyl
alcohol as indicated above. The aqueous phase from the second extraction was isolated
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and the DNA was precipitated with 3 volumes of ice cold ethanol, centrifuged, and
washed 2 times as above. The DNA was then given to Paul Skipper and Rosa Liberman,
both in the Tannenbaum laboratory at MIT, for analysis by AMS as described in
Liberman, et al. (Liberman et al. 2004).
Results
E2-7a Inhibits the Growth of HeLa Xenografts. E2-7a was administered to mice
containing HeLa xenografts to assess its potential as a chemotherapeutic agent. Figure
4.4 shows the results of the treatment of the mice after 3 weekly, 5 day cycles of 75
mg/kg administered IP and Figure 4.5 shows representative mice from each group.
Figure 4.6 shows the results of mice treated with 25 mg/kg administered Sub-Q. As
evident in the graph, E2-7a had a significant effect on the xenografts (P=0.0003 and
0.0030, respectively) as it inhibited their growth by 70% as assessed on the final day of
the study (mean tumor volume of treated versus mean tumor volume of the control on
day 18). The dose was well tolerated as evident by the modest weight loss of 10% in the
IP treated group (Fig 4.7) and 0% in the Sub-Q group. These data indicate that E2-7a
inhibits the growth of the HeLa xenografts and this therapeutic dose is well tolerated by
the mice.
Chlorambucil was administered to mice in order to gauge the efficacy of E2-7a
against a proven chemotherapeutic. As in the previous results, E2-7a inhibited the
growth of the HeLa xenografts but to a slightly lesser extent, 40% as assessed on the last
day of therapy. Chlorambucil, however, actually induced a reduction in the size of the
tumor by approximately 50% (inhibited the growth of the tumor by 83 %). See Figure
4.8. Despite the therapeutic benefit in the shrinking of the HeLa xenograft, chlorambucil
was almost two-fold more toxic to the mice than E2-7a as indicated by the nearly 20%
reduction in body weight. Mice treated with E2-7a lost only 10% of their body weight.
See Figure 4.9.
Chronic Doses of E2-7a are Well Tolerated by Mice. Following the administration of
3 cycles of E2-7a, mice were sacrificed in order to assess the toxicity after chronic
exposure to the compound. Weight loss was limited to 10% in IP treated animals and 0%
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in the Sub-Q treated mice. Mice treated with the lower Sub-Q dose of E2-7a showed no
differential toxicity as compared to the Sub-Q vehicle group and therefore will not be
discussed further. The results from the hematology and blood chemistry reports for the
mice injected with 75 mg/kg of E2-7a or vehicle alone via IP injection are shown in
Tables 4.1 and 4.2, respectively. Slight leukopenia was evident in mice treated with 75
mg/kg E2-7a IP - a reduction in white blood cells from 6.9 to 3.9 (x mm3 ) as compared
to the tumor bearing mice. The IP vehicle group also saw a moderate reduction in white
blood cells to an average of 5.4 (x mm3 ). Additionally, an alteration in the ratio of
neutrophils to lymphocytes was observed in the E2-7a treated group such that the
percentage of neutrophils increased as compared to the percentage of lymphocytes.
Creatinine kinase (CK), an indicator of muscle and cardiac toxicity, was elevated slightly
in all mice bearing a tumor and is therefore unlikely to be related to E2-7a toxicity.
Finally, aspartate aminotransferase (AST) and alkaline phosphatase were slightly
elevated in the treated and vehicle control groups and is unlikely to be related to E2-7a
toxicity. Overall, the toxic profile of a 75 mg/kg dose of E2-7a administered IP was
extremely moderate.
E2-7a Forms DNA Adducts in Tumor and Liver Tissue. HeLa xenograft mice were
injected with '4C-E2-7a either Sub-Q with a 25 mg/kg dose or IP with a 75 mg/kg dose.
The mice were sacrificed four hours following administration of the compound, the liver
and tumor tissue was surgically removed, and the DNA was isolated in order to quantify
the number of DNA adducts per cell. Figure 4.10 illustrates the number of DNA adducts
formed per tumor or liver cell by either route of administration. Even though the Sub-Q
dose was 3-fold lower than the IP dose, twice as many adducts formed in tumor cells
when E2-7a was administered Sub-Q (16,000 Vs 7,500 adducts per cell). Not
surprisingly, the number of DNA adducts formed in liver tissue was greater when the
compound was administered IP than when injected Sub-Q (13,000 Vs 3,000 adducts per
cell).
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Discussion
In the previous two chapters, I described several experiments indicating the
potential of E2-7a to be an effective anticancer agent in the treatment of ER(+) cancers.
E2-7a has a low log D, differential toxicity in favor of an ER(+) MCF-7 cell line over an
ER(-) MDA-MB231 cell line, favorable pharmacokinetics and a low toxicity profile at
doses as high as 200 mg/kg. Furthermore, DNA adducts were isolated from liver tissue,
indicating that the compound remains intact and is not rapidly degraded by metabolic
processes prior to reaching its intended target. These results prompted further research in
assessing the chemotherapeutic value of E2-7a.
Although we had previously used the ER(+) MCF-7 cell line in culture and
showed excellent ER-selective cytotoxicity, we decided not to use these cells because
they require an estradiol pellet in order for the cells to grow into tumors. Based on our
hypothesized mechanisms, we reasoned that high levels of estrogen could titrate away the
activity of E2-7a. Therefore, we decided to proceed with an ER-LBD-expressing HeLa
cell line that was designed in our laboratory. These cells are not dependent on estradiol
for growth.
The ability of E2-7a to inhibit the growth of ER-LBD (+) HeLa xenografts in
nude mice was therefore addressed. Mice were treated with E2-7a at a dose of 75 mg/kg
injected IP or 25 mg/kg injected Sub-Q for 3 cycles of 5 days on and 2 days off. HeLa
cells are a rapidly growing cell line and xenograft tumors are apparent as early as 5 days
after inoculation of 3 x 106 cells. The Sub-Q dose of 25 mg/kg inhibited the growth of
ER(+) HeLa xenografts by 81% whereas the IP dose of 75 mg/kg inhibited the growth by
72%, as compared to the control groups on the 18th day of therapy. This result illustrates
that much of the dose when administered IP does not distribute to the tumor. The
rationale in the design of our molecules, however, is such that we expect the compound
to distribute throughout the body, but selective retention could occur in the tumor because
of the presence of the ER and its high affinity for E2-7a. Therefore, we do not
necessarily require a large fraction of the dose to reach the tumor. Nevertheless, we
would want to use as low of a dose as possible when treating patients to minimize toxic
side effects to the patient and to minimize the costs associated with the therapy both to
the patient and to the manufacturer.
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The poor distribution of E2-7a to tumor tissue could also be a reason why the
growth inhibition of ER-LBD HeLa xenografts by chlorambucil was so much more
effective than E2-7a. Chlorambucil shrank the tumors after only 11 days of therapy
while E2-7a inhibited their growth but did not actually shrink them. In Chapter 2, I
reported the log P of chlorambucil (1.44 by HPLC but -0.66 in other literature reports)
(Greig et al. 1990) and E2-7a (5.32). Even though E2-7a would likely be ionized under
physiological conditions, the log P clearly illustrates that chlorambucil is much more
water soluble than E2-7a. Therefore, one of the possible reasons why chlorambucil was
more effective in shrinking the growth of the ER-LBD (+) HeLa xenografts was
increased distribution to the tumor as a result of its increased water solubility.
Despite the increased efficacy of chlorambucil in treating the xenografts, toxicity
to the mice was much greater than when E2-7a was administered. In fact, chlorambucil
was 2-fold more toxic than E2-7a as assessed by the percent of weight loss during the
therapy. Overall, E2-7a is well tolerated by mice injected with a 75 mg/kg therapeutic
dose administered IP. Weight loss was limited to less than 10% in all mice treated with 2
or 3 cycles of E2-7a. The dose limiting toxicity for tumor ablation therapy could be
leukopenia since the white blood cell level dropped from 6.9 (x mm3) to 3.9 (x mm3),
although the normal mouse range provided by Taconic is as low as 4.3 (x mm3 ). This
fact is not surprising as many anticancer agents, including chlorambucil, induce
myelosuppression. The dose limiting toxicity of chlorambucil is, in fact, neutropenia, or
a decrease in neutrophils (Blumenreich et al. 1988). As in the acute dose of E2-7a, the
ratio of neutrophils to lymphocytes is altered such that the percent of neutrophils
increases as compared to the percent lymphocytes. The alteration seen here, however, is
to a much greater extent. The elevation of neutrophils and suppression of lymphocytes is
commonly the result of an active infection.
Alternatively, the elevation of neutrophils and suppression of lymphocytes may
indicate that E2-7a is interacting with the glucocorticoid receptor (GR). The GR is a
member of the same class of nuclear hormone receptors as the ER and AR.
Corticosteroids, the natural ligands for the GR, have profound effects on lymphocytes
and neutrophils. Corticosteroids actually induce the apoptosis of lymphocytes, (Di et al.
2000; Negoescu et al. 1998) whereas they inhibit the death of neutrophils in vitro (Cox
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and Austin 1997; Liles et al. 1996). The mechanisms by which human lymphocyte and
neutrophil apoptotic responses to glucocorticoids differ are unknown. However,
glucocorticoid action is mediated through the GR and therefore these apoptotic
differences may arise from downstream targets of the GR (O'Malley 1971; Strickland et
al. 2001; Wenzel et al. 1997). An off-target interaction of E2-7a with the GR may
mediate the alteration of the neutrophil to lymphocyte ratio.
The blood chemistry profile after chronic administration of E2-7a is also
extremely mild. CK is elevated in all tumor bearing mice and therefore the increased
levels are unlikely related to the compound or the vehicle. AST and alkaline phosphatase
were both slightly elevated in the treated and vehicle control groups. These enzymes are
typically elevated in cases of hepatotoxicity. However, the levels are only slightly
elevated, and the fact that these enzymes are elevated in both the treated and control
groups eliminates the possibility of E2-7a induced toxicity.
The toxicity in the mice is likely a result of the formation of DNA adducts in non-
target tissues (Bank 1992; Fox and Scott 1980; van Zeeland 1996). Nitrogen mustards
elicit their mechanism of action by the alkylation of DNA. They are capable of
producing a number of different DNA adducts, the majority of which are monoadducts as
a result of a single alkylation event. A small proportion of monoadducts then go on to
form crosslinks as a result of a second alkylation (Kundu, Schullek, and Wilson 1994;
Povirk and Shuker 1994; Sunters et al. 1992). The formation of crosslinks between the
2 strands of DNA, interstrand crosslinking, is considered to be a critical event, and there
is clear evidence that their formation and subsequent persistence correlates with in vitro
cytotoxicity (O'Connor and Kohn 1990; Sunters et al. 1992). The two main reasons for
the low abundance of the toxic cross-link adducts are a slower rate of alkylation for the
second arm of a nitrogen mustard (Gould, Nixon, and Tilby 2004; Ross, Ewig, and Kohn
1978) and a comparatively quick rate of repair of a monoadduct. Compounds such as
chlorambucil and melphalan form a critical number of adducts so as to saturate the repair
capacity of a cell and thus result in lethal effects to a tumor cell. A potential advantage of
E2-7a is its ability to attract the ER. An association between the ER and an E2-7a
monoadduct could provide more time for the formation of a cross-link and thus render an
E2-7a monoadduct more toxic than a monoadduct from other nitrogen mustards.
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We incorporated AMS in an effort to quantify DNA adducts after therapeutic
doses of E2-7a. We determined the number of adducts formed after a 75 mg/kg IP dose
was approximately half of a 25 mg/kg Sub-Q dose (7,500 and 16,000 adducts per cell,
respectively). The level of adduction seen here with E2-7a is much less than what has
been reported previously for a patient with plasma cell leukemia treated with high doses
of melphalan. In the tumor cells of this patient, 160,000 melphalan-DNA adducts formed
after a therapeutic dose (Tilby et al. 1993). This number is at least 10-fold higher than
what was observed in HeLa xenografts treated with E2-7a, also at a therapeutically
beneficial level. Although it is somewhat difficult to compare directly two different
compounds (with different pharmacokinetics and aqueous solubility) in two different cell
types, such a drastic difference in DNA adduct burden may imply mechanism(s) other
than saturation of the DNA repair machinery may play a role in the cytotoxicity of E2-7a.
Until such a time as a direct comparison of DNA adduct levels achieved by doses of
melphalan and E2-7a in the same cell type can be made, speculation on additional
mechanisms, related or unrelated to DNA alkylation, is futile at best. One possibility,
however, is the repair shielding hypothesis by which we designed E2-7a. Since the HeLa
cells only contain the ER-LBD, the transcription factor hijacking hypothesis cannot be
valid in this cell line as the LBD alone can not induce transcription.
Conclusion
In previous chapters, I have discussed many of the properties suggesting that E2-
7a could act as a chemotherapeutic agent - high affinity for the ER, differential toxicity
in favor of killing ER expressing cell lines, and favorable pharmacokinetics. Here I have
described experiments indicating that E2-7a can inhibit the growth of ER(+) HeLa
xenografts in mice by as much as 82%. Furthermore, following the administration of an
IP dose of 75 mg/kg, the mice lost only 10% of their body weight and showed essentially
no signs of organ specific toxicity. This illustrates that the dose is very well tolerated and
possibly even higher doses could be administered in order to achieve better tumor
inhibition. Finally, the results of the AMS experiment illustrated that 10-15,000 DNA
adducts formed in the HeLa xenografts 4 hours after the administration of 14C-E2-7a.
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These adduct levels are substantially lower than what has been previously reported with
other compounds and may implicate the repair shielding hypothesis.
Future Work
As discussed in the future directions section of Chapter 3, there is an acute need
for a new delivery vehicle. The results here illustrate a dose much lower than 75 mg/kg
can be effective provided that more of the dose accesses the tumor - a 3-fold lower dose
of E2-7a was actually more effective in inhibiting the growth of the ER(+) HeLa
xenografts as a result of administering the compound by a different route of injection
(Sub-Q). The results from this chapter further illustrate the necessity in exploring new
formulation options. Upon obtaining a new vehicle, tumor therapy and chronic toxicity
experiments would need to be completed. However, the work here is a foundation for
which subsequent vehicles can be judged.
The results obtained with both the acute (Chapter 3) and chronic toxicity
experiments reveal an interesting phenomenon with respect to the ratio of neutrophils to
lymphocytes. In both toxicity experiments, the percent of white blood cells that were
neutrophils increased as compared to the percent that were lymphocytes. One possible
explanation involves the glucocorticoid receptor. If the GR has an affinity for the
estradiol moiety of E2-7a, it may be possible that the compound is acting as a
corticosteroid resulting in the induction of apoptosis in lymphocyte cells and the
stimulation of neutrophil proliferation. One way to address this issue is to obtain an RBA
for the GR. Additionally, lymphocytes and neutrophils in culture could be exposed to
E2-7a in order to monitor an induction of apoptosis and increased proliferation. Since
E2-7a is a reactive nitrogen mustard and may actually be toxic to both cell lines because
of its DNA damaging properties, a "defanged" version could be made by replacing the
chloride atoms with hydroxyl or methoxy substituents. These unreactive molecules
would not be able to damage DNA and therefore may be capable of stimulating
neutrophil proliferation.
John Marquis and Peter Rye have constructed an ER-LBD-expressing HeLa cell
line using the tet-off expression system. These cells were designed with the hope that
E2-7a would be more toxic to the ER-LBD-expressing HeLa cells than to the ones
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containing an empty vector. Unfortunately, E2-7a is equitoxic to both cell lines in
culture and when implanted as xenografts (data not shown). Western blot analysis has
illustrated that the ER-LBD is indeed present and ligand binding experiments using
whole cell extracts from the ER-LBD-expressing HeLa cells indicate the protein is
capable of binding estradiol at levels similar to what has been seen with the full length
protein. Despite this evidence, the repair shielding hypothesis is not necessarily ruled out
as a potential contributing mechanism for E2-7a induced cytotoxicity. Under normal
circumstances, ligand binding would induce conformational changes that would allow the
ER to dimerize and attract coactivators (Klinge et al. 1997; Ylikomi et al. 1998). The
truncated version of the protein in HeLa cells may not be of sufficient size to shield DNA
adducts from repair enzymes. Furthermore, the ER-LBD does not contain the DNA
binding domain or the transcriptional activation region which are necessary for the
initiation of transcription. Therefore, any cytotoxic contribution from transcription factor
hijacking would be absent in the ER-LBD HeLa cells.
Ideally an isogenic cell line containing the full length ER would be used in order
to assess any differential toxicity in response to E2-7a. One such cell line has been
described by Jiang and Jordan. Using MDA-MB231 cells, these researchers have derived
isogenic clones with the ER (MDA-S30) and without the ER (MDA-1OA). The growth
of the S30 cells were found to be inhibited by estradiol at concentrations as low as 10'-1
M and prolonged the doubling time of the culture by 2.5 fold at this concentration.
Estradiol had no effect on the MDA-1OA clone, however (Jiang and Jordan 1992). Since
E2-7a contains an estradiol moiety and the concentrations currently used to treat cells in
culture are 105 fold higher, it likely would inhibit the growth of the S30 line as a result of
the same surprising antagonistic properties as was seen with estradiol. Therefore, it
would be impossible to parse out repair shielding and transcription factor hijacking
effects with these cells. Other cell lines have also been transfected with the ER - Chinese
hamster ovary (Kushner et al. 1990), HeLa (Maminta, Molteni, and Rosen 1991; Touitou,
Mathieu, and Rochefort 1990), and osteosarcoma (Watts, Parker, and King 1989) - but in
all cases estradiol has an inhibitory effect on cell growth.
In lieu of this research, we have decided the best option is to test the efficacy of
E2-7a in other ER expressing cell lines. Towards this end we have initiated a
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collaboration with the Tyler Jacks Laboratory at MIT. Daniela Dinelescu, et al. recently
described their work in the cover article of Nature Medicine. They have designed an (ER
expressing) endometrioid ovarian adenocarcinoma mouse model based on the activation
of a K-ras oncogenic allele. This model induces invasive and widely metastatic
endometrioid ovarian adenocarcinomas with complete penetrance and a disease latency of
only 7 weeks. This ovarian cancer model recapitulates the specific tumor
histomorphology and metastatic potential of the human disease (Dinulescu et al. 2005).
We will be working closely with Dinelescu in testing our compounds in her model.
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E2-7a Shows Minimal Toxic Side
Effects as Assessed by Hematology
Profile after Tumor Ablation Therapy
Test
WBC (xmm 3)
RBC (x 106 m m 3)
Hgb (g/dL)
HCT (%)
Neutrophils (%)
Lymphs (%)
Monos (%)
Eos (%)
Platelets (1 03/pL)
MCV (fL)
MCH (pg)
MCHC (g/dL)
IP
N=3
3.9 0.9
8 + 0.6
12.3 + 0.6
44.4 + 0.5
90.5 0.7
9+ 1.4
1 +0
871 + 106
55.8 + 3.4
15.5 ± 0.4
27.7 ± 1
IP Vehicle
N=3
5.4 + 2.1
9.6 ± 0.3
14.3 ± 0.8
51.7 ± 2.7
46 ± 5.2
52 ± 3.5
3+0
1142 + 92
45.1 16.9
15 ± 0.4
27.7 ± 0.1
Tumor Ave
N=4
6.9 + 1.6
8.3 ± 2.1
9.3 ± 2.4
45.1 + 10.3
41.5 ± 11.8
58 ±+ 12.1
934 ± 542
54.4 + 3.6
11.2 ± 2
20.6 + 2.5
Norm. Ave
N=4
5.4 ± 0.4
9.3 ± 0.8
11.3 ± 0.3
50.6 ± 3.3
42 + 8.3
57.8 ± 7.8
1101
54.3
12.2
22.4
± 372
+ 1.3
+ 0.9
+ 1.1
Taconic
Nude
4.3-13.5
6.9-8.52
7.5-15.2
39.4-43.5
0.04-0.68
0-0.19
790-1014
51.1-53.4
17.6-19.1
34.3-36.1
Table 4.1 Hematology report for mice injected with E2-7a .
Values in bold represent abnormally elevated or suppressed
levels. The most notable toxicity is leukopenia. Additionally the
ratio of neutrophils to lymphocytes is altered in the IP treated
group.
(Note: Since the test groups contained relatively few mice, the abnormal levels are
deviations from the normal range and do not necessarily reflect statistical
significance.)
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E2-7a Shows Minimal Toxic Side Effects as
Assessed by Blood Chemistry Profile after
Tumor Ablation Therapy
Test
Alk. Phosphatase (IU/L)
ALT (SGPT) (IU/L)
AST (SGOT) (U/L)
CK (U/L)
GGT (IU/L)
Albumin (g/dL)
Total Protein (g/dL)
Globulin (g/dL)
Total Bilirubin (mg/dL)
Direct Bilirubin (mg/dL)
BUN (mg/dL)
C(reatinine (mg/dL)
(Cholesterol (mg/dL)
Glucose (mg/dL)
Calcium (mg/dL)
Phosphorous (mg/dL)
Bicarbonate (mEq/L)
Chloride (mEq/L)
Potassium (mEq/L)
Sodium (mEq/L)
A/G Ratio
B/C Ratio
Indirect Bilirubin (mg/dL)
Na/K Ratio
Anion Gap (mEq/L)
Amylase (IU/L)
Lipase (IU/L)
IP
N=3
95± 17
29 ± 8
171 + 79
462 + 334
1.0 ± 1.0
2.7 0.2
4.7 ± 0.3
2 ± 0.1
0.1 ±0
0 ± 0.1
24.3 ± 0.6
0.2 O0
90 9
195 ± 32
10.1 0.3
8.6 ± 1.7
26 ± 4.4
113 2
11.8 ±4.3
155 ± 6
1.4 ± 0.1
122 ± 3
0.1 ±0.1
14.3 ± 4.7
27.7 ± 4.7
1458 ± 362
129 ± 122
IP Vehicle
N=3
389 + 72
55+ 11
150 + 118
606 + 505
1.3 ± 1.2
3.2 ± 0.2
5.5 ± 0.5
2.3 ± 0.3
0.1 +0
0 0
19.3 + 4.2
0.2 ± 0.1
99 11
234 + 10
10 1.7
9.3 ± 1.8
26.7 4.5
92 + 22
8.1 +2.8
132 ± 29
1.4 ± 0.1
87 ± 31
0.1 i0
16.7 3.1
21 ± 13.1
1155 372
73 ± 5
Tumor Ave
N=4
58 18
36 10
112 ± 46
722 + 411
1.8 ± 0.5
2.8 ± 0.7
5 ± 0.6
2.3 ± 0.1
0.2 ± O0
0.1 ± 0.1
20 ± 34.7
0.3 ± 0.1
215 ± 187
238 ± 31
10.5 ± 0.4
6.4 ± 0.9
28 ± 2.4
108 ± 2
6.7 1
152 ± 3
1.3 0.3
79.2 ± 22.4
0±0
23.8 ± 4.3
21.3 0.5
Norm. Ave
N=4
65 ± 8
26 ± 7
64 ± 22
184 ± 146
2 0
2.9 + 0.1
5.4 ± 0.3
2.6 ± 0.2
0.1 ±0.1
0 ± 0.1
18.8 ± 2.2
0.3 ± 0.1
133 ± 11
253 ± 13
10.5 0.5
9.5 ± 1.8
28.3 ± 2.2
108 ± 1
7 ± 0.7
153 ± 2
1.1 ±0.1
69.6 ± 12
0 0
22.3 ± 2.1
24 ± 4.2
1283 ± 180
79± 19
Table 4.2 Blood Chemistry report for mice injected with E2-7a.
Values in bold represent abnormally elevated or suppressed
levels. E2-7a is very well tolerated by the mice.
(Note: Since the test groups contained relatively few mice, the abnormal levels are
deviations from the normal range and do not necessarily reflect statistical
significance.)
Taconic
Nude
96-117
61-119
3.4-4.1
4.8-5.6
1.1-1.6
0.3-0.8
30-37
0.5-0.7
116-155
173-288
10.0-12.0
12.3-16.1
118-124
13.8-16.7
157-163
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Accelerator Mass Spectrometry:
Sample Loading
1 pL sample
C
Laser He and
SampleHe
(in)
To the
Sample
Chamber
Fig 4.1 AMS sample loading and conversion to molecular ions.
Sample is pipetted onto a ceramic disc containing copper oxide
(CuO). A high powered laser combusts the sample, using CuO
as an accelerant, converting the sample into molecular ions.
These ions are then passed into the negative ion source seen
in Fig 4.2.
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Accelerator Mass Spectrometry:
Sample Combustion to 14C2+
Detection
Tandem Accelerator
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Fig 4.2 Schematic of an Accelerator Mass Spectrometer. The
sample is introduced into the negative ion source through the
He line following combustion, eliminating 14N as a contaminant
in 14C analysis. A low energy mass analyzer isolates molecular
ions of 14 m/z. These negatively charged carbon ions are
accelerated by a tandem Van De Graff accelerator and the
valence electrons are stripped resulting in positively charged
carbon ions. A second high energy mass spectrometer isolates
ions with the correct charge and energy, in this case 14C2+.
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AMS is >10,000-Fold More Sensitive
than Traditional Scintillation Counting
7000
6000
5000
4000
3000
2000
1000
0 100 200 300 400 500
Time (sec)
Dilution Disc 1 Disc 2 Average
52.4 ± 1.6
64.5 + 7.3
67.8 1.8
59.5 + 8.3
69.9 2.5
65.5 7.7
56.5 + 7.0
67.2 + 5.7
66.9 5.7
Fig 4.3 Liver homogenate for a 14C E2-7a treated mouse. The
cellular homogenate was loaded onto a disc after several dilutions
(500-10,000-fold). BSA was used as a standard. The peak area is
related to the concentration of 14C. Normalized CPM (to take into
account the dilution factors) are in the table. Sixty CPM is near
background for our scintillation counter. AMS is therefore at least
-10,000 times more sensitive than traditional scintillation counting.
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E2-7a Inhibits the Growth of HeLa
Xenografts when Administered
Intraperitoneally
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Fig 4.4 E2-7a therapy of HeLa xenografts in mice. Groups of 5
mice were injected IP with 75 mg/kg of E2-7a () or vehicle only
(o). The vehicle was 43% Cremophor-EL, 30% saline, 27%
ethanol. Error bars are the standard deviation of the mean and a
paired t-test provided a P= 0.0003. The gray bars indicate days
of treatment.
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HeLa Xenograft Bearing Mice Treated
with E2-7a have Smaller Tumors than
Mice Treated with Vehicle Alone
A
B
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Fig 4.5 Pictures of HeLa xenograft bearing NIH
mice. A. A mouse treated IP with 3 cycles of 75
B. A mouse treated with vehicle alone.
Swiss Nude
mg/kg E2-7a.
E2-7a Inhibits the Growth of HeLa
Xenografts when Administered Sub-
Cutaneously
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Fig 4.6 E2-7a therapy of HeLa xenografts in mice. Groups of
5 mice were injected Sub-Q with 25 mg/kg of E2-7a () or
vehicle only (o). The vehicle was 43% Cremophor-EL, 30%
saline, 27% ethanol. The injection was proximal to, but not
directly into, the tumor. Error bars are the standard deviation
of the mean and a paired t-test provided a P= 0.0030. The
gray bars indicate days of treatment.
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E2-7a is Well Tolerated by Mice Treated
with 75 mg/kg Intraperitoneally
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Fig 4.7 Percent change in mouse body weight after E2-7a
therapy of HeLa xenografts in mice. Groups of 5 mice were
injected IP with 75 mg/kg of E2-7a () or vehicle only (o ). The
vehicle was 43% Cremophor-EL, 30% saline, 27% ethanol. The
treated mice lost approximately 10% of their body weight after
three cycles of therapy.
Comparison of Chlorambucil and E2-7a
Against HeLa Xenografts
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Fig 4.8 Percent change in tumor volume after IP injections of
E2-7a (A), chlorambucil (), or vehicle alone (). Error bars
are the standard deviation of the mean and a paired t-test
provided a P< 0.006 for both chlorambucil and E2-7a as
compared to the vehicle group. The gray bars indicate days of
treatment.
Chlorambucil is Two-Fold More Toxic
than E2-7a as Assessed by Weight
Loss in Mice
10
.Ocm
3
.C
a)
a)
a)
0L_
0
-10
-20
0 3 6 9
Days of Therapy
Fig 4.9 Percent change in mouse body weight after IP
injections of E2-7a (), chlorambucil (), or vehicle alone
(*). The treated mice lost approximately 10% of their body
weight after two cycles of therapy.
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E2-7a Readily Forms Adducts with DNA
in Mouse Liver and Tumor Tissue
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Fig 4.10 Number of DNA adducts per cell in tumor and liver
tissue by AMS analysis. Mice were injected with 25 mg/kg 14C-
E2-7a Sub-Q () or 75 mg/kg IP (D). They were sacrificed
4 hours after administration of the compound. More adducts
formed in tumor tissue with the Sub-Q route of administration
despite the fact that it was a 3-fold lower dose. Errors bars are
the standard deviation of the mean.
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Chapter 5
The Repair of E2-7a DNA Adducts and
Implications into Mechanism
Introduction
DNA alkylating agents represent one class of anticancer agents, but nitrogen
mustard compounds, such as chlorambucil and melphalan, have only modest success in
the clinic and their uses have been mainly limited to therapies of hematological cancers.
These agents achieve their cytotoxicity by forming covalent adducts with DNA (Hurley
2002; Teicher 1997). Unfortunately, patients on these chemotherapies often suffer from
serious side effects, with neutropenia being dose limiting, as a result of the formation of
DNA adducts in non-target tissues (Blumenreich et al. 1988; Inoue et al. 1987). By
inhibiting the DNA repair machinery selectively in cancer cells, a clinician could increase
the therapeutic index of the alkylating agents and provide a better outcome for the patient
with fewer toxic side effects (Barret and Hill 1998; Dolan 1997; Frankfurt 1991).
An additional way to improve the therapeutic outcome for a patient is by using an
alkylating agent in combination with other agents that act by different mechanisms.
Many clinical trials have illustrated the additional therapeutic benefit of combination
drug therapies over the use of single agents for breast cancer treatment (Hortobagyi
1998). Rather than using several drugs in combination, we have set out to design a single
agent that can simultaneously function by several different mechanisms. Our compounds
are designed to disrupt DNA repair processes and cellular signaling and transcriptional
events that are necessary for cell growth and proliferation.
The molecules that we have designed consist of a DNA damaging warhead that
can form covalent adducts with DNA, like many conventional alkylating
chemotherapeutics. They additionally have a ligand binding domain that can attract
proteins found predominantly in a cancer cell. We have utilized the fact that the estrogen
receptor (ER) is over expressed in many breast cancers (Ferno et al. 1990) by designing
an agent that links a DNA damaging agent to an estradiol moiety capable of attracting the
ER to the site of DNA damage. A DNA-adduct-ER complex could potentially inhibit
repair enzymes from accessing the lesion, resulting in persistence of the adduct and
eventual cell death. This mechanism would be selective to ER-expressing breast cancer
cells because other cells of the body would not contain high levels of the ER.
Furthermore, the ER is a transcription factor, so a high binding affinity to the DNA-
adduct could titrate the ER from necessary cellular transcriptional events, again resulting
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in cell death. These two mechanisms, DNA repair shielding and transcription factor
hijacking, could produce lethal results for a cancer cell. Rink, et al. rationally designed a
molecule that could exert its cytotoxic potential by the combination of these mechanisms
(Rink et al. 1996).
A second derivative, E2-7a, was later synthesized and shown to have better
affinity for the ER, as well as increased toxicity to ER(+) cells, than the molecules
designed by Rink (Mitra et al. 2002). In the previous chapters, I have described many
experiments by which E2-7a and a series of derivatives function (Mitra et al. 2002;
Sharma et al. 2004). The evidence presented illustrates that the compound binds the ER
with good affinity, adducts DNA, is selectively more toxic to cells expressing the ER,
and is therapeutically effective in an ER(+) xenograft mouse model. Many of these
experiments suggest the possibility that the repair shielding and, possibly, the
transcription factor hijacking mechanisms play a role in the cytotoxicity of the
compound. Here, however, I shall present more direct evidence in support of the repair
shielding phenomenon using the AMS technology I described in the previous chapter.
Furthermore, I have used a biochemical whole cell extract assay to characterize the repair
pathway by which E2-7a-DNA adducts are likely repaired.
Materials and Methods
Preparation of Plasmid DNA Substrates Containing Damage. pGEM plasmid DNA
was randomly modified by UV or E2-7a. UV damaged pGEM DNA was prepared by
irradiating DNA at a concentration of 50 pg/mL in 20 pL droplets with 450 J/m2 of UV
light (254 nm). The irradiated DNA was treated with the E. coli Nth protein
(endonuclease III) (New England Biolabs, Beverly, MA) to remove pyrimidine hydrates
(which produce background nicking and are a substrate for base excision repair) at 37°C
for 30 min, heated at 65°C for 2 min, and then subjected to sucrose banding for the
isolation of super coiled plasmid (see below). The pGEM plasmid DNA was also
allowed to react with 100 jiM E2-7a in TE (10 mM Tris-Cl, 1 mM EDTA) buffer (pH
7.5), at 37°C for 1 hour. After drug modification, unreacted drug molecules were
removed by phenol/chloroform extraction followed by ethanol precipitation. The DNA
pellet was dissolved in TE at a concentration of 500 pg/mL and then layered on top of a
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12 mL sucrose gradient containing 5-20% sucrose in 1.0 M NaCi, 5 mM EDTA, 25 mM
Tris-HCl (pH 7.5). The gradient was centrifuged at 4°C for 21 hours at 31,000 rpm in a
Beckman SW41Ti rotor. After centrifugation, fractions of 0.5 mL were collected by
pumping out from the bottom of the tube. The fractions (10 VLL each) were run on a 0.8%
agarose gel containing 0.5 ptg/mL ethidium bromide. The fractions of supercoiled DNA
were pooled, concentrated using a Centricon (YM-50) filtration system, and stored in TE
buffer (pH 8.0).
Repair Synthesis Assay. The repair reaction mixture (50 ptL) contained 200 ng pBR322
(undamaged internal control) plasmid, 200 ng damaged pGEM, 40 mM Hepes-KOH (pH
7.8), 70 mM KCl, 5 mM MgCl 2, 0.5 mM dithiothreitol, 2 mM ATP, 20 ptM of dGTP, 20
pM of dCTP, 20 ptM of TTP, 8 ptM dATP, 23 mM phosphocreatine, 2.5 ptg creatinine
phosphokinase, 18 Cpg bovine serum albumin, 2 pCi [a-32 P]-dATP, and HeLa whole cell
extract, as described (Wood, Biggerstaff, and Shivji 1995). For the reaction containing
the ER-LBD (ligand binding domain), the plasmid substrates in 10 ptL of TE were
incubated with 10 pIL of ER-LBD in whole cell extract buffer at room temperature for 20
min, and then combined with the repair reaction mixture. For the reaction containing
XPA-antibody and/or XPA protein, the plasmid substrates in 10 jL of TE were incubated
with a 20 ptL mixture including whole cell extracts, XPA-antibody, XPA protein, and
whole cell extract buffer at 30°C for 30 min, and then combined with the repair reaction
mixture. The repair reaction was conducted at 30°C for 1 hour. After incubation, EDTA
(20 mM final concentration) and RNAse A were added to the reaction, thoroughly mixed
and incubated at 37°C for 10 min. SDS (0.5% final concentration) and proteinase K (190
ltg/mL final concentration) were added, thoroughly mixed, and incubated at 37°C for 30
min. The DNA was then extracted with phenol/chloroform, precipitated with ammonium
acetate, and washed with 70% ethanol. The DNA pellet was dried, resuspended in Hind
III buffer (New England Biolabs, Beverly, MA), digested with Hind III, and separated on
0.8% agarose gel containing 0.5 gpg/mL ethidium bromide. The gel was photographed
under UV transillumination and subsequently dried on gel blot paper. The dried gel was
exposed to a phosphor screen, scanned by PhosphorImager (Storm 840, Molecular
180
Dynamics), and analyzed using ImageQuaNT software to quantify the radioactivity
incorporated into DNA.
Cell Culture. The human cervical breast cancer cell lines, MCF-7 and MDA-MB23 1,
were obtained from the American Type Culture Collection (Rockville, MD). Both cell
lines were maintained in Minimal Essential Media (MEM) (Gibco) supplemented with
10% fetal bovine serum, 2 mM glutamine, and 1 mM sodium pyruvate in a humidified
CO2/air atmosphere at 37°C. GM02345 cells were purchased from the Coriell Institute
for Medical Research (Camden, NJ) and cultured in Roswell Park Memorial Institute
(RPMI) medium with 10% fetal bovine serum, and 2 mM glutamine in a humidified
CO2/air atmosphere at 37°C.
Repair of E2-7a DNA adducts in MCF-7 and MDA-MB231 cells. MCF-7 cells were
exposed to a 0.75 jiM dose of 14C-E2-7a (specific activity 50 pCi/pmol) or 0.15 itM
melphalan (specific activity 50 tCi/[tmol) for 2 hours. MDA-MB231 cells were exposed
to a 0.25 tM dose of 14C-E2-7a (specific activity 50 gCi/[tmol) or 0.25 [tM melphalan
(specific activity 50 pCi/jmol) for 2 hours. At the end of the treatment, the media was
removed, the cells were washed 3 times with PBS and fresh media was added. Repair of
the DNA adducts was monitored by harvesting cells 0, 1, 3, 6, 9, 15, and 24 hours after
the removal of 14C-E2-7a. The DNA was then isolated as indicated below.
Quantification of DNA Adducts in cells. MCF-7 and MDA-MB231 cells were
exposed to various doses of 14C-E2-7a dissolved in DMSO. At the end of the incubation
the cells were scraped, pelleted, and washed with phosphate buffered saline (PBS). The
cells were resuspended in 2 mL of cold (4°C) 10 mM Tris (pH 6.9), 250 mM sucrose, 2
mM calcium chloride buffer. Triton X-100 (25% in water) was added to make a final
concentration of 5%. The solution was briefly vortexed and then centrifuged at 100OG in
a Sorvall RC-2B Centrifuge with a GSA rotor at 4°C for 20 min. The supernatant was
removed by aspiration and the nuclear pellet was resuspended in 1 mL of buffer. To this
solution was added 5% sodium dodecyl sulfate (SDS) and 5 M sodium chloride (NaCl) to
make a solution with a final concentration of 1% SDS and 1 M NaCl. An equal volume
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of chloroform:isoamyl alcohol (24:1) was then added and the biphasic mixture was
shaken vigorously for 15 min. The mixture was then centrifuged at 7000G for 15 min at
4°C. The aqueous phase was collected and re-extracted with another volume of
chloroform:isoamyl alcohol, shaken, and centrifuged. The aqueous phase was then
collected, and the nucleic acids were precipitated with 3 volumes of ice cold ethanol,
chilled at -20°C for 20-30 min, and subsequently pelleted by centrifugation at 7000G for
15 min at 4°C. The nucleic acids were washed 2 times with cold ethanol and then dried
in vacuo. The dried pellet was reconstituted with 0.5 mL of 0.05 M Tris (pH 7.5), 0.1 M
NaCl on ice. In order to remove any contaminating RNA, 0.2 mg of RNAse A was added
and incubated at 37°C for 10 min. The reaction was stopped by cooling on ice, the NaCl
concentration was adjusted to 0.9 M, and the DNA was extracted by subsequent additions
of chloroform:isoamyl alcohol as indicated above. The aqueous phase from the second
extraction was isolated and the DNA was precipitated with 3 volumes of ice cold ethanol,
centrifuged, and washed 2 times as above. The concentration of the DNA was obtained
by monitoring the absorbance at 260 nm. The DNA was dissolved in 0.1-0.5 mL of
water, depending on the DNA concentration, and then given to Paul Skipper and Rosa
Liberman, both in the Tannenbaum laboratory at MIT, for analysis by Accelerator Mass
Spectrometry (AMS) as described in Liberman, et al. (Liberman et al. 2004)
Results
Repair of E2-7a DNA Adducts in vitro and the Role of NER. Nucleotide excision
repair (NER) is one of the many repair pathways a cell uses to defend itself from
exogenous and endogenous DNA damage (Friedberg, Walker, and Siede 1995). NER is
most closely associated with the removal of cyclobutane pyrimidine dimers and (6-4)
photoproducts as a result of exposure to UV-C light (Beukers and Berends 1960; Boyce
and Howard-Flanders 1964; Setlow and Carrier 1964). However, NER has also been
shown to be involved in the removal of bulky alkylating agents such as cisplatin and
melphalan (Grant, Bessho, and Reardon 1998; Kartalou and Essigmann 2001b; Reardon
et al. 1999). Research from Rick Wood's laboratory has provided an in vitro means of
monitoring NER using whole cell extracts, appropriate buffers, 32 P-dATP, and plasmid
substrates (Wood, Biggerstaff, and Shivji 1995). The design of this system is illustrated
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in Figure 5.1. Briefly, a plasmid is exposed to a damaging agent (in our case either UV
light or E2-7a) and globally modified. The adducted plasmid is then incubated with
cellular extracts which contain the proteins necessary for repair. Since NER typically
removes a patch of bases 26-29 nucleotides in length (de Laat, Jaspers, and Hoeijmakers
1999; de and Hoeijmakers 2000; Petit and Sancar 1999; Prakash and Prakash 2000),
rather than a single base as is the case for base excision repair (BER), radiolabeled 32p_
dATP will be incorporated into essentially all repair patches. The amount of radioactive
incorporation is thus related to the amount of DNA repair.
The amount of repair is dependent on the incubation time of the damaged plasmid
substrates with the HeLa whole cell extracts (data not shown) and on the protein
concentration in the incubation reaction. Figure 5.2 shows the results of E2-7a damaged
pGEM plasmid incubated with increasing amounts of cell extracts (70-280 gtg/reaction).
The agarose gel in Figure 5.2A depicts increased repair in the E2-7a damaged pGEM
plasmid with increasing whole cell extract concentration. The amount of repair in the
undamaged pBR plasmid is independent of cell extract concentration as evident by the
same low level of background repair in all three lanes. As indicated by Wood, et al. the
results after exposure to a phosphor screen can be quantified by determining the ratio of
repair in the damaged plasmid (pGEM) to that of the internal control (pBR) (Wood,
Biggerstaff, and Shivji 1995). These values are then normalized for any differences in
DNA recovery between the tracks by densitometric scan of the ethidium-bromide stained
gel. Figure 5.2B shows the results of this quantification. As expected, E2-7a damaged
pGEM plasmids are repaired the most in the lane with the greatest amount of whole cell
extracts (280 [tg in lane 3). This indicates that E2-7a DNA adducts can be repaired by
this system, and that this system can be used further in monitoring the repair of these
adducts.
Since NER has been shown to be involved in the removal of bulky adducts and
alkylating agents (Grant, Bessho, and Reardon 1998; Kartalou and Essigmann 2001b;
Reardon et al. 1999), we wanted to assess the contribution of NER in the repair of E2-7a
DNA adducts. The NER pathway has been characterized and consists of more than two
dozen proteins (Fig 5.3). In human cells, NER involves the recognition of DNA damage,
incision of the DNA strand containing the lesion, and synthesis and ligation in the region
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of the excised oligonucleotide (Costa et al. 2003; de Laat, Jaspers, and Hoeijmakers
1999; Lindahl and Wood 1999; Wood 1997). The dual incision factors are the XPA
protein, the single-strand DNA binding heterotrimer RPA, the XPC-hHR23B complex,
the 6-9 subunit TFIIH complex, and two nucleases, XPG and ERCC 1-XPF. A key
intermediate is an open unwound structure formed around the lesion in a reaction that
uses ATP-dependent helicase activities of XPB and XPD, two of the TFIIH subunits.
This intermediate creates sites for cutting by the XPG and ERCC 1-XPF enzymes, which
recognize junctions between single-strand and duplex DNA and cut with specific
polarities. A 24- to 32- residue oligonucleotide is released, and the gap is filled in by POL
6 or £ holoenzyme (Budd and Campbell 1997; Wood and Shivji 1997) and sealed by
DNA ligase I (Nocentini 1999; Tomkinson and Levin 1997).
The XPA protein is involved in the initial DNA adduct recognition event and is
therefore an ideal protein to inhibit in order to suppress the activity of NER (Asahina et
al. 1994; Jones and Wood 1993; Robins et al. 1991). Kuraoka, et al. have indeed
inhibited NER by targeting antibodies specific for XPA (Kuraoka et al. 2000). He and
Rick Wood have kindly supplied us with both the XPA antibody and XPA protein. Upon
addition of XPA antibody to HeLa whole cell extracts, the repair of both UV damaged
and E2-7a damaged pGEM plasmids is diminished. Figure 5.4A depicts the agarose gel
after exposure to a phosphor screen and Figure 5.4B quantifies the differences in each
lane. The pBR plasmid is an internal control that serves as a measure of background
DNA damage. The ratio of the damaged (pGEM) to undamaged (pBR) plasmids in the
positive control is set as 100 % repair. As compared to the positive control in which no
XPA antibody was added, the repair of UV damaged plasmid decreased by 75%, whereas
the repair of E2-7a damaged plasmid decreased by 60%. Furthermore, the decrease in
repair of the damaged plasmids is specific to NER as the addition of XPA protein to
cellular extracts containing the XPA antibody restores the activity. Figure 5.5A depicts
the agarose gel after exposure to a phosphor screen and Figure 5.5B depicts the data
graphically. As seen in Figure 5.4, the addition of XPA antibody decreases the amount of
repair of E2-7a damaged pGEM plasmids by approximately 50% as compared to the
positive control. However, upon addition of XPA protein, the repair capacity of the
extracts is restored.
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It is of interest to note that the magnitude in the inhibition of NER by the XPA
antibody was considerably less for E2-7a damaged DNA than for UV damaged DNA
(i.e., cyclobutane pyrimidine dimers and (6-4) photoproducts). In fact, XPA antibody
inhibited the repair of UV induced lesions by 75% versus only a 50% inhibition in the
repair of E2-7a induced DNA damage. One possible reason for this difference is that
other DNA repair mechanisms may be involved in the repair of E2-7a induced DNA
damage. In order to address this possibility, an XPA- /- cell line, GM02345, was cultured
in order to obtain cellular extracts that were completely deficient in NER (Jones and
Wood 1993; Robins et al. 1991). As expected, UV damaged plasmids incubated in
GM02345 cellular extracts were not repaired (Fig 5.6). Surprisingly, E2-7a DNA
adducts were still repaired, although to a lesser degree than when the E2-7a DNA
damaged plasmids were incubated with NER proficient HeLa cell extracts (Fig 5.6). This
result may indicate that other modes of DNA repair are involved in the removal of E2-7a
adducts.
E2-7a DNA Adducts Persist Longer in ER Expressing Cells. In Chapter 2, I described
the results of an experiment conducted by John Marquis that illustrate the differential
toxicity of E2-7a towards ER(+) cells. The ER(+) MCF-7 cell line is approximately two
fold more sensitive to E2-7a than is the ER(-) MDA-MB231 cell line. The differential
toxicity is likely not the result of increased accumulation of E2-7a in the MCF-7 cell line
since a 10 i[M dose produced roughly the same number of DNA adducts in both cell lines
over a 24 hour period. (Note: The data are not shown here because for an unknown
reason replicate experiments produced a 3-4 fold difference in DNA adduct levels.
However, the results from each individual experiment were analyzed by AMS several
times and in both cases the initial values were reproduced. This suggests that the
differences between the two experiments are unrelated to the analyzing methodology of
AMS.)
An alternative possibility for the observed differential toxicity between the two
cell lines is the desired repair shielding and/or transcription factor hijacking mechanisms
by which we designed E2-7a. If the repair shielding phenomenon is a valid mechanism
for the increased toxicity of E2-7a towards MCF-7 cells, then the rate of repair in these
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cells should be less than that of the MDA-MB231 cells. In order to address this question
we treated both cell lines for a brief two hour period with [14C]E2-7a, replaced the drug
containing media with fresh drug-free media, isolated the DNA at various time points,
and analyzed the number of DNA adducts over time by AMS. Figure 5.7A illustrates the
removal of E2-7a DNA adducts is indeed slower in the ER(+) MCF-7 cell line than in the
ER(-) MDA-MB231 cell line. To ensure the differences in removal of E2-7a was not
related to differential repair capacity between the two cell lines, we also treated both lines
with [14C]-melphalan. Figure 5.7B illustrates that the repair capacity of both cell lines is
essentially the same in the removal of melphalan DNA adducts. These results suggest
that the repair shielding mechanism may indeed be a valid reason for the differential
toxicity between the two cell lines.
Discussion
The covalent modification of DNA in malignant cells is one approach that has
been used clinically to rid a patient from potentially fatal tumors (Hurley 2002; Teicher
1997). One means of improving the therapeutic index of alkylating agents is by
inhibiting the DNA repair machinery selectively in cancer cells (Barret and Hill 1998;
Dolan 1997; Frankfurt 1991). Towards this end, we have rationally designed an agent,
E2-7a, capable of forming DNA adducts and attracting tumor specific proteins (Mitra et
al. 2002; Sharma et al. 2004). E2-7a was designed to attract the ER, which is aberrantly
expressed in approximately 50% of all breast cancers (Ferno et al. 1990). The attraction
of the ER to the site of an E2-7a lesion could inhibit repair enzymes from accessing the
lesion and disrupt signaling events in a cancer cell since the ER is also a transcription
factor. Furthermore, these adducts would be readily repaired in non-cancerous cells
where the ER is not abundant and the overall toxicity to a patient could be significantly
reduced.
In order to address these possible mechanisms, I first monitored the repair of E2-
7a using an in vitro whole cell extract assay developed by the Wood laboratory (Wood,
Biggerstaff, and Shivji 1995). E2-7a DNA adducts were found to be repaired by the
NER pathway since an antibody against XPA, a protein involved in the initial recognition
event of NER, diminished the amount of repair of E2-7a damaged plasmids.
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Furthermore, the addition of XPA protein to cellular extracts containing XPA antibody
restored the repair capacity of the extracts. Interestingly, however, the suppression of
repair of E2-7a DNA adducts occurred to a lesser degree than the suppression of repair of
UV damaged plasmids. Approximately 80% fewer UV induced DNA adducts were
repaired upon the addition of XPA antibody, whereas only 50% of DNA adducts were
removed in plasmids damaged with E2-7a. This observation prompted me to use a cell
line completely deficient in NER activity, the XPA-/- GM02345 (Jones and Wood 1993;
Robins et al. 1991). UV induced DNA lesions were completely unrepaired using cellular
extracts derived from these cells. However, E2-7a damaged plasmids were still repaired,
although only 25% as efficiently as HeLa cell extracts that are proficient in NER activity.
One explanation for this result could be E2-7a DNA adducts depurinate readily
and at a much faster rate than the depyrimidination of cyclobutane pyrimidine dimers or
(6-4) photoproducts (the major UV induced adducts monitored in this assay). Pyrimidine
nucleosides are considerably more stable than purine nucleosides with respect to the
glycosidic linkage of the base to deoxyribose. The mechanism of depyrimidination is
the same as for depurination, but the loss of cytosine and thymine occur at rates of only
1/20 of that for adenine and guanine (Lindahl and Karlstrom 1973). Furthermore, the
observed rate of decomposition of an N7-deoxyguanosine chlorambucil adduct in a 0.2 M
cacodylic acid buffer (pH 6.8) at 37°C was 0.73 x 10-2 min-' with the only reported stable
product resulting from the cleavage of the glycosidic bond to produce N-(7-guanyl)ethyl-
N-hydroxyethyl-p-aminophenylbutyric acid (Haapala et al. 2001). These two lines of
evidence suggest that the depurination of E2-7a DNA adducts may help explain the
somewhat surprising results that NER is not solely responsible for the repair of the
lesions.
Other modes of DNA repair are likely involved in the repair of E2-7a DNA
adducts directly or through the possible depurination events. Depurination (and
depyrimidination) produce apurinic (and apyrimidinic) sites (AP sites). These AP sites
are substrates for AP endonucleases that catalyze the incision of DNA exclusively at AP
sites, thereby preparing the DNA for subsequent excision, repair synthesis, and DNA
ligation (Friedberg et al. 1981; Lindahl 1979; Lindahl 1982). Although we currently
have no evidence that E2-7a forms adducts with adenine, any adducts that are formed and
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depurinate would form an AP site. An AP endonuclease would then repair the lesion and
incorporate [a-32 P]dATP from our reaction mixture. As a note, 20% of melphalan
adducts are at the N3 position of adenine (Osborne and Lawley 1993).
In addition to the incorporation of radiolabeled ATP by AP endonucleases,
glycosylases involved in the BER pathway may also play a role in the repair of E2-7a
DNA adducts. Even though NER is generally considered to be involved in the repair of
bulky alkylating agents such as chlorambucil, cisplatin, and melphalan (Grant, Bessho,
and Reardon 1998; Kartalou and Essigmann 2001b; Reardon et al. 1999), there is
evidence that BER plays a role in the repair of these lesions as well. For example, both
the bacterial and human 3-methyladenine-DNA glycosylase (MPG) can remove
chlorambucil adducts from oligonucleotides (Lindahl 1993). Additionally, reviews by
Kartalou and Essigmann indicate the possible involvement of mismatch repair, BER,
recombination and other repair pathways in the removal of cisplatin DNA adducts
(Kartalou and Essigmann 2001a; Kartalou and Essigmann 2001b). These additional
repair pathways may also play a role in the removal of E2-7a adducts. The results here
are consistent with the fact that bulky alkylating agents are generally substrates for NER,
but our results also imply other repair pathways may be playing a role in the removal of
E2-7a DNA adducts.
E2-7a was designed to disrupt the repair pathways discussed above by attracting
the ER to the site of DNA adducts. Using the same DNA repair assay that I used to
illustrate the role of NER on the repair of E2-7a damaged plasmids, Hyun-Ju Park, a
former post-doctoral fellow in the Essigmann laboratory, tested the repair shielding
hypothesis by co-incubating the ER-LBD with cell extracts. Figure 5.8 illustrates the
results of her experiments. The ER-LBD inhibited the repair of E2-7a damaged plasmids
but not UV damaged plasmids. This finding provided the first line of evidence that the
repair shielding hypothesis may indeed be valid.
A second line of evidence was described in Chapter 2 in that E2-7a is selectively
more toxic towards the ER(+) MCF-7 cell line over the ER(-) MDA-MB231 line. The
results by Park indicate that the repair shielding phenomenon may be a contributing
factor in the differential toxicity. I have provided additional evidence in support of the
repair shielding mechanism by treating the ER(+) MCF-7 and ER(-) MDA-MB231 cell
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lines with E2-7a and monitoring the repair of the DNA adducts in the two lines. In the
MCF-7 cells, the DNA adducts seemed to take slightly longer to reach peak adduction
level (as evident by the 3 hour time point in Figure 5.7A), and the adducts persisted
longer than they did in the MDA-MB23 1 cells. In fact only 20% of E2-7a DNA adducts
were removed after 15 hours in the MCF-7 cells while 70% were removed in MDA-
MB231 cells at the same time point (as compared to the peak adduction level).
Furthermore, the evidence from both cell lines treated with melphalan indicated that there
is likely no differential repair capacity between the two cell lines. Reduction in adduct
levels with time did not result from dilution through DNA synthesis or from selective loss
of highly damaged cells, because during the 24 h after exposure to E2-7a or melphalan,
there were no significant increases in intact or apoptotic cells and the doubling time of
both cell lines is approximately the same. These results suggest that repair shielding of
E2-7a DNA adducts may be a cause of the differential toxicity towards the MCF-7 cells.
The design of the experiment was such that the initial number of DNA adducts
formed in either cell line by either drug would be essentially the same. As shown in
Figure 5.7 all combinations produced roughly 2,000 DNA adducts per cell. This low
level of initial adducts was chosen because we did not want to saturate the repair capacity
of the cell or cause the cells to undergo apoptosis. Therefore sub-lethal doses of both
drugs were given to cells. Surprisingly, however, the increase in DNA adduct formation
after removal of the drugs was drastically different. In the case of E2-7a, the peak level
in both cell lines was 10,000 adducts per cell 3 hours after the withdrawal of drug.
However, cells treated with melphalan reached a peak adduct level of only -3,000
adducts per cell, also 3 hours after the removal of drug from the media. These
differences may be the result of how these two compounds differ in their entry into cells.
Melphalan is taken up by amino acid transporter systems that discriminate between
melphalan and hydrolyzed melphalan (Begleiter et al. 1979), whereas it is likely that E2-
7a enters through passive diffusion.
In order to show that the two cell lines do not differ in their repair capacity, it
would be ideal to see a greater degree of repair from peak adduction levels when cells are
treated with melphalan. Unfortunately, this may not be possible. In a recent publication
by Gould, et al. the rate of repair of melphalan DNA adducts was addressed. Gould
189
treated myeloblastic leukemia, ML1, cells with 33 M or 66 gpM doses of melphalan for
1 hour, exchanged the drug-containing media for drug-free media, and monitored the
level of DNA adduction. At both doses approximately 50% of the adducts were removed
by 24 hours (as compared to the peak adduction level at 4 hours) (Gould, Nixon, and
Tilby 2004). Likewise, approximately 50% of the melphalan DNA adducts were
removed from both the MCF-7 and MDA-MB231 cells by 24 hours (also, as compared to
the peak adduction level at 3 hours). Gould also found that the peak adduction level is
50% greater than the initial adduction level, as we did. Finally, it is interesting to note
that the number of DNA adducts formed in Gould's work is approximately 100-fold
higher than what we observed with an approximately 100-fold lower dose. These results
suggest that the formation of DNA adducts is dose dependent but the rate of repair of
these adducts is not.
Conclusion
The design of novel genotoxins that can selectively destroy cancer cells while
sparing normal, healthy ones is a formidable challenge. Cancer cells have developed
many mechanisms that allow for resistance to current therapies. We have rationally
designed a multifunctional agent that has the ability to combat these mechanisms of
resistance. We have combined the ability to adduct DNA and to disrupt cellular signaling
into a single agent. The work from previous chapters has illustrated the ability of our
lead compound, E2-7a, to form DNA adducts, attract tumor specific proteins (i.e., the
ER), and selectively kill malignant cells that contain the ER.
Here I present the first line of evidence in support of our desired mechanisms of
action. E2-7a DNA adducts persist longer in ER(+) MCF-7 cells than in ER(-) MDA-
MB231 cells. Differences in repair capacity between the two cell lines is likely not a
factor as both cell lines remove the same number of melphalan DNA adducts over a 24
hour period. Furthermore, evidence gathered by Hyun-Ju Park is in agreement with this
result, as she illustrated that the addition of the ER to HeLa cell extracts diminished the
amount of repair of E2-7a DNA adducts in vitro, whereas there was no difference in the
removal of UV induced DNA adducts in the presence or absence of the ER. Finally, I
have provided evidence that the repair of E2-7a DNA adducts is in part due to NER;
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however, other repair pathways are also likely to be involved in a portion of these
adducts.
The results presented here and in previous chapters provide strong evidence in
support of the repair shielding and transcription factor hijacking mechanisms. Although
no direct evidence in support of transcription factor hijacking was provided an interaction
with the ER in vivo would likely disrupt cellular signaling events. The ER has a good
affinity for E2-7a DNA adducts and its association with these adducts has proven to
inhibit their repair in two independent experiments. We are optimistic about the fate of
E2-7a in a clinical setting and hope to some day have the resources available to begin
such an investigation.
Future Directions
I have illustrated that NER plays a role in the removal of E2-7a DNA adducts,
however our evidence also illustrates other repair pathways are likely involved in the
removal of the lesions. Using a similar methodology as what was employed here will
help us understand what other repair pathways may be involved. The glycosylase, MPG,
has previously been shown to repair chlorambucil DNA adducts (Lindahl 1993) and
would therefore represent an initial target. Either cell extracts that are deficient in MPG
or an antibody against the protein could be used to assess the role of this glycosylase in
the repair of E2-7a DNA adducts. The repair of E2-7a by MPG could be of clinical
value as it was recently shown to interact with the ER, and this interaction increased the
catalytic rate of the enzyme (Likhite et al. 2004). If the ER is attracted to the site of E2-
7a adduction, the interaction between the ER and MPG could result in increased repair of
the adduct and as a result could be deleterious in the development of E2-7a as a clinical
candidate. (Note: HeLa cells used to make the cellular extracts for the repair assay do
not express the ER). If it is shown that MPG is not involved in the repair of E2-7a DNA
adducts, we will continue our investigations into other glycosylases and other repair
pathways.
I have had the privilege of being taught by some of the world's most renowned
biochemists while a graduate student at MIT. One such individual, JoAnne Stubbe, taught
me that you can never prove a mechanism, but rather you can only disprove other
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alternatives. The evidence that I have presented in this chapter strongly suggests that the
repair shielding mechanism is likely to play a role in the cytotoxicity of E2-7a. However,
these experiments, while sound in design and execution, still contain gaps that need to be
addressed. One possibility is that the differences seen in the rates of repair of E2-7a
DNA adducts between the MCF-7 and MDA-MB231 cells may be due to differences in
cell proliferation. If for example the MDA-MB231 cells grow at a quicker rate than
MCF-7 cells, then this observation could explain some of the differences in the repair of
the two cell lines. I do believe this is unlikely however, as the doubling time of MCF-7
and MDA-MB23 1 cells is very similar and after the treatment of these cells in our hands,
there were no obvious differences in total cell number. To err on the side of caution, we
plan on determining the concentration of DNA in the two cell lines over time using a
protocol described in Smith and Engelward (Smith and Engelward 2000).
Furthermore, we would like to repeat the experiment in order to see if a higher
dose of melphalan would result in a more dramatic repair profile. However, based on the
work by Gould, et al., this is unlikely to be the case. Therefore, in order to show that
differences in repair capacity of the MCF-7 and MDA-MB231 cell lines are not
responsible for the differences observed for the removal of E2-7a DNA adducts, we may
have to use another alkylating agent. Ideally, chlorambucil would be used since it is also
a nitrogen mustard similar in structure to both melphalan and our E2-7a. However,
[14C]-chlorambucil is extremely expensive and may be cost prohibitive for our purposes.
We currently possess a [14C]-nitrogen mustard reaction intermediate that could be used
instead and are in the process of exploring these options.
These experiments will make the results described in this chapter more concrete.
In Chapter 8, I will describe the results of some experiments with our lead compound
used to target prostate cancer, 11 p. These results will illustrate that the treatment of
androgen receptor-expressing LNCaP cells with this compound results in altered
expression levels of several signaling proteins. These alterations may be consistent with
the transcription factor hijacking mechanism but also may be entirely unrelated to DNA
adduction. No such studies have been attempted with E2-7a (further work is still
necessary to identify the mechanisms responsible for the cytotoxicity of 11 P3 and these
will be discussed in the Future Directions section of Chapter 8). Therefore, we must
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begin to investigate cellular signaling events that could imply transcription factor
hijacking or other mechanisms unrelated to DNA damage.
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Fig 5.1 An in vitro system used to monitor DNA repair. Plasmid
DNA is globally modified and incubated with cellular extracts
and 32P-dATP. The radiolabeled dATP is subsequently
incorporated into the plasmid where the adduct was removed.
The plasmid is then linearized and run on an agarose gel. The
relative radioactive incorporation between lanes can be
compared.
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Fig 5.2 Assessing the repair of E2-7a damaged pGEM
plasmids. A. Lane 1: 70 pg of HeLa whole cell extract, Lane 2:
140 Ipg of extract, Lane 3: 280 pg of extract. B. Quantification
of the results expressed as ratio of repair in the damaged pGEM
plasmid to that of the control pBR plasmid. E2-7a damaged
pGEM plasmids are substrates for the repair assay and
increasing concentration of cellular extracts increases the
amount repair in the damaged (pGEM), but not in the
undamaged (pBR) plasmids.
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Fig 5.4 Inhibition of NER by XPA-antibody. A. Lane 1: positive
control, Lane 2: UV damaged pGEM plasmid co-incubated with
XPA-antibody, Lane 3: E2-7a damaged pGEM plasmid co-
incubated with XPA-antibody. B. Quantification of the results
expressed as percent of repair in the positive control. XPA-
antibody suppressed the repair of both UV and E2-7a damaged
plasmids as compared to a positive control where no XPA-
antibody was present.
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Fig 5.5 Inhibition of NER by XPA-antibody. The relative
contribution of NER in the repair of E2-7a damaged pGEM
plasmid was assessed. A. Lane 1: positive control, Lane 2: 1
pJL XPA-antibody, Lane 3: 2 L XPA-Antibody, Lane 4: 3 + 450
ng XPA, Lane 5: 3 + 900 ng XPA. B. Quantification of the
results expressed as percent of repair in the positive control.
Addition of XPA-antibody inhibits the repair of E2-7a adducts by
40%. Upon addition of XPA protein, the repair is restored,
indicating that NER is involved in the repair of E2-7a DNA
adducts.
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Fig 5.6 Repair of damaged plasmids in cell extracts that are proficient or
deficient (XPA-/-) in NER. A. XPA proficient extracts: Lane 2 and 4.
XPA-'- deficient extracts: Lane 3 and 5. No cell extracts (negative
control): Lane 1. UV damaged pGEM: Lane 2 and 3. E2-7a damaged
pGEM: Lane 4 and 5. B. Quantification of the results expressed as ratio
of repair in the damaged pGEM plasmid to that of the control pBR
plasmid. A ratio of 1 indicates no repair. UV damaged plasmids are not
repaired in XPA-'- extracts. However, XPA-'- are still capable of repairing
E2-7a damaged pGEM plasmids, possibly indicating pathways other than
NER are involved in the repair of these lesions.
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E2-7a DNA Adducts, but not Melphalan
DNA Adducts, Persist Longer in ER (+)
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Fig 5.7 Repair of E2-7a (A) and Melphalan (B) in ER (+) MCF-
7 cells (4-*) and ER (-) MDA-MB23 cells (-o-). E2-7a adducts
persist longer in cells expressing the ER while melphalan
adducts are repaired with similar kinetics independent of ER
expression. These results suggest that E2-7a adducts are
shielded from repair by the ER. Error bars are standard error of
the mean of replicate AMS analyses, not replicate dosings.
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The work from the previous four chapters describes my results with our
chemotherapeutic agent that targets ER(+) breast cancers. We have similarly designed an
agent, 11 3, that targets AR(+) prostate cancers. The work presented in the subsequent
chapters will follow the same basic sequence as what was presented for E2-7a: in vitro
experiments, pharmacokinetics, and finally therapeutic potential. In all chapters, I shall
discuss how the results support our intended mechanism(s) of action.
Chapter 6
The Rational Design and Biophysical Properties of an
Anti-cancer Agent that Targets Androgen Receptor
Expressing Prostate Cancers
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Introduction
DNA damaging agents were among the first chemotherapeutics used in the clinic
and continue to remain an important component in combination chemotherapy regimens
(Hurley 2002; Teicher 1997). DNA damaging agents, in combination with other drugs
that act by different mechanisms, can place the tumor into a state of stasis and in some
cases even cure the patient of their cancer. Such is the case in patients with testicular
cancer treated with the DNA damaging agent cisplatin, in combination with etoposide
and bleomycin. This therapy results in a cure rate of 93% in men with the disease
(Masters and Koberle 2003) and is also effective in treating patients with cancers of the
ovary, head, neck, and lung.
Until recently, the therapeutic landscape for men with advanced prostate cancer
did not include traditional cytotoxic chemotherapeutic agents (Kish, Bukkapatnam, and
Palazzo 2001; Morris and Scher 2000). The demonstration of the palliative effects of
mitoxantrone combined with prednisone in patients with advanced prostate cancer has
sparked interest in the development of new agents and regimens utilizing cytotoxic agents
to improve patient outcomes (Martel et al. 2003; Morris and Scher 2003). The
combination of the taxane, docetaxel, with prednisone has proven to be the most effective
regimen to date with a mean increased survival time of 3 months in patients with
advanced prostate cancer (Walsh 2005).
The paltry improvement in patient survival is due to the resistance of prostate
cancers to cytotoxic drugs. Prostate cancers often overexpress anti-apoptotic proteins,
such as Bcl-2, allowing for the tumors to survive the cytotoxic therapy regimens used to
treat advanced stages of the disease (Lebedeva et al. 2000; Raffo et al. 1995; Vlietstra et
al. 1998). Furthermore the utility of androgen ablation therapy is no longer beneficial in
late stage disease as a result of a cellular transition from androgen-dependence to
androgen-independence. Despite the increased expression of anti-apoptotic proteins in
advanced prostate cancer, several studies have indicated that these cells are still capable
of undergoing apoptosis (Denmeade et al. 1999; Marcelli et al. 2000; Wang et al. 1999).
The ability to target resistance mechanisms and induce apoptosis in advanced stages of
the disease is central to the development of more effective drugs and treatment regimens.
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The strategy of combining several agents that can increase the effectiveness of
alkylating agents is one approach to overcoming resistance. However, occasionally drug-
drug interactions or overlapping side effects preclude certain multi-drug regimens from
being used in the clinic. We have therefore employed a novel approach in which we have
designed a single agent capable of alkylating DNA and simultaneously disrupting
multiple cellular signaling pathways responsible for tumor growth and survival. In
androgen -dependent and -independent prostate cancer, the AR is frequently over-
expressed at both the mRNA and protein level (Gioeli 2004; Morris and Scher 2003;
Wang, Ossowski, and Ferrari 2004). We have therefore taken advantage of this fact by
designing molecules capable of covalently modifying DNA and attracting the AR to the
site of the damage. Protein-adduct complexes formed in prostate cancer cells would
likely camouflage the lesion from repair enzymes resulting in cellular toxicity.
Furthermore, the attraction of the AR to DNA adducts would likely titrate away its
normal transcriptional activities responsible for cell growth and survival. This two-
pronged attack of DNA damage combined with the disruption of necessary cellular
signaling events could produce a single molecule capable of inducing apoptosis in
advanced prostatic cancers.
Based on the structural similarity of the AR with other steroid receptor proteins
(Sack et al. 2001), we have incorporated the molecular features of molecules we have
designed to target estrogen receptor (ER) expressing breast cancers (described in the
previous 4 chapters). We linked an aniline nitrogen mustard to a testosterone-like ligand
that has a high affinity for the AR. Previous work by Rink, et al. has illustrated the
importance of a hexanyl chain linked to the steroid ligand in order for the remainder of
our molecule to exit the steroid binding pocket (Rink et al. 1996). We decided on the
attachment of the 6-carbon linker at the 11 p position on the basis that the antiprogestin
drug RU486 and several derivatives with long alkyl chains at this position retain a high
affinity for the AR (Berrevoets, Umar, and Brinkmann 2002; Muddana et al. 2004).
There are a few examples in the literature of compounds that incorporate steroid
receptor ligands combined with chemically reactive genotoxins (Brix et al. 1990;
Eisenbrand et al. 1989; Knebel and von 1988). However, in most cases these agents are
designed as a means of selectively delivering the genotoxin to the malignant cell. The
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linkers in these molecules are designed to be hydrolyzed so as to release the active toxin
within its target cell. Our molecules are designed for chemical stability as well as to
resist hydrolysis and degradation by proteases and esterases. We intend for our
molecules to form DNA adducts in many different tissue types. In non-target tissue we
expect the adducts to be quickly repaired. However, in malignant tissue, we hope the
expression of a tumor specific protein which our molecule was designed to attract (for
example, the AR in prostate cancer) would cause a persistence of the adduct and thus
result in cell lethality. Furthermore if the protein is a transcription factor (as is the AR),
the DNA adducts could titrate away necessary cellular signaling events and therefore
result in further toxicity to the cell.
We have designed and characterized a molecule, 11 3 (Fig 6. 1A), which we
believe can function by the intended mechanisms of action. In this chapter, I shall
discuss the work which illustrates the ability of 11 3P to form DNA adducts and that the
compound, both alone and when adducted to DNA, has a good affinity for the AR. I
shall discuss my work on identifying DNA adducts formed after the treatment of 11 3
with salmon testes DNA. I shall also describe the solubility of our lead compound as
assessed by measuring its log D using an HPLC methodology.
Furthermore, I shall briefly describe some experiments that others in the
Essigmann laboratory have completed. Specifically, I shall discuss the RBA, the amount
of DNA adduction as assessed by piperidine cleavage, the ability of DNA adducts to
interact with the AR, the selective toxicity towards AR(+) LNCaP cells, and the
molecular changes brought about by a 10 [M treatment of the LNCaP cells. In order to
address the mechanistic features unrelated to DNA damage, i.e. repair shielding and
transcription factor hijacking, we have synthesized an unreactive 1 1 derivative, 11 P-
dimethoxy. See Figure 6. 1B. The results with the 1 13 -dimethoxy compound will also be
discussed. Although I did not conduct some of these experiments, I believe it is very
important to discuss them in brief as these results provide insight into mechanism and
also have established a basis for my subsequent work.
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Materials and Methods
Synthesis. The complete chemical synthesis of all 1 p-substituted 17P-hydoxy-estra-
A4(5),9(11)-3-one-linked genotoxicants have been conducted by various members of the
Essigmann laboratory. The work is described in Marquis, et al (Marquis et al. 2005).
Mass Spectrometric Analysis of lip DNA Adducts. Reaction of DNA with 11p was
performed on a large scale to obtain sufficient material for structural analysis of covalent
products. Salmon testes DNA (20 mg, Sigma-Aldrich) was dissolved in 20 mL of 5 mM
sodium cacodylate, 25% N,N-dimethylformamide. To the DNA solution was added 100
[tL of 10 mM E2-7a in DMSO, final concentration of 11p was 50 ptM. After incubation
for 16 hours at 37°C, unbound 11P was removed by extraction with
phenol:chloroform:isoamyl alcohol (25:24:1) and subsequent ethanol precipitation. The
DNA was then reconstituted in water and subsequently hydrolyzed in 0.1 N HCl for 30
min at 70°C. The solution was then neutralized with IN NaOH and adjusted to 20 mM
Tris-HCl (pH 7.4), 10% methanol. The hydrolyzed DNA was loaded onto a C 18 Sep-
Pak® (Waters Co.) column and eluted sequentially with 10 mL of 10% and 50% aqueous
methanol solutions and finally with 100% methanol. The 100% methanol fraction was
reduced in vacuo and analyzed by HPLC and mass spectrometry. HPLC analyses were
performed using a Beckman ODS 4.6 x 250 mm Ultrasphere column eluted at 1 mL/min.
with a 20 min. linear gradient of 50% 0.1 M ammonium acetate/10% acetonitrile, 50%
methanol to 100% methanol. Aliquots of samples obtained from HPLC fractionation
were analyzed by electrospray ionization mass spectrometry (ESI-MS) using flow
injection (0.2 mL/min.) in methanol:water:acetontrile (50:45:5) in positive ion mode.
The mass spectrometric analysis was conducted with the help of Dr. John Wishnok and
Dr. Beatrice Zayas.
Cell Culture. The human prostate cell line, LNCaP was obtained from the American
Type Culture Collection (Rockville, MD). The LNCaP cell line was maintained in RPMI
1640 supplemented with 2.5 mg/ml glucose, 10% fetal bovine serum (FBS; Hyclone, Salt
Lake City, UT), 2 mM glutamax, 1 mM sodium pyruvate and 100 mM HEPES. Cells
were grown in a humidified 5% C0 2/air atmosphere at 37DC.
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Identification of DNA Adducts in cells. LNCaP cells were exposed for 6 hours to a
OM dose of 11 j3 dissolved in DMSO. At the end of the incubation the cells were
scraped, pelleted, and washed with phosphate buffered saline (PBS). The cells were
resuspended in 2 mL of cold (4°C) 0.01M Tris (pH 6.9), 0.25M sucrose, 2 mM calcium
chloride buffer. Triton X-100 (25% solution) was added to make a final concentration of
5%. The solution was briefly vortexed and then centrifuged at 100OG in a Sorvall RC-2B
Centrifuge with a GSA rotor at 4°C for 20 min. The supernatant was removed by
aspiration and the nuclear pellet was resuspended in 1 mL of buffer. Sodium dodecyl
sulfate (SDS) (5%) and sodium chloride (NaCl) (5 M) was added to make a solution with
a final concentration of 1% SDS and 1 M NaCl. An equal volume of chloroform:isoamyl
alcohol (24:1) was then added and the biphasic mixture was shaken vigorously for 15
min. The mixture was then centrifuged at 7000G for 15 min at 4°C. The aqueous phase
was collected and re-extracted with another volume of chloroform:isoamyl alcohol,
shaken and centrifuged. The aqueous phase was then collected and the nucleic acids
were precipitated with 3 volumes of ice cold ethanol, chilled at -20°C for 20-30 min, and
subsequently pelleted by centrifugation at 7000G for 15 min at 4°C. The nucleic acids
were washed 2 times with cold ethanol and then dried in vacuo. The dried pellet was
reconstituted with 0.5 mL of 0.05 M Tris (pH 7.5), 0.1 M NaCl on ice. In order to
remove any contaminating RNA, 0.2 mg of RNAse A was added and incubated at 37°C
for 10 min. The reaction was stopped by cooling on ice, the NaCl concentration was
adjusted to 0.9 M, and the DNA was extracted by subsequent additions of
chloroform:isoamyl alcohol as indicated above. The aqueous phase from the second
extraction was isolated and the DNA was precipitated with 3 volumes of ice cold ethanol,
centrifuged, and washed 2 times as above. The DNA was then hydrolyzed as described
above and analyzed by ESI-MS for the characterization of DNA adducts.
Determination of the Partition Coefficient (log P):
Computer Simulation: In order to determine a feasible methodology for the
determination of the log P (and log D) values of 11 3 (and E2-7a), the structure of various
reference compounds, 11 JI, E2-7a, and the E2-7a derivatives were entered into the
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following web sites: 1. http://www.logp.com and 2. http://www.molinspiration.com.
The log P of the reference compounds determined by the computer simulations were
compared to experimentally derived log P values found in the literature to test the
accuracy of these simulations. This has been previously reported in Chapter 2 and will
not be discussed further here. Based on the results described in Chapter 2, an HPLC
methodology was employed.
HPLC: The log P of all compounds was determined by the HPLC method of Donovan
and Pescatore. (Donovan and Pescatore 2002) Briefly, 1 mg of the test compound was
dissolved in 1 mL internal standard solution: 2 mL toluene and 20 mg triphenylene
dissolved in 200 mL of methanol. The compound/internal standard solution (2 !aL) was
injected into a Rainin HPLC with an octadecyl poly(vinyl alcohol) (ODP-50) 20x4 mm, 5
im, 250 A pore size column (Supelco), 10-100% 0.01 M sodium phosphate(pH
adjusted)/methanol gradient over 9.4 min, and a flow rate of 1.5 mL. The pH of the
aqueous buffer was incrementally adjusted by 1 pH unit (from pH 7 - 12) to find the pH
that produced the longest retention time. At this pH, the compound was injected in
triplicate. The compounds were detected at 260 nm by a Dynamax UV-1 detector. The
log P of the test compound is calculated by Equation 6.1. The log D at physiological pH
was calculated based on the equation derived by Horvath, Equation 6.2 (Horvith,
Melinder, and Molnar 1977).
Results
11p Forms DNA Adducts with Guanine Residues in vitro. 11 3 contains a reactive
aniline mustard capable of adducting DNA. The formation and identification of these
adducts was determined using a combination of HPLC and ESI-MS. Figure 6.2
illustrates an HPLC trace after 11 3 was allowed to react with salmon testes DNA in vitro.
The broad peak at 2-3 min corresponds to unreacted free bases while the peak at 16 min
revealed a prominent signal at 813.5 m/z by ESI-MS (Fig 6.3A). Collision induced decay
(CID) on the 813.5 molecular ion yielded prominent fragment ions at m/z 662.3 and
372.1. See Figure 6.3B. The 813.5 mass and the resulting CID are consistent with a
chemical structure in which one ethylene arm of the mustard of 11 3 is attached to
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guanine and the other has a substituted --hydroxyl group for the chlorine atom. See
Figure 6.4 left panel. As shown in Figure 6.4 (left), these ions are consistent with the loss
of the guanine fragment from the adduct (m/z 662.3) and from the fragmentation of the
proposed structure at the secondary amino group in the linker (m/z 372.1). Confirmation
of these structures and of the 813.5 molecular ion resulting from an 11 3P-Guanine adduct
was provided by analysis of covalent products from E2-7a and a tetradeuterated analog of
E2-7a (d4 -E2-7a) (Fig 6.4 right panel) as described in Chapter 2. Unfortunately, a
tetradeuterated analog of 1113 has yet to be synthesized and therefore the only comparison
to be made is with the E2-7a analogs that have the same structure, with the exception of
the steroid moiety, and same molecular weight. HPLC and ESI-MS analysis of the
hydrolysis products of d4-E2-7a under identical conditions identified a compound that
formed a molecular ion of 817.5 with a similar HPLC retention time as the 11 P
compound that produced the m/z 813.5 ion. This result is consistent with a d4-E2-7a-
Guanine adduct. See Figure 6.4 right panel. CID on the 817.5 molecular ion yielded
fragment ions of m/z 666.5 and 372.1, indicating that the m/z 666.5 ion contained the
deuterated portion of the molecule while the m/z 372.1 did not. (as described in Chapter
2) These results with the E2-7a compounds support the proposed structure for the 11 3-
Guanine adduct and the proposed fragmentation pattern.
11p-Guanine Adducts are also Identified in LNCaP cells. LNCaP cells were exposed
to a 10 [pM dose of 11 3 for 6 hours and the DNA from these cells was isolated,
hydrolyzed, and analyzed by ESI-MS for the identification of 11 P-DNA adducts. A
prominent 813.5 m/z signal was observed indicating the formation of an 11 P3-guanine
adduct. See Figure 6.5. This result provides the first evidence that 11 forms DNA
adducts in cells and the formation of these adducts is likely involved in the cytotoxic
properties of the molecule.
The Partition Coefficient (log P): The log P of a compound can be predictive of
aqueous solubility, absorption, and permeability (Lipinski et al. 1997). The lipophilicity
of 1 p and its dimethoxy analog was assessed by the HPLC method of Donovan and
Pescatore (Donovan and Pescatore 2002). Based on the results described in Chapter 2,
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we employed this methodology as a result of the suspected high lipophilicity of our
compounds. A representative HPLC chromatogram is shown in Figure 6.6. 11p (11.48
min.) is bracketed by toluene (8.65 min.) and triphenylene (12.89 min.). The log P of
11 3 and 11 -dimethoxy was found to be 5.05 and 4.07, respectively. The log D at pH 7.4
was estimated using an equation derived by Horvath et al (Horvith, Melinder, and
MolnAr 1977). See equation 6.2. The log D of 11 3 and 11 3-dimethoxy was calculated to
be 2.00 and 0.97, respectively. The log D values indicate that the aqueous solubility of
the 11 P-dimethoxy compound is approximately 10-fold greater than 11 3 under
physiological conditions.
Discussion
Our studies on E2-7a demonstrated that a selective antitumor agent could be
created by incorporating additional mechanisms of action into a traditional alkylating
chemotherapeutic agent. E2-7a and its predecessor, 2-PI, are multifunctional agents
which have the ability to modify DNA covalently and attract tumor specific proteins to
the site of these lesions (Mitra et al. 2002; Rink et al. 1996; Sharma et al. 2004). The
results describing the biological activity of E2-7a were described in Chapters 2-5. Here,
I report the application of our strategy to improve conventional chemotherapeutics
through the creation of a novel molecule, 113, designed to target AR(+) prostate cancers,
which have been problematic from the clinical management perspective.
Key to the biological activity of 11 3 is the ability to modify DNA covalently and
interact with the AR. Kasuhik Mitra, of the Essigmann Laboratory, illustrated that
approximately 75% of the self-complimentary deoxyoligonucleotide, 5'[32p]_
d(ATTATTGGCCAATAAT)-3', was found to be piperidine labile after a 4 hour
incubation with 100 [tM 11 , indicative of the formation of covalent DNA adducts. (data
not shown) (Marquis et al. 2005). Nicole Dinaut, also of the Essigmann Laboratory,
illustrated the ability of 11 3 to bind to the AR in a competitive binding experiment. 11 3
was found to have a relative binding affinity (RBA) of 11 for the AR in LNCaP whole
cell extracts, when compared to the synthetic androgen [3H]-R1881 (Marquis et al. 2005).
See Figure 6.7. Since the affinity for R1881 is about twice that of the natural ligand
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dihydrotestosterone, an RBA of 11 implies that the affinity of 11 3 is approximately 20%
that of the natural ligand (Zhao et al. 1999). Furthermore, 11 3-DNA adducts were found
to have a weaker yet still finite affinity for the AR (RBA = 0.2). Of note for experiments
to be discussed later in this section, the 11 P3-dimethoxy compound was not able to adduct
DNA, but had an affinity for the AR similar to that of 1113. These two experiments
provided crucial evidence that shows 11 3 is capable of forming DNA adducts and that
these adducts are capable of attracting the AR to the site of the lesion.
Since we had shown that 111 3was capable of adducting DNA, we investigated
whether it would act analogously to chlorambucil and predominantly adduct the N7
position of guanine. The N7 position of guanine is the most nucleophilic site in DNA
and is therefore the most typical site of aniline mustard adduct formation (Singer and
Grunberger 1983; Sunters et al. 1992; van Zeeland 1996). 11p was incubated with DNA
in vitro and the formation of DNA adducts was characterized by ESI-MS. A molecular
ion of 813.5 m/z was obtained, which is consistent with the substitution of the two
chloro- groups by a guanine on one ethylene arm of the nitrogen mustard and a hydroxyl
group on the other arm. Unfortunately, a tetradeuterated version of 1 has yet to be
synthesized and therefore the only structural comparison which can be made is between
the fragmentation pattern observed when E2-7a and a tetradeuterated version, d4-E2-7a,
reacted with DNA. Such a comparison may be valid in this situation as both 11 p and E2-
7a have identical molecular weights and identical structures, with the exception of the
steroid end that, coincidentally, remains intact upon CID. E2-7a also yielded an 813.5
m/z molecular ion and the d4-E2-7a produced a molecular ion of 817.5 m/z. The CID of
E2-7a was identical to what was observed with 11 , and the d4-E2-7a had one fragment
of identical molecular weight and another of +4 m/z. These ESI-MS results illustrate that
the adducts formed with 11 3 are likely identical to what was previously reported with E2-
7a (Mitra et al. 2002), indicating that 11 P forms DNA adducts at the N7 position of
guanine in a similar manner as to what was previously reported with chlorambucil
(Haapala et al. 2001; Povirk and Shuker 1994).
The AR(+) LNCaP cell line was exposed to 11 for 6 hours and the DNA from
these cells was isolated, hydrolyzed, and analyzed by ESI-MS. The results illustrate that
the same 11 P-guanine adducts that formed in vitro also form in LNCaP cells. The
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formation of these adducts indicates that the molecule is not rapidly degraded through
hydrolysis of the bis-2-chloroethyl arms. The importance of this discovery lies in the fact
that the molecule crossed two bio-physical membranes in order to reach the intended
DNA target.
The permeability of 11 p in crossing two biomembranes was quantitatively
derived by using an HPLC methodology for calculating its log P. 11 3 had a log P value
of 5.05 and a log D of 2.00 as calculated using an equation derived by Horvath, et al
(Horvdth, Melinder, and Moln.r 1977). These values in addition to the fact that 11 13
contains fewer than 10 hydrogen bond acceptors and fewer than 5 hydrogen bond donors
satisfy 3 of the 4 "rules of 5" that Lipinski has proposed (Lipinski et al. 1997).
Molecules that comply with Lipinski's "rule of 5" generally have favorable aqueous
solubility and permeability across biomembranes. The one criteria that does not satisfy
Lipinski's rule is the molecular weight of 11p is in excess of 500 Da (11p3 has a molecular
weight of 716 Da). The low log D suggests that the compound may have favorable
pharmacokinetics (as will be discussed in Chapter 7) and, as evident with the results from
the formation of DNA adducts in LNCaP cells, cellular permeability.
John Marquis, of the Essigmann Laboratory, further investigated the permeability
and also the toxicity of 11 3 by exposing the AR(+) LNCaP cells with 0-10 ItM doses in
culture. In an effort to gain insight into possible mechanistic aspects of the compound,
the AR(-) PC-3 and DU-145 cell lines were also exposed to 0-10 [tM concentrations of
11 P. Chlorambucil was used as a control in all three cell lines. The results shown in
Figure 6.8A illustrate that a 10 [tM dose of 11 3 for a brief 2 hour exposure to LNCaP
cells is much more toxic than the same dose in PC-3 and DU-145 cells. Furthermore, the
alkylating agent, chlorambucil, was no more toxic to any one cell line and the overall
toxicity of chlorambucil is much less than what was observed for 1 13 (Fig 6.8B). These
results are consistent with our intended mechanism of action in which cells that express
the AR would be selectively more toxic than cell lines that do not, possibly as a result of
the repair shielding and transcription factor hijacking hypotheses.
To further address the possible mechanism(s) of 11 3, John Marquis and Bob Croy
treated the AR(+) LNCaP cells with 11 , 11 13-dimethoxy, or chlorambucil. Cells treated
with 11 p displayed dramatic cytoplasmic contraction and detachment from the culture
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dish within 6 hours, whereas chlorambucil treated cells did not. Treatment with 11 P3-
dimethoxy produced a less dramatic and transient change in cell morphology. The cells
remained attached to the culture dish and recovered to their pretreatment shapes by 24
hours. Only the cells treated with 11 3 underwent apoptosis as characterized by Annexin
V staining, DNA laddering, and poly-ADP ribose polymerase (PARP) cleavage (Fig 6.9
A-C, respectively). These results suggest that 11 p is effective in overcoming the
roadblocks in LNCaP cells that prevent other alkylating agents, such as chlorambucil,
from activating apoptosis (Marquis et al. 2005).
Although 11 3-dimethoxy was unable to initiate an apoptotic response, LNCaP
cells treated with the compound arrested in the G1 phase of the cell cycle. These results
led us to investigate the expression of the G1 cell cycle checkpoint proteins, specifically
the cyclin-dependent kinase (CDK) inhibitors, p21 CiPl and p27KiPl . The expression level
of p21 constantly increased over time in LNCaP cells treated with chlorambucil.
However, in cells treated with 1 p and 11 3-dimethoxy, the level of p21 was initially
suppressed, but was then restored to basal levels in cells treated with 11 B3-dimethoxy and
eventually elevated by several fold in cells treated with 11 3 (Marquis et al. 2005). See
Figure 6.1 OA. p21 plays an essential role in growth arrest after DNA damage (Gartel and
Tyner 2002b). Our findings suggest that p21 expression is modulated by DNA damage
produced by the reactive compounds, most likely through activation of the p53 pathway.
LNCaP cells express wild-type, functional p53 (Isaacs 2000), which is a major regulator
of p21 transcription in response to DNA damage (el-Deiry et al. 1993). There are several
reports indicating that increased expression of p21 protects prostate cancer cells as well
as other cell types against apoptosis induced by a variety of different anticancer agents
(Gartel and Tyner 2002a; Martinez et al. 2002). These findings suggest significance to
the different patterns of p21 induction that we observed in LNCaP cells treated with
chlorambucil or 11 P3-dichloro. While chlorambucil produced a rapid increase in the level
of p21, the 11 3-dichloro compound initially decreased levels of p21 in LNCaP cells.
Since the initial reduction of p21 levels also occurred with the unreactive 11 P3-dimethoxy
analog, other features of our compounds, unrelated to DNA damage, are likely involved
in this response.
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The expression of the other CDK we investigated, p27, was unchanged by
chlorambucil but elevated in cells treated with either of the 11 p compounds (Marquis et
al. 2005). See Figure 6.1 OA. This result could be explained by a direct interaction of our
compounds with the AR. The effects of androgens on the proliferation of LNCaP cells
are well characterized. Low concentrations of androgens such as DHT stimulate growth
while high concentrations are inhibitory (Kim et al. 1996; Lee et al. 1995). Treatment of
growing LNCaP cells with a high dose of DHT (100 nM) results in the accumulation of
p27 and growth arrest within 24 h (Tsihlias et al. 2000).
In addition, p27 accumulation during androgen-induced growth arrest has been
linked to decreased expression of the p45SKP 2 subunit of the ubiquitin E3 ligase SCFSKP2
(Lu, Schulz, and Wolf 2002b). The direct binding of the Skp2 subunit to the cyclin
kinase subunit CKS 1 directs the ubiquitination and subsequent proteolysis of p27
(Ganoth et al. 2001; Spruck et al. 2001). Therefore, the levels of p27 can be regulated by
its ubiquitin-dependent degradation through the ubiquitin E3 ligase SCFSkp2 (Skp2)
(Carrano et al. 1999; Lu, Schulz, and Wolf 2002a). Both 11 p compounds decreased the
expression of Skp2 as seen in Figure 6. 10 OB (Marquis et al. 2005). The decreases in Skp2
expression correlate well with the relative levels of increase in expression of p27 as
expected with the involvement of Skp2 in the turnover of p27. Unlike the 11 P-dimethoxy
compound, which temporarily arrests cells in the G1 phase of the cell cycle, 1 O does not
arrest LNCaP cells in G1, but instead rapidly induces apoptosis. These results may be
explained by the unique nature of 11 3-dichloro in that the AR can be attracted to the site
of DNA adducts and thus disrupt cellular signaling events, perhaps through the
transcription factor hijacking mechanism.
Conclusion
Based upon mechanistic studies of the anticancer agent cisplatin, we have
designed a single molecule that can form DNA adducts and attract tumor specific
proteins to the site of the lesions. Using the work described in Chapters 2-5 as a model,
we have incorporated a new steroid moiety which provided a molecule that could be used
to treat AR(+) prostate cancers. This new molecule, 11 3, has features derived from E2-
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7a - a DNA reactive warhead based on the aniline mustard chlorambucil, a stable linker,
and a steroid that has a good affinity for the AR.
The work described here illustrates several important features of this molecule
that demonstrate its potential as a chemotherapeutic agent. I have shown that 11 3 has
good aqueous solubility as described by its low log D. 11 p forms DNA adducts, and
these adducts have been identified as mono-guanine adducts after reaction with DNA in
vitro and isolated from the DNA of LNCaP cells exposed to 1 for 6 hours.
Furthermore, 11 3 has a good affinity for the AR both alone and when adducted to DNA,
and it displays increased toxicity towards the AR(+) LNCaP cell line over the AR(-) PC-
3 and DU-145 cell lines. The differences in the expression levels of the cell cycle
regulatory proteins, p21, p27, and Skp2, after LNCaP cells were treated with
chlorambucil, 1 3-dimethoxy, or 11 3, illustrate the unique nature of 11 3. Only 1 [3 was
capable of inducing apoptosis in this cell line. These results indicate features in addition
to DNA adduction are responsible for the cytotoxicity of 11 P. Therefore, a molecule
such as 1113, that combines several different mechanisms into a single agent, may have a
unique place in the pharmacopoeia of anticancer agents.
The results here illustrate a unique response of LNCaP cells exposed to 1 3.
These promising results have given us confidence in further exploring the properties of
11 BP to address its usefulness as a drug. In the subsequent chapters, I shall discuss
experiments designed to evaluate the pharmacokinetics, acute and chronic toxicity, and
(antitumor) therapeutic potential.
Future Directions
The results from this chapter illustrate several key features of i1 : a log D
indicative of good permeability and absorption, the formation of DNA adducts with
guanine in vitro and in LNCaP cells in culture, a good affinity for the AR, the induction
of apoptosis in LNCaP cells, and altered expression levels of cell cycle checkpoint
proteins. These experiments indicate that 1i1 p is unique from other alkylating agents that
do not induce apoptosis in a prostate cancer cell line. Furthermore, the ability of 11 P, but
not 1 1P-dimethoxy, to induce apoptosis indicates that the role of DNA damage is
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essential. It is the combination of DNA damage and the disruption of cellular pathways
that enable 11 3 to achieve its cytotoxic effects.
The work described here illustrates some differences between chlorambucil, 11 P3,
and 11 fP-dimethoxy. However, these experiments are not conclusive in proving the repair
shielding, transcription factor hijacking, or other unknown mechanism(s) of action by
which 1 3 acts. Therefore, considerable efforts must be made in identifying the
molecular mechanisms involved. For example, LNCaP cells treated with chlorambucil
arrest in S phase. This arrest is likely elicited through the capacity of p21 to halt cell
cycle progression by inhibiting CDKs and interacting with the proliferating cell nuclear
antigen (PCNA), thereby stopping DNA synthesis (Waga and Stillman 1998). In
contrast, LNCaP cells treated with 1 3 result in a decrease in the number of cells in S
phase. The early elimination and delayed increase in the expression of p21 in cells
treated with 11 3, as described above, may disable a key checkpoint that arrests cell
growth in S phase allowing for the repair of damage and sensitizing cells to apoptosis.
However, it will require further investigation to identify the mechanism(s) underlying the
reduction of p21 and the role it plays in the cytotoxic effects of our compounds.
The results here were accomplished using the AR(+) LNCaP cell line. The
AR(-) PC-3 and DU-145 cell line displayed lower toxicity when treated with our
compound. The differential toxicity between the lines also needs to be addressed. As
initial experiments, it would be of interest to monitor the response of the cell cycle
checkpoint proteins of these cells to treatments with chlorambucil, 1 , and 11 3-
dimethoxy. Since they lack the AR, differences in p27 expression level from what was
observed with the LNCaP cells may indicate that the increased levels after treatment with
either 1 compound was indeed a result of a direct interaction with the AR.
Finally, the work with the AMS technology described in Chapter 5 can be
translated to the 1 3 compound. A comparison in the rates of DNA adduct formation and
repair in the AR(+) LNCaP to that in either the AR(-) PC-3 or DU-145 cell line could
provide important evidence in favor of the repair shielding hypothesis. If the rate of
repair in the LNCaP cell line is significantly slower than what is observed in one of the
AR(-) cell lines, it would imply DNA adducts formed by 11 3P are indeed attracting the AR
to the site of the lesion and inhibiting repair. Further support of this hypothesis would be
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provided if the rates of repair were identical for a traditional alkylating agent such as
chlorambucil or melphalan.
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Equations Used to Calculate the
Log P and Log D
log Punk = (log Ptol - log Ptriph)*tunk + ttol*log Ptriph - ttriph*log Ptol
ttol - ttriph
Equation 6.1 t is the retention time as determined by HPLC (tol
= toluene, triph = triphenylene, unk = unknown). The log P of
toluene and triphenylene were 2.61 and 6.27 respectively as
previously reported.
log D = log (P * 10pKa + Pi * 10PH) - log(1OpKa + 10PH)
Equation 6.2 P is the partition coefficient for the neutral
molecule (as determined by HPLC), Pi is the partition coefficient
for the ion (not measured but assumed the log Pi was 3.15 less
than the log P of the neutral molecule), Ka is the equilibrium
constant for acids.
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Chapter 7
Probing the Biochemical Mechanism of
11P In Vivo:
Pharmacokinetics, Toxicity, and Adduct Identification
Introduction
Prostate cancer is the second most commonly diagnosed cancer and the fourth
leading cause of cancer death among men in developed countries (Weir et al. 2003).
Most prostate cancers are dependent on the presence of androgens for their growth, and
therefore chemical or surgical castration is often an adjuvant therapy (following the
surgical removal of the tumor) resulting in the apoptotic death of androgen-sensitive cells
(Bruckheimer, Gjertsen, and McDonnell 1999; Kozlowski, Ellis, and Grayhack 1991;
Kreis 1995; Santen 1992). Unfortunately for the patient, these treatments often result in
the transition to aggressive and metastatic androgen-independent prostate cancer or
hormone-resistant prostate cancer (HRPC). This transition to androgen-independence
occurs likely through selection for growth of androgen-independent cells that may have
coexisted with an androgen-dependent population prior to the androgen deprivation
therapy (Gingrich et al. 1997; Isaacs and Coffey 1981; Kyprianou 1994). Several reports
have illustrated that the androgen-refractory prostate cancer cells, although impervious to
androgen receptor (AR) antagonism, retain the capacity to undergo apoptosis (Denmeade
et al. 1999; Marcelli et al. 2000; Wang et al. 1999). Novel approaches toward HRPC
treatment, including anti-angiogenesis agents, cancer vaccines, antisense
oligonucleotides, and novel chemotherapeutics, have been proposed, but these therapies
are years away from having a clinical impact and may be of limited efficacy (Gulley and
Dahut 2003). Furthermore, current therapies have very limited efficacy in HRPC.
Therefore, the need exists for new therapies that can attack both androgen-dependent and
androgen-independent prostate cancer cells.
In androgen -dependent and -independent prostate cancer, the AR is frequently
over-expressed at both the mRNA and the protein level (Gioeli 2005; Gioeli 2004; Wang,
Ossowski, and Ferrari 2004). We have taken advantage of this biological effect by
designing compounds that have the ability to adduct DNA and attract the AR to the site
of the modified DNA. A protein-drug-DNA complex formed in a prostate cancer cell
would shield the DNA adduct from repair enzymes, and the persistence of the DNA
adduct would be lethal to the cell. Furthermore, an interaction with DNA adducts would
likely titrate away the normal transcriptional activities of the AR and result in the
disruption of pro-survival cellular signaling events. The combined repair shielding and
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transcription factor hijacking effects would likely be very toxic for an AR expressing
prostate cancer cell. The dependency on androgen for growth would be irrelevant and
therefore our compound could be effective in treating both androgen -dependent and -
independent cancers.
In Chapter 6, I reported the results of several experiments describing the in vitro
activity of our current lead compound, 1 , against prostate cancer. 11 p interacts well
with the AR (RBA -36 as compared to testosterone), has a log D indicative of oral
administration (2.00), covalently modifies guanine in DNA, is cytotoxic to AR(+)
LNCaP cells, and induces apoptosis in these cells. Despite these promising results there
are other factors that impact the ability of a molecule to become a potential drug
candidate, such as the bio-distribution, pharmacokinetics, toxicity, ability to remain
intact, and ability to form DNA adducts in vivo. These features of 11 3 will be discussed
in this chapter.
Based on the results seen in Chapter 3 with E2-7a, 11 p was formulated in
Cremophor-EL (CR-EL) and injected intraperitoneally (IP). (Note: CR-EL is currently
part of the formulation for the clinically used Taxol (paclitaxel) in the therapy of ovarian
cancer, breast cancer, Kaposi's Sarcoma, and non-small cell lung cancer.) The
distribution in mice injected with 11 3P will be discussed as will the pharmacokinetic
parameters derived from these studies.
Additionally, a dose range finding study was performed to address the acute
toxicity of 1 . Blood chemistry and hematology reports provided a means of addressing
organ specific toxicity. This information is critical in deciding upon a therapeutic dose
when initiating a tumor ablation study and in more focused monitoring of the side-effect
profile of the treated mice (to be discussed in Chapter 8). I will also discuss the
identification of E2-7a DNA adducts isolated from tissue in vivo. These results parallel
the in vitro work discussed in Chapter 6.
Materials and Methods
Animals. Four to six week old NIH Swiss Webster mice were purchased from Charles
River Laboratories, Wilmington, MA. NIH Swiss nu/nu athymic mice (25g) were
purchased from the National Cancer Institute-Frederick Cancer Center (NCI) (Frederick,
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MD). The mice were housed under standard conditions in MIT approved facilities with
12 hour light/dark cycles and food and water ad libitum. All protocols were performed in
compliance with the regulations of the Animal Care Committee at MIT.
Bio-Distribution. 11f (45 mg/kg) spiked with 5 giCi of 14 C-1 1p was dissolved in 50 pL
of a CR-EL based solution (43% CR-EL, 30% saline, 27% ethanol) and injected IP.
Mice were sacrificed by carbon dioxide asphyxiation at 0.25, 1, 2, 4, 6, and 24 hours post
injection. Blood was obtained by cardiac puncture. The following tissues were removed
surgically: lung, liver, spleen, kidney, GI, feces, and in some instances adipose, heart,
and skeletal muscle. Approximately 100 mg of each tissue (10 L of whole blood) were
isolated for liquid scintillation counting. To each tissue sample was added 1 mL of
Solvable (Packard Biosciences, Meriden, CT) and heated to 65°C for 3 hours or until the
tissue was completely dissolved. Two 100 j.L aliquots of 30% hydrogen peroxide were
added to the cooled off solution to decolorize. Approximately 15 mL of Hionic Flour
scintillation fluid (Packard Biosciences, Meriden, CT), which is compatible with
Solvable, was added and counted in a Beckman LS 1801 Liquid Scintillation Counter.
The data are calculated as % injected dose per gram of tissue (% ID/g).
Pharmacokinetic Analysis. Pharmacokinetic parameters after administration of 1 j3
were calculated by standard noncompartmental methods with GraphPad Prism version
3.00 for Windows (GraphPad Software, San Diego California USA). The area under the
blood concentration vs. time curve (AUC) was calculated by the linear trapezoidal rule.
The systemic clearance (CL) was calculated by dividing the dose by the AUC. The
volume of distribution (Vd) was calculated by dividing the dose by the extrapolated
concentration of drug in the blood at time equals zero hour. Since the drug concentration
(post-peak) declined nearly exponentially, the half-life (tl/2) was determined by nonlinear
regression analysis using a single phase exponential decay model. Cmax and tmax were
read directly from the data.
Plasma Analysis. Whole blood was collected by cardiac puncture from the mice after
14C-1 13 injection. The plasma was isolated by adding two volumes of acetonitrile to one
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volume of whole blood to precipitate the red blood cells and plasma proteins. The
colloidal suspension was centrifuged for 5 min at 13,000 x G, and the supernatant was
collected and separated into two aliquots. One aliquot was used to determine the amount
of protein binding, and the other aliquot was used to determine the concentration of 11 P
in the plasma.
The aliquot used to determine the amount of protein binding was isolated,
combined with scintillation fluid, and counted on a Beckman LS 1801 Liquid Scintillation
Counter. Additionally, the pellet obtained from the acetonitrile precipitation was
collected, combined with 1 mL of Solvable (Packard Biosciences), and heated overnight
at 70°C. Subsequently, two 100 gL aliquots of hydrogen peroxide were added to
decolorize the solution, and finally scintillation fluid was added to quantify the
radioactivity in the pellet. The percentage of 11 P in the plasma was calculated by
dividing the amount of radioactivity in the plasma by the sum of the amount in the
plasma and the amount in the pellet.
In order to determine the concentration of 11 p in the plasma the second aliquot
was dried in a speed-vac. The dried residue was reconstituted with 100 [tL of acetonitrile
and injected onto a Rainin HPLC (Rainin HPXL) with a Rainin UV-1 UV Detector
monitored at 260 nm and an in-line Packard Flow Scintillation Analyzer Model 150TR.
The analyses were performed using a Beckman ODS 4.6 x 250 mm Ultrasphere column
eluted at 1 mL/min using 0.1 M ammonium acetate/10% acetonitrile in water and
methanol as solvents. A 20 min linear gradient of 50% methanol to 100% methanol was
used. Only the radioactive 14C-11 p parent peak was used to determine the concentration
of the compound in plasma. A 4C-1l 13 standard was counted on a Beckman LS 1801
Liquid Scintillation Counter prior to injection onto the HPLC. It was determined that a
peak with an area under the curve (AUC) of 432,000 on HPLC corresponded to 13,300
CPM.
Acute Toxicity. Groups of 3-4 NIH Swiss nu/nu athymic mice from the NCI were
injected IP with 10-150 mg/kg of 11P formulated in a CR-EL solution (43% CR-EL, 30%
saline, 27% ethanol). Additionally, 4 mice were injected with vehicle and 4 others were
left untreated as controls. The mice were sacrificed by carbon dioxide asphyxiation 24
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hours after the injection. Blood was obtained by cardiac puncture and sent to IDEXX
(formerly Tufts Veterinary Diagnostic Laboratory, North Grafton, MA) for hematology
and blood chemistry analysis.
Identification of 11p DNA Adducts in Vivo. 11 3 (25 mg/kg, not radiolabeled) was
injected into NIH Swiss Webster mice by IP injection. The mice were sacrificed after 4
hours by carbon dioxide asphyxiation. The liver was removed surgically, snap frozen on
dry ice, and stored at -80°C until it could be worked up. The liver sample was thawed
and homogenized in a Dounce homogenizer on wet ice with 15 mL of cold (4°C) 0.01M
Tris (pH 6.9), 0.25M sucrose, 2 mM calcium chloride buffer. The homogenate was
filtered through a coarse and then a fine nylon mesh to remove all connective tissue. To
the filtrate was added 25% Triton X-100 to make a final concentration of 5%. The
solution was briefly vortexed and then centrifuged at 1000 x G in a Sorvall RC-2B
Centrifuge with a GSA rotor at 4°C for 20 min The supernatant was removed by
aspiration, and the nuclear pellet was resuspended in 2.5 mL of buffer. To this solution
was added 5 % sodium dodecyl sulfate (SDS) and 5 M sodium chloride (NaCl) to make a
solution with a final concentration of 1% SDS and 1 M NaCl. An equal volume of
chloroform:isoamyl alcohol (24:1) was then added, and the biphasic mixture was shaken
vigorously for 15 min The mixture was then centrifuged at 7000 x G for 15 min at 4°C.
The aqueous phase was collected and re-extracted with another volume of
chloroform:isoamyl alcohol, shaken, and centrifuged. The aqueous phase was then
collected, and the nucleic acids were precipitated with 3 volumes of ice cold ethanol,
chilled at -20°C for 20-30 min, and subsequently pelleted by centrifugation at 7000 x G
for 15 min at 4°C. The nucleic acids were washed 2 times with cold ethanol and then
dried in vacuo. The dried pellet was reconstituted with 2 mL of 0.05 M Tris (pH 7.5), 0.1
M NaCl on ice. In order to remove any contaminating RNA, 0.5 mg of RNAse A was
added and the solution incubated at 37°C for 10 min. The reaction was stopped by
cooling on ice. The NaCl concentration was adjusted to 0.9 M, and the DNA was
extracted by subsequent additions of chloroform:isoamyl alcohol as indicated above. The
aqueous phase from the second extraction was isolated, and the DNA was precipitated
with 3 volumes of ice cold ethanol, centrifuged, and washed 2 times as above. The DNA
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was finally hydrolyzed in 0.1 N HCl for 30 min at 70°C. The solution was neutralized
with N NaOH and adjusted to 20 mM Tris-HCl (pH 7.4), 10% methanol. The
hydrolyzed DNA was loaded onto a C18 Sep-Pak (Waters Co. Milford, MA) column
and eluted sequentially with 10 mL of 10% and 50% aqueous methanol solutions and
finally with 100% methanol. The 100% methanol fraction was reduced in vacuo and
analyzed by HPLC and mass spectrometry. HPLC analyses were performed as described
in the Plasma Analysis section. Aliquots of samples obtained from HPLC fractionation
were analyzed by electrospray ionization mass spectrometry (ESI-MS) in positive ion
mode using flow injection (0.2 mL/min) in methanol:water:acetontrile (50:45:5).
Results
Bio-Distribution and Pharmacokinetics. 11 3 was injected into mice in order to obtain
pharmacologically relevant information about the compound. Based on the results
discussed in Chapter 3, 11p3 was formulated in a CR-EL based vehicle (43% CR-EL, 30%
saline, 27% ethanol) and administered IP. The results of this experiment are summarized
in Table 1 and expressed in terms of percent injected dose per gram of tissue (% ID/g).
11 p is quickly absorbed in the mouse. At the 15 minute time point, the highest
concentration of E2-7a could be found in the blood (5% ID/g). The organs with the most
accumulation at all time points include the liver, intestines, and kidneys. Surprisingly,
very little 11 p accumulated in the feces until the 6 hour time point, when it contained
approximately 9% ID/g.
The concentration of 11 3P in whole blood was determined by liquid scintillation
counting. However, the concentration of 1 3 in plasma was determined by precipitating
the red blood cells and proteins from the plasma and injecting the serum only onto an
HPLC. The concentration of 1 1p in plasma was derived from the integration of the AUC
of the 25 min peak on the HPLC. The 15 min, 1 hour, and 4 hour time points are shown
in Figure 7.1 A-C. At the 15 min time point, the only radioactive peak that is present
corresponds to intact 1 . However, the 1 and 4 hour time points have smaller peaks
eluting at 4 and 13 min which are likely metabolic breakdown products.
The concentration of 11 p in whole blood and in plasma is shown in Figure 7.2 A
and B, respectively. Only the AUC of the 25 min peak was used to calculate the plasma
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curve shown in Figure 7.2B. 1113 has a peak concentration in whole blood of 128 [M and
190 pM in plasma. These results indicate that 11 p is likely not bound to proteins in
blood nor does it accumulate in erythrocytes. This hypothesis was confirmed by the
experimental evidence shown in Figure 7.3 in which > 87% of the radioactivity in the
blood was in the plasma compartment and not associated with erythrocytes or covalently
bound to proteins for the first 6 hours after administration of 11 p. At 24 hours nearly
60% of the radioactivity in the blood was still in the plasma compartment.
The pharmacological parameters of 11 p after IP administration with the CR-EL
based vehicle were also calculated. Table 2 compares the following pharmacological
parameters: AUC: area under the plasma concentration-vs.-time curve; tin2: half-life; CL:
clearance; Vd: volume of distribution; Cux: maximum concentration in blood; tma,,: time
at which Cmax was achieved. The tmax at 15 minutes indicates that 11 3 is rapidly absorbed
by the body even though it was administered IP. The low apparent Vd (0.49 L/kg)
indicates that 11 p distributes into total body water (Jang, Harris, and Lau 2001).
Acute Toxicity. The acute toxicity of 11p3 was determined by injecting 3-4 NIH Swiss
Nude mice with 0-150 mg/kg of 11 3 IP. The mice were sacrificed 24 hours post-
injection and their blood was obtained for hematology and blood chemistry analysis. The
results of these findings are summarized in Table 7.3 and Table 7.4, respectively. Values
that are abnormally high or low are shown in bold italics and all values are expressed in
terms of measurable units with the exception of neutrophils, lymphocytes, monocytes,
and eosinophils, which are expressed in relative terms as % of total white blood cells.
Hematological abnormalities included an increase in the total number of white blood cells
at the highest doses of 100 and 150 mg/kg and an increase in the ratio of neutrophils to
lymphocytes as compared to the control mice. The most notable result, however, is the
hepatotoxicity which is first evident at the 50 mg/kg dose with elevated levels of
aminotransferase (AST), alanine aminotransferase (ALT), amylase, and lipase. Renal
toxicity is apparent at doses of 75 mg/kg and above with increased blood urea nitrogen
(BUN) levels as well as increased creatinine and phosphorous and decreased calcium at
the 100 and 150 mg/kg doses. Possible cardiac toxicity is evident at the 75 mg/kg dose
and above given the elevated creatinine kinase (CK). The LD 50 was determined to be
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between 100-150 mg/kg since the dose was lethal to 50% of the mice within 24 hours
after treatment in both groups.
11 Forms DNA Adducts with Guanine Residues in Vivo. In order to assess the
ability of 11 3 to adduct DNA in vivo, mice were injected with 25 mg/kg of 1113. The
bio-distribution results indicated that more of the dose was absorbed by the liver than by
any other organ. Therefore, the liver was harvested and homogenized in order to isolate
11 3 DNA adducts that had formed in vivo. The DNA was isolated, hydrolyzed, and
analyzed by ESI-MS. Figure 7.4A shows the main molecular ion is at 813.5 m/z. This is
the same mass as the ion observed when 11 was reacted with DNA in vitro as discussed
in Chapter 6. CID of the 813.5 m/z peak resulted in the same 662.5 m/z and 372.1 m/z
fragmentation as observed previously with the in vitro adducts (Fig 7.4B). The proposed
structures of the daughter ions are shown in Fig 7.4C. The daughter ions are the same as
what has been seen for 11 p adducts in vitro (as described in Chapter 6) and for E2-7a in
vitro and in vivo (as reported in Chapter 2 and 3 and in Mitra et al) (Mitra et al. 2002).
Unfortunately, a deuterated derivative of 11 3 has not yet been synthesized. However,
E2-7a and 11 3 have the same exact molecular weight, and therefore it is reasonable to
extrapolate the deuterated and undeuterated results with E2-7a to 11 . This provides us
with confidence that the 813.5 m/z molecular ion was indeed an 11 3-guanine adduct in
which one arm was hydrolyzed.
Discussion
11 3 was formulated in a CR-EL based vehicle and injected IP in order to obtain
information regarding the distribution and pharmacokinetics of the compound. 11 p was
rapidly absorbed by the body and distributed to all major organs. A large fraction of 11p
accumulated in the liver, indicating that the liver is likely the major route of metabolism
with excretion through the feces. Paclitaxel and docetaxel, both formulated in a CR-EL
solution, are also predominantly excreted by the liver and into the feces (Bissery et al.
1995; Sparreboom et al. 1997; Sparreboom et al. 1998; Sparreboom et al. 1996). At the
earliest time points the feces contained less than 3% ID/g of 113i, and not until the 6 hour
time point did any significant accumulation occur (9% ID/g). The rate of excretion of
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113 is slower than what has been reported for paclitaxel, possibly implying more
favorable therapeutic efficacy (Klecker et al. 1994; Sparreboom et al. 1996).
Other organs with high accumulations of 113 included the intestines and kidneys.
Perhaps one reason the intestines had a high concentration of compound was because of
the route of administration and/or the vehicle used. However, a Caco-2 permeability
study would be needed in order to confirm this hypothesis. The concentration of 11 in
the kidneys increases with time until it reaches a peak concentration at 4 hours. This
could be the result of renal absorption or excretion of 11 3P and/or its metabolic breakdown
products. Unfortunately metabolic cages were not used in this experiment and therefore
future experiments would be needed to analyze concentrations in the urine and to better
understand the excretion of 11 .
11 p was rapidly absorbed in the mouse with peak concentrations in the blood of
128 [tM and 190 gM in the plasma (Cmax) at the 15 minute time point (tmx). The higher
concentration of 11 3 in plasma compared to that in whole blood indicates that the
compound is almost entirely in the plasma compartment of whole blood and very little
1113 accumulates in erythrocytes or is covalently bound to plasma proteins. The protein
adduction curve provides additional experimental evidence in that >87% of the drug in
whole blood was found in plasma, not taken up by erythrocytes or covalently adducted to
plasma proteins for the first 6 hours after IP administration (Fig 7.3). However, 11 3
could still be associated with plasma proteins non-covalently. Chlorambucil has been
shown to be 99 % (non-covalently) bound to proteins in mouse plasma (Lee, Coe, and
Workman 1986).
Nakai et al, showed that various conventional antitumor drugs can be grouped
into two types with respect to cytotoxic action in vitro: cell cycle phase nonspecific (type
I) and specific (type II) drugs. The cytotoxic activity of type I drugs, which includes
alkylating agents and antitumor antibiotics, is AUC specific. However, the cytotoxic
activity of type II drugs, which include antimetabolites and vinca alkaloids, is time
dependent. Therefore, not only the AUC in the target organ, but also the exposure time is
an important factor for evaluating the efficiency of any delivery system for antitumor
drugs (Nakai et al. 1996). 11 is an alkylating agent, and therefore the cytotoxicity of the
compound should correlate with the AUC. Pharmacokinetic data from Newell et al,
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show the AUC of chlorambucil is 22 lpg x hr/mL when a therapeutic dose of 10 mg/kg
was administered sub-cutaneously in rats (Newell, Shepherd, and Harrap 1981). The
AUC of 113 was found to be 402 [g x hr/mL when a 45 mg/kg dose was administered IP
in mice. Assuming linear pharmacokinetics, a 10 mg/kg dose of 11 p would yield an
AUC of 89 lag x hr/mL, 4-fold greater than the AUC found for chlorambucil.
Furthermore, the exposure necessary for 11 3 to be therapeutically active could be much
less than what is needed for chlorambucil if the repair shielding and transcription factor
hijacking hypotheses are valid. In either case, 11 p would be selectively retained in tumor
tissue and therefore potentially a lower number of DNA adducts would be required for
tumor lethality. This evidence illustrates the potential of 11 3P as an effective anticancer
agent.
To assess further the likelihood of 11 p as a chemotherapeutic agent, blood
chemistry and hematological analyses were performed in order to gauge organ specific
toxicity after an acute dose of 1 If3 in mice. No toxicity was evident at doses at or below
30 mg/kg. At all doses of 11 3, a slight alteration in the ratio of lymphocytes to
neutrophils was observed, such that the ratio of neutrophils increased -- 50% of the white
blood cells were neutrophils while 50% were lymphocytes, whereas in the control group
80% of the white blood cells were lymphocytes and only 20% were neutrophils. Despite
the alteration in the ratio of lymphocytes to neutrophils, the total number of leukocytes
increased slightly with dose until it reached a maximum at 150 mg/kg (although the
number of WBCs after a 150 mg/kg dose is still in the normal range provided by
Taconic). This fact is rather surprising as many anticancer agents, including
chlorambucil and melphalan, induce myelosuppression (according to their respective
package inserts). The dose limiting toxicity of chlorambucil is, in fact, neutropenia, or a
decrease in neutrophils (Blumenreich et al. 1988; Inoue et al. 1987). 11 seemingly does
not induce myelosuppression but rather stimulates neutrophil proliferation or inhibits the
production of lymphocytes so as to alter their respective ratios.
Alternatively, the elevation of neutrophils and suppression of lymphocytes may
indicate that 11 p3 is interacting with the glucocorticoid receptor (GR). The GR is a
member of the same class of nuclear hormone receptors as the ER and AR.
Corticosteroids, the natural ligands for the GR, have profound effects on lymphocytes
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and neutrophils. Corticosteroids actually induce the apoptosis of lymphocytes, (Di et al.
2000; Negoescu et al. 1998) whereas they inhibit the death of neutrophils in vitro (Cox
and Austin 1997; Liles et al. 1996). The mechanisms by which human lymphocyte and
neutrophil apoptotic responses to glucocorticoids differ are unknown. However,
glucocorticoid action is mediated through the GR and therefore these apoptotic
differences may arise from downstream targets of the GR (O'Malley 1971; Strickland et
al. 2001; Wenzel et al. 1997). An off-target interaction of 11 IP with the GR may mediate
the responses seen in the alteration in the ratio of neutrophils to lymphocytes. In fact
Nicole Dinaut, a former post-doctoral associate in the Essigmann Laboratory, has shown
the RBA of 11 3 for the GR to be 2. Although this is not a tight interaction, it may be
sufficient in decreasing lymphocyte count and increasing neutrophil count as we have
seen here.
The blood chemistry profile of an acute dose of 11 p also shows apparent toxicity.
Most significantly, hepatotoxicity is evident at doses of 50 mg/kg and above as evident
by increased ALT, AST, amylase, and lipase. These enzymes are all involved in liver
function and therefore an increase in the levels of these enzymes signifies hepatotoxicity.
Hepatotoxicity has also been documented in patients treated with chlorambucil
(Blumenreich et al. 1988).
The evidence of renal toxicity is evident by the alterations in blood urea nitrogen
(BUN), creatinine, phosphorous, and calcium at doses of 100 and 150 mg/kg (there is
also some indication of renal toxicity at the 75 mg/kg dose as BUN is elevated). Amino
acids are catabolized by the liver to produce ammonia. The ammonia is combined with
bicarbonate to form urea, which is transported to the kidneys for excretion. Therefore, an
increase in BUN is indicative of renal toxicity as a result of a decreased rate in
glomerular filtration. Creatinine is also excreted by the kidneys, and an elevated level
confirms a decrease in the glomerular filtration rate and therefore renal toxicity. Finally,
increased phosphorous and decreased calcium levels further indicate renal toxicity. All
of the above conditions are satisfied at doses of 11 p above 100 mg/kg.
CK, a sensitive indicator of myocardial injury and muscle damage, was also found
to be elevated at doses of 75 mg/kg and above. CK is found primarily in the heart,
skeletal muscle, and brain and catalyzes the phosphorylation reaction of ADP by
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creatinine. Acute liver damage has no effect on CK, so the elevated level seen in the
mice treated with 11 f3 is likely related to muscle damage. Further tests would be needed
to determine if 11 fp has a deleterious effect on cardiac muscle or skeletal muscle. For
example, lactate dehydrogenase and troponins are both elevated following cardiac injury.
An elevation in these proteins would further suggest cardiac toxicity.
In Chapter 6, the identification of 11 3 DNA adducts formed in vitro was
discussed. Using ESI-MS techniques, we illustrated that 11 p covalently modified
guanine, most likely at the N7 position. The identification of these adducts was
remarkable considering the related nitrogen mustard, chlorambucil, has a relatively short
half-life of only 18 minutes in a non-nucleophilic 0.2 M cacodylic acid solution at 37°C
(Haapala et al. 2001). The rapid decomposition of chlorambucil is a result of an
intramolecular, rate-determining attack of the unprotonated nitrogen atom to form an
aziridinium ion intermediate followed by attack of an external nucleophile (such as
water) (Chatterji, Yeager, and Gallelli 1982; Kundu, Schullek, and Wilson 1994; Owen
and Stewart 1979). Hence, chlorambucil (and other nitrogen mustards) is a reactive
compound that decomposes rapidly in aqueous solutions and forms covalent bonds with
other nucleophiles.
In blood, where the chloride ion concentration approximates 100 mM,
chlorambucil has a much longer half-life of 2.4 hours (Newell, Shepherd, and Harrap
1981). With the half-life of chlorambucil in mind, we chose the 4 hour time point to
monitor the formation of 1 If3 DNA adducts. We believed 4 hours would be ample time
for 1 3 to covalently modify DNA and form stable adducts prior to being repaired or
metabolized. Furthermore, the pharmacokinetic analysis revealed that the highest
amount of drug accumulated in the liver, approximately 10% ID/g between 2 and 4 hours.
Therefore, liver tissue was analyzed for the presence of DNA adducts.
As in Chapter 6, a molecular ion with a mass of 813.5 m/z was found. This is
consistent with one arm of the nitrogen mustard adducted to guanine whereas the second
arm had been hydrolyzed. Unfortunately, there is no way of telling when the second,
non-reacting arm of the nitrogen mustard warhead underwent hydrolysis. It is possible
that the second arm remained chlorinated in vivo and only in the procedure used to isolate
the DNA adducts did the chloroethyl arm convert to hydroxyethyl. However this may be
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an unlikely scenario as the half-life of the related nitrogen mustards, chlorambucil and
melphalan, were found to be 2.4 hours and 1.5 hours, respectively, in plasma (Honess et
al. 1985; Newell, Shepherd, and Harrap 1981). Currently, we do not have any data on the
hydrolysis rate of 11 p in vivo.
The identification of 11 P DNA adducts in vivo is extremely encouraging even
though the adducts were found in non-target tissue. This data illustrates that 1113 can be
injected into a mouse, distribute throughout the body, and form DNA adducts while
remaining intact. The repair shielding and transcription factor hijacking hypotheses
require 1i1 p to form DNA adducts in target tissues and attract tumor specific proteins. In
non-target tissues we expect the adducts to be repaired since the tissue would lack the
tumor specific protein for which the molecule was designed to attract. Therefore, the
formation of DNA adducts in non-target tissues is expected, and in this case it serves as
an illustration of the robustness of the molecule: 1 p was administered to mice,
distributed throughout the body, remained intact, and covalently modified DNA.
Conclusion
11p has previously been shown to contain properties favorable to our intended
mechanisms of action: it has a high RBA (36) for the AR, it is capable of covalently
modifying DNA, its log D (2.00) indicates it should have favorable pharmacokinetics,
and it displays significant toxicity towards the AR(+) LNCaP cell line. These results
have been described in Chapter 6. Based on its log D, and other properties making it an
attractive chemotherapeutic agent, we have continued to investigate the compound by
monitoring its pharmacokinetics, acute toxicity, and ability to adduct DNA in vivo.
1113, when formulated with a CR-EL based vehicle and injected IP, illustrates
good overall distribution into tissues. At 45 mg/kg, the peak plasma concentration was
190 gM (19-fold higher than what was necessary to kill AR(+) LNCaP cells in culture)
and remained greater than 10 jiM for nearly 6 hours. Indicators of hepato-, renal, and
possible cardiotoxicity were first evident at a dose of 75 mg/kg following an acute dose.
However, this observation is not surprising as anticancer agents generally have
significant toxicity profiles and a narrow therapeutic index. The LD50 was found to be
between 100 and 150 mg/kg. Finally, 118 formed DNA adducts in vivo indicating the
252
compound is relatively stable and is not rapidly metabolized or excreted. The DNA
adducts identified were the same as those found in vitro and described in Chapter 6: a
mono-guanine adduct with the other arm of the nitrogen mustard having undergone
hydrolysis.
In summary, these results further support the notion of 11 as a potential drug
candidate. Following the encouraging pharmacokinetic results, we have continued to use
the CR-EL based vehicle for tumor ablation studies. Chapter 8 shall describe the
effectiveness of 11 p as an anticancer agent using xenograft animal models. I will also
quantify the penetrance of 11 3 into xenograft tumor tissue and describe the toxicity to
mice after a therapeutic dose of 11 3.
Future Work
CR-EL has provided us with a means of administering 113 into mice; however, as
noted in Chapter 3, it is by no means an ideal delivery vehicle. The literature is
inundated with reports on the toxic side effects of CR-EL. A number of studies have
reported that CR-EL induced side effects such as hypersensitivity, neurotoxicity,
nephrotoxicity, and the extraction of plasticizers from intravenous infusion lines (Cheon
et al. 2003; Gregory and DeLisa 1993; Mazzo et al. 1997; Onetto et al. 1993). We
acknowledge the limitations of CR-EL and therefore we have begun a collaboration with
the Sasisekharan Laboratory at MIT in an effort to formulate 11 3 using liposomes. We
have conducted a pilot experiment in which we injected a liposomal solution into two
mice. Blood was drawn over time and the percent of the dose in blood over a 24 hour
period is shown in Fig 7.5. The data show the liposomes circulate in plasma for a
considerable period of time -- as much as 80% of the drug was still circulating in blood
24 hours later. (I do note however, that the theoretical recovery is over 100% in one of
the mice. Even still, the amount of compound circulating at 24 hours in this mouse is
50% of that in the blood at 15 min In the second mouse 80% of the dose is still
circulating at 24 hours as compared to what was recovered at the 15 min time point.)
Unfortunately, a full bio-distribution experiment was not able to confirm these results.
Figure 7.6 illustrates that the concentration of 11 3 in whole blood after a CR-EL or
liposomal administration is nearly identical. The results seen with the full bio-
253
distribution of 11 p formulated in liposomes contradicts the results seen in the pilot
experiment. The most likely reason for this result was the unfortunate oxidation of the
lipids used to prepare the liposomes (something we did not realize at the time of the bio-
distribution). The collaboration is still ongoing and we anticipate promising results in the
near future. Any new delivery agent would have to undergo the same rigorous
experiments described in this chapter: bio-distribution, pharmacokinetic analysis, and
acute toxicity. However, the work here sets a foundation for which alternative delivery
agents can be measured. If, however, a suitable alternative delivery agent cannot be
found, it is possible to continue the use with CR-EL since Taxol is formulated as a
concentrated solution of 6 mg per mL of CR-EL:dehydrated ethanol (1:1 v/v) which must
be further diluted 5 to 20-fold with saline prior to IV administration (Goldspiel 1994).
Charles Morton and I have begun work using human liver microsomes to address
the metabolic fate of 11 3P. Initial experiments have been relatively unsuccessful;
however, a recent search of the literature indicates that we may have been using too much
drug for the assay and thus saturated the system. We are confident that in the near future
we will be able to identify the metabolites of 11 3 and also the P450s likely responsible
for its breakdown.
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Distribution of 11 3 in Mouse Tissue
with a Cremophor-EL Based Vehicle
0.25 hr. 1 hr. 2 hr. 4 hr. 6 hr. 24 hr.
Blood
Heart
Lung
Liver
Spleen
Kidney
GI
Feces
Sk. Muscle
Adipose
4.90 + 0.23
0.23 + 0.04
0.67 ± 0.34
3.82 + 1.74
1.15 + 0.05
0.49 ± 0.12
2.54 ± 0.23
0.27 + 0.10
0.13 0.06
4.63 + 1.11
1.40
0.83
1.84
6.62
2.62
2.42
3.81
1.78
0.25
2.22
+ 0.25
+ 0.23
± 1.32
+ 1.47
+ 0.19
+± 0.15
± 0.04
± 0.31
+ 0.08
± 1.01
2.09 ± 1.3
1.26 ± 0.71
3.76 ± 0.64
9.41 + 0.79
3.64 + 0.55
4.08 + 0.37
7.15 ± 4.55
2.93 + 1.78
0.23 + 0.06
2.71 0.76
1.28 ± 0.45
2.02 + 0.06
4.29 + 0.27
11.10 + 0.95
4.20 ± 0.92
5.59 ± 0.39
3.87 + 0.74
1.94 0.36
0.39 + 0.02
2.53 0.71
Table 7.1 Mice were injected IP with 5 pCi of 14 C-1 1 dissolved
in 43 % CR-EL, 30 % saline, 27 % ethanol. They were
sacrificed at 0.25, 1, 2, 4, 6, or 24 hours after the injection. The
results are reported as the mean percent injected dose per
gram (of each organ) standard deviation.
0.70
0.98
3.38
4.61
2.42
4.31
2.54
8.78
0.33
1.25
± 0.04
+ 0.04
± 0.14
+ 0.97
+ 0.22
+ 0.01
± 0.05
± 2.24
± 0.00
+ 0.35
0.41
0.21
0.66
1.81
0.79
1.08
1.00
2.49
0.08
0.54
± 0.11
± 0.05
± 0.20
±0.15
± 0.02
± 0.02
+ 0.01
± 0.37
+ 0.01
± 0.17
Pharmacokinetic Parameters of 11 
Parameter
AUCa (pg x hr/mL)
b
CLC
(hr)
(m L/hr)
Vd (L/kg)
DMSO IV
403
1.3
4.7
0.49
t max
(pM)
0.25
Table 7.2 Pharmacokinetic parameters following the
administration of 11f3 IP with a CR-EL based vehicle. a area
under the blood concentration-Vs-time curve, b half-life, c
clearance, dvolume of distribution, e maximum concentration in
blood, f time at which Cmax was achieved.
t 1/2
eC max
f (hr)
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Acute Toxicity of 1 1 :
Hematology
Control Vehicle 10 mg/kg 30 mg/kg 50 mg/kg 75 mg/kg 100 mg/kg 150 mg/kg Taconic
Test N=4 N = 3 N = 3 N = 3 N=4 N = 4 N =2 N = 2 Nude
WBC (xmrm3)
RBC (x 106 mm3)
Hgb (g/dL)
HCT (%)
Neutrophils (%)
Lymphs (%)
Monos (%)
Eos (%)
Platelets (103/pL)
MCV (fL)
MCH (pg)
MCHC (g/dL)
Table 7.3 Hematology report for mice injected with 11 3.
Values in bold represent abnormally elevated or suppressed
levels. The ratio of neutrophils to lymphocytes is altered at all
doses of 11 3. Additionally, the hemoglobin is elevated in the
100 mg/kg dose and both the hemoglobin and WBC are
elevated in the 150 mg/kg dose.
(Note: Since the test groups contained relatively few mice, the abnormal levels are
deviations from the normal range and do not necessarily reflect statistical
significance.)
5.4
10.1
14.8
53.7
19.8
76.8
3.0
1177
53.1
14.7
27.6
8.2
10.0
14.6
52.4
17.0
80.3
3.0
2.0
1263
52.5
14.6
27.8
6.6
9.8
14.9
53.4
54.5
45.0
1.0
1214
55.0
15.3
27.8
7.3
8.8
13.5
47.6
49.7
48.7
1.3
1.0
1226
53.8
15.2
28.4
7.5
10.4
15.4
53.5
55.0
42.8
2.3
1.0
1442
51.9
14.8
28.8
10.2
9.8
14.7
54.6
48.8
48.5
2.5
1.0
1462
56.0
15.0
26.8
10.0
12.0
16.8
63.2
42.0
54.0
4.0
934
52.7
14.2
27.1
13.5
12.4
17.6
64.1
50.0
47.5
2.5
900
51.8
14.2
27.5
4.3-13.5
6.9-8.52
7.5-15.2
39.4-43.5
7.0-39
56-92
0-7
0-4
790-1014
51.1-53.4
17.6-19.1
34.3-36.1
Acute Toxicity of 11 13:
Blood Chemistry
Control Vehicle 10 mg/kg 30 mg/kg 50 mg/kg 75 mg/kg 100 mg/kg 150 mg/kg Taconic
Test N=4 N=3 N=3 N=3 N=4 N=4 N = 1 N=2 Nude
Alk. Phosphatase (IU/L) 101 90 72 77 59 69 117 83 96-117
ALT (SGPT) (U/L) 40 41 50 47 509 2109 1482 1544
AST (SGOT) (lUl/L) 73 99 201 105 594 3581 2904 3879 61-119
CK (IU/L) 191 321 651 290 552 53580 79308 159453
GGT (IU/L) 0.0 <3 <3 0.0 <3 <3 3.0 9.0
Albumin (g/dL) 3.3 3.3 2.9 2.6 3.0 2.6 2.1 1.8 3.4-4.1
Total Protein (g/dL) 5.9 5.7 5.5 4.8 6.1 4.9 3.6 3.0 4.8-5.6
Globulin (g/dL) 2.6 2.4 2.5 2.2 3.1 2.3 1.5 1.2 1.1-1.6
Total Bilirubin (mg/dL) 0.1 0.2 <.3 0.1 0.2 0.4 0.3 0.3 0.3-0.8
Direct Bilirubin (mg/dL) 0.0 <.3 <.3 0.0 0.1 0.3 <.3 <.3
BUN (mg/dL) 25.0 20.7 25.7 25.7 35.8 76.8 117.0 108.0 30-37
Creatinine (mg/dL) 0.3 <.3 <.3 0.2 <.3 <.3 0.6 0.8 0.5-0.7
Cholesterol (mg/dL) 226 202 156 134 218 135 144 75 116-155
Glucose (mg/dL) 334 295 270 258 220 170 957 336 173-288
Calcium (mg/dL) 10.9 11.5 10.8 10.3 11.3 10.4 6.6 6.6 10.0-12.0
Phosphorous (mg/dL) 8.7 11.0 10.8 11.2 11.1 11.9 29.4 34.5 12.3-16.1
Bicarbonate (mEq/L) 19.8 15.7 19.0 25.0 25.5 31.0 6.0 42.0
Chloride (mEq/L) 102 <180 101 105 <180 <140 <180 <180 118-124
Potassium (mEq/L) 8.2 11.5 37.5 8.6 9.1 8.9 11.4 10.8 13.8-16.7
Sodium (mEq/L) 151 158 155 154 154 171 147 150 157-163
A/G Ratio 1.3 1.4 1.1 1.2 1.0 1.1 1.4 1.5
B/C Ratio 104 >80 >80 128 245 >341 195 151
Indirect Bilirubin (mg/dL) 0.1 <.3 <.3 0.1 <.3 <.3 <.3 <.3
Na/K Ratio 19.0 15.5 18.0 18.3 18.3 20.0
Anion Gap (mEq/L) 37.8 49.5 41.0 26.3 31.0 25.0
Amylase (IU/L) 1373 1456 1352 1231 3307 3948 12096 >9000
Lipase (IU/L) 99 108 268 130 1104 1665 >1650 >1650
Table 7.4 Blood Chemistry report for mice injected with 1 1 .
Values in bold represent abnormally elevated or suppressed
levels. Hepatotoxicity is evident starting at a 50 mg/kg dose.
Also renal and cardiac toxicity is evident at doses of 75 mg/kg
and above.
(Note: Since the test groups contained relatively few mice, the abnormal levels are
deviations from the normal range and do not necessarily reflect statistical
significance.)
HPLC Chromatograms of 11P in
Mouse Plasma
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Fig 7.1 HPLC chromatograms of intact 1 1P in plasma A. 15
min. B. 1 hour. C. 4 hour. Plasma was isolated from whole
blood, precipitated with acetonitrile and injected onto HPLC.
The peak at 25 min is intact 1 1P. The peak at 13 min and 4 min
in B and C are likely metabolic breakdown products.
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Distribution of 1 1 in Blood and
Plasma
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Fig 7.2 1 1 Blood Curve (A) and Plasma Curve (B). 11 p was
administered to mice and the concentration in whole blood and
plasma was determined. The peak concentration is 128 pM in
whole blood and 190 pM in plasma, both at the 15 minute time
point.
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Identification of 1 1 DNA Adducts in
Mouse Liver Tissue
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Fig 7.4 A. ESI-MS of an 11 -guanine adduct from liver tissue.
B. CID of the 813.5 m/z ion results in two daughter ions of 662.5
and 372.1 m/z. C. The proposed structure of the 662.5 and
372.1 m/z daughter ions.
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Distribution of 1113 in Blood using a
Liposomes Based Delivery Vehicle
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Time (Hr)
Percent of 14C-1 1 in blood. Two mice (A and A) were
IV with 1 4 C11 3 formulated in liposomes. At 24 hours
80% of the dose remained circulating in the blood in one of the
mice.
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Comparison of Liposomal and
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Distribution of 1113 in Mouse Blood
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Fig 7.6 Comparison of CR-EI ( )and liposomal (1 )
formulated 14 C-1 1 in blood. 1 4 C-1 1 was administered to mice
and the concentration in blood was determined. This graph
illustrates that the concentration of 1 1 3 in blood is nearly
identical for either formulation, contradictory to what was seen
in Fig 7.5.
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Chapter 8
Probing the Biochemical Mechanism of
11p in Vivo:
Efficacy against AR(+) Tumors, DNA Adduct Levels
and Chronic Toxicity
Introduction
Prostate cancer is the most frequently diagnosed cancer among males in the U.S.
with an incidence of 170.1 cases per 100,000 men and a death rate of 32.9 per 100,000
men (Weir et al. 2003). In its earliest stages prostate cancer is curable through surgical
intervention and/or radiation therapy. However, in more aggressive forms of the disease
and in men diagnosed at a later stage, the cancer can advance to stages characterized by
local invasion of the seminal vesicles, followed by metastasis primarily to the bone
(Abate-Shen and Shen 2000). The transition to metastatic disease is generally followed
by a shift from androgen-dependence to androgen-independence, which is often provoked
by androgen-ablation therapy. Androgen ablation therapy is no longer effective in
treating androgen-independent, or hormone refractory, prostate cancer (HRPC).
Oncologists adjust the therapeutic regimen by introducing chemotherapeutics alone or in
combination to try to stop metastases. Unfortunately, chemotherapeutics are not very
effective, in part because several anti-apoptotic factors are present in malignant prostate
cells (Lebedeva et al. 2000; Raffo et al. 1995; Vlietstra et al. 1998). Some clinical
oncologists debate that doing nothing at all may be the right course of action as some
HRPC prostate metastases are slow growing and the quality of life of the patient
outweighs the potential benefits of chemotherapy (Bhatnagar et al. 2004; Gulley and
Dahut 2003).
For many patients, the HRPC is aggressive and requires further intervention. The
androgen receptor (AR) is expressed at high levels in both androgen-dependent and -
independent cancers at both the primary and metastatic sites and therefore has
represented an obvious chemotherapeutic target (Hobisch et al. 1995; Marcelli and
Cunningham 1999). However, mutations in the AR along with the aberrant expression of
co-activator proteins can induce transcriptional activation in response to antiandrogens
and endogenous hormones leading to cancer progression and therapeutic resistance
(Buchanan et al. 2001; Heinlein and Chang 2002). Therefore, new modalities are needed
not only for HRPC, but also in the treatment of primary prostate cancer prior to
metastasis and androgen-independence.
Towards this end, we have designed a multi-functional molecule which
incorporates several mechanisms of action into a single anticancer agent. Our molecule
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produces covalent DNA adducts that have high affinity for the AR, a protein essential for
tumor growth and survival. The attraction of the AR to the sites of damaged DNA would
camouflage the adducts from repair enzymes and prevent the AR from performing its
transcriptional activities necessary for tumor growth and survival. We believe the sum of
these mechanisms of action - DNA damage, repair shielding, and transcription factor
hijacking - could lead to increased efficacy in the treatment of prostate cancers.
In the previous two chapters I have described many of the properties which
indicate our lead compound, 11 p, to be a potentially effective anticancer agent. In
Chapter 6, I discussed the results of several in vitro experiments, which indicated that 11 P
has a high affinity for the AR, a low log D, and differential toxicity in favor of killing AR
expressing cell lines in culture. In Chapter 7, I discussed the results of in vivo
experiments in which I illustrated the favorable pharmacokinetics, bio-distribution, and
low toxicity of 1i1 p. Here I will discuss the potential of 11 p as a chemotherapeutic in the
treatment of LNCaP xenografts as well as the toxicity to mice treated with several cycles
of this agent. Furthermore, I shall discuss the results of several experiments in which I
have quantified the number of DNA adducts formed in cells treated in culture and in liver
and tumor tissue from mice treated with 11 p. I believe these experiments will indicate
the potential therapeutic benefit for patients with prostate cancer.
Materials and Methods
Animals. Four to six week old NIH Swiss nu/nu athymic mice (25 g) were purchased
from the National Cancer Institute-Frederick Cancer Center (NCI), (Frederick, MD). The
mice were housed under standard conditions in MIT approved facilities with 12 hour
light/dark cycles and food and water ad libitum. All protocols were performed in
compliance with the regulations of the Animal Care Committee at MIT.
Cell Culture. The human prostate cell lines, LNCaP and T-47D, the human cervical
cancer cell line, HeLa, and the human colon cancer cell line, DLD-1, were obtained from
the American Type Culture Collection (Rockville, MD). The LNCaP cell line was
maintained in RPMI 1640 supplemented with 2.5 mg/ml glucose, 10% fetal bovine serum
(FBS; Hyclone, Salt Lake City, UT), 2 mM glutamax (Gibco), 1 mM sodium pyruvate
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and 100 mM HEPES. The T-47D line was maintained in MEM-alpha medium
containing 10% FBS (Hyclone), 0.1 mM non-essential amino acids (Invitrogen), 100 mM
HEPES, 2 ug/ml bovine insulin, and 1 ng/ml human epidermal growth factor. The HeLa
cell line was maintained in DMEM with glutamax (Gibco) supplemented with 10% fetal
bovine serum. Cells were grown in a humidified 5% C0 2/air atmosphere at 3 7 [C. When
the cells were used for injection into mice, the cells were grown in a P-150 plate to 50-
70% confluence. The cells were trypsinized, washed, and pelleted.
Tumor Ablation Therapy. LNCaP, HeLa, and DLD-1 cells were collected and
suspended in 50% saline, 50% Matrigel (Becton Dickinson, Franklin Lakes, NJ) and
diluted to a concentration of 1 X 107 cells/mL. Into the right hind flank of each mouse
was injected 0.25 mL of the cell suspension. Additionally, the DLD-1 cells, which are an
extremely rapidly growing cell line, were administered into the peritoneal cavity and
therapy commenced 3 days after the injection of the cells. Therapy commenced in all
other cell lines when a palpable tumor of approximately 4 x 4 mm formed (5-7 days for
HeLa cells, 1-2 months for LNCaP cells, and 4-5 days for DLD-1 cells). 1 1B was
formulated in 43% CR-EL, 30% saline, and 27% ethanol and administered IP at a dose of
30 mg/kg. Chlorambucil was dissolved in the same vehicle and injected at an equi-molar
dose of 12 mg/kg. Tumor dimensions were measured five times per week with vernier
calipers. Tumor volumes were calculated using the formula of an elipse: it/6 x (smaller
diameter)2 x larger diameter. Statistical analyses were performed using a paired t-test.
Mice with HeLa xenografts were treated with 3 cycles of 5 days on and 2 days off, mice
with LNCaP xenografts were treated with 6.5 cycles, mice with DLD-1 xenografts were
treated with 2 cycles, and mice with DLD-1 cells injected intraperitoneally were treated
for 1 cycle.
Assessment of Chronic Exposure of 11 p. At the end of the LNCaP tumor therapy
study, mice were euthanized by CO2 asphyxiation. Blood was obtained by cardiac
puncture and sent to IDEXX (formerly Tufts Veterinary Diagnostic Laboratory, North
Grafton, MA) for hematology and blood chemistry analysis.
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Quantification of DNA Adducts in cells. LNCaP and T-47D cells were exposed to a
10, 5, 2.5 or 0 pM dose of 14C-1 1p (specific activity 5 pCi/jimol) dissolved in DMSO for
4 hours. At the end of the incubation the cells were scraped, pelleted, and washed with
phosphate buffered saline (PBS). The cells were resuspended in 2 mL of cold (4°C) 0.01
M Tris (pH 6.9), 0.25 M sucrose, 2 mM calcium chloride buffer. Triton X-100 (25%
solution) was added to make a final concentration of 5%. The solution was briefly
vortexed and then centrifuged at 1 OOOG in a Sorvall RC-2B Centrifuge with a GSA rotor
at 4°C for 20 min. The supernatant was removed by aspiration and the nuclear pellet was
resuspended in 1 mL of buffer. Sodium dodecyl sulfate (SDS) (5%) and 5 M sodium
chloride (NaCl) was added to make a solution with a final concentration of 1% SDS and
1 M NaCl. An equal volume of chloroform:isoamyl alcohol (24:1) was then added and
the biphasic mixture was shaken vigorously for 15 min. The mixture was then
centrifuged at 7000G for 15 min at 4°C. The aqueous phase was collected and re-
extracted with another volume of chloroform:isoamyl alcohol, shaken and centrifuged.
The aqueous phase was then collected and the nucleic acids were precipitated with 3
volumes of ice cold ethanol and chilled at -20°C for 20-30 min and subsequently pelleted
by centrifugation at 7000G for 15 min at 4°C. The nucleic acids were washed 2 times
with cold ethanol and then dried in vacuo. The dried pellet was reconstituted with 0.5
mL of 0.05 M Tris (pH 7.5), 0.1 M NaCl on ice. In order to remove any contaminating
RNA, 0.2 mg of RNAse A was added and incubated at 37°C for 10 min. The reaction
was stopped by cooling on ice, the NaCl concentration was adjusted to 0.9 M, and the
DNA was extracted by subsequent additions of chloroform:isoamyl alcohol as indicated
above. The aqueous phase from the second extraction was isolated and the DNA was
precipitated with 3 volumes of ice cold ethanol, centrifuged, and washed 2 times as
above. The concentration of the DNA was obtained by measuring the absorbance at 260
nm. The DNA was dissolved in 0. 1-0.5 mL of water, depending on the DNA
concentration, and then given to Paul Skipper and Rosa Liberman, both in the
Tannenbaum laboratory at MIT, for analysis by AMS as described in Liberman, et al.
(Liberman et al. 2004).
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Kinetics of lp DNA adduction in LNCaP cells. LNCaP cells were exposed to a 10
jM concentration of 14 C-1li1 (specific activity 10 tCi/[pmol) for 0, 3, 6, 9, 15, and 24
hours. At the end of each incubation period, the cells were scraped, pelleted, and washed
with PBS. The DNA was isolated using the above procedure.
Repair of 11p DNA adducts in LNCaP cells. LNCaP cells were exposed to a 2.5 gpM
dose of 14C- 11 (specific activity 27 pCi/gpmol) for 2 hours. At the end of the treatment,
the media was removed, the cells were washed 3 times with PBS, and fresh media was
added. Repair of the DNA adducts was monitored by harvesting cells at 0, 1, 3, 6, 9, 15,
and 24 hours after the removal of 14C- 11 p. The DNA was then isolated as indicated
above.
Quantification of DNA Adducts in Tissue. NIH Swiss nu/nu mice with LNCaP
xenografts were injected with 14C- 1 lp in order to quantify the number of DNA adducts
formed in the tumors. 1 1 was administered intraperitoneally (IP) at a dose of 50 mg/kg
spiked with 1 ICi of 14C-1 P. The mice were sacrificed after 4 hours by carbon dioxide
asphyxiation. The liver was surgically removed, snap frozen on dry ice, and stored at -80
°C until it could be worked up. The DNA was obtained by a similar procedure as
described in the "Quantification of DNA adducts in cells" section with a few noted
changes. The liver and tumor samples were thawed and homogenized in a Dounce
homogenizer on wet ice with 15 mL of cold (4°C) 0.01M Tris (pH 6.9), 0.25 M sucrose, 2
mM calcium chloride buffer. The homogenate was filtered through coarse and then a
fine nylon mesh to remove all connective tissue. Triton X-100 (25%) was added to make
a final concentration of 5 %. The solution was briefly vortexed and then centrifuged at
100OG in a Sorvall RC-2B Centrifuge with a GSA rotor at 4°C for 20 min. The
supernatant was removed by aspiration and the nuclear pellet was resuspended in 2.5 mL
of buffer. Sodium dodecyl sulfate (SDS) (5%) and 5 M sodium chloride (NaCl) was
added to make a solution with a final concentration of 1% SDS and 1 M NaCl. The
nucleic acids were isolated as above and the dried pellet was reconstituted with 2 mL of
0.05 M Tris (pH 7.5), 0.1 M NaCl on ice. In order to remove any contaminating RNA,
0.5 mg of RNAse A was added and incubated at 37°C for 10 min. The DNA was
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extracted and the concentration was determined by the same procedures as indicated
above. Rosa Liberman and Paul Skipper analyzed the samples.
Results
11ip Inhibits the Growth of Xenografts. The cytotoxicity of 1 1P towards LNCaP cells
in culture prompted us to investigate its antitumor properties in a xenograft mouse model.
1 p was administered to mice for 6.5 weekly 5-day cycles with a dose of 30 mg/kg and
administered IP. As shown in Figure 8.1, this regimen resulted in a 90% growth
inhibition of the LNCaP xenografts as assessed on the 4 5th day of therapy (mean tumor
volume of the 1 1 treated group versus the mean tumor volume of the vehicle only
group; P<0.0001). During the course of this regimen, mice in the treated group lost an
average of 10 % of their body weight, indicating the treatment was well tolerated by the
mice (Fig 8.2). Pictures of representative mice from the 1 1P treated and vehicle group
are shown in Figure 8.3A and B, respectively. The LNCaP tumors are very well
vascularized as evident by the blue nodular tumor in Figure 8.3B. Even though there is
no tumor evident in the mouse shown in Figure 8.3A, upon removal of 11 p the tumor
eventually grew back. This indicates that the 45 day regimen was not sufficient in killing
100% of the tumor cells.
In a second experiment with LNCaP xenografts, we compared the efficacy of i1 
to chlorambucil at equi-mole doses (30 mg/kg for 1 and 12.6 mg/kg for chlorambucil).
Chlorambucil is a clinically used alkylating agent that the DNA damaging portion of 113
was designed after. As shown in Figure 8.4, chlorambucil is more effective in inhibiting
the growth of LNCaP xenografts and actually shrinks the tumors, unlike 1 P which only
inhibits their growth as compared to the vehicle group. In both cases, a paired t-test
indicated that P<0.0001 as compared to the vehicle group (error bars were omitted for
clarity sake). Despite its increased toxicity towards the LNCaP xenografts, a 12.6 mg/kg
dose of chlorambucil was also toxic to the mice as illustrated in Figure 8.5. Mice treated
with chlorambucil lost up to 30% of their body weight while 1 was better tolerated,
reducing body weight by only 7%. Furthermore, only one chlorambucil treated mouse
survived the 45-day treatment regimen, but this lone survivor died 6 days after the
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therapy ceased (Fig 8.6). Therefore, at this dose level it seems that the toxicity of
chlorambucil to the tumors was also overwhelming to the mice.
1 13 has also shown toxicity to other cell lines in culture that do not express the
AR for reasons yet unknown but possibly unrelated to, or in addition to, the proposed
repair shielding and transcription factor hijacking models. (These additional mechanisms
were discussed in Chapter 6) Therefore, 11 p was administered to mice containing HeLa
xenografts to assess its potential as a broader chemotherapeutic agent. Figure 8.7 shows
the results of the treatment of the mice after 3 weekly 5 -day cycles of 30 mg/kg
administered IP. As evident in the graph, 11 p had a significant effect on the xenografts
(P<0.0001) as it inhibited their growth by 80% as assessed on the final day of the study
(mean tumor volume of treated versus mean tumor volume of the control on day 18).
The dose was well tolerated as evident by the modest weight loss in the treated group of
10% (Fig 8.8). Representative examples of the mice treated with 1 113 and or vehicle
alone are illustrated in Fig 8.9A and B, respectively. Unlike the LNCaP tumors, HeLa
tumors are not as well vascularized and grow to large, white, nodular tumors. These data
indicate that 1 113 inhibits the growth of the HeLa xenografts and is well tolerated by the
mice at this therapeutic dose.
A second cell line that does not express the AR is the colon cancer derived cell
line, DLD-1. Cells were injected either as xenografts in the right hind flank of the mice
or into the peritoneal cavity. 113 did not have a therapeutic effect on the DLD-1
xenografts that were injected into the flank of mice (data not shown). However, 1 did
inhibit the growth of the DLD-1 cells injected into the peritoneal cavity as shown in
Figure 8.1 OA. As a comparison a mouse treated with vehicle only had larger and a
greater number of tumors in its abdomen (Fig 8. 10 OB). Unfortunately, the toxicity to the
mice in both groups was rather substantial after only 7 days of therapy. Upon necropsy
both the vehicle treated and 11 P treated mice had adhesions in their abdomen, usually
intestinal-to-intestinal but occasionally skeletal muscle or adipose tissue-to-intestinal.
The fusing of tissue to a segment of intestines inhibited peristalsis, caused the abdomen
of the mice to swell, inhibited the excretion of feces, and caused the mice to lose weight.
These data illustrate that 11 3 is effective against LNCaP and HeLa xenografts but not
against DLD-1 xenografts. Although it was also effective against DLD-1 cells injected
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into the peritoneal space, this model is not deemed to be very useful as a result of the
formation of adhesions in both the treated and vehicle control groups.
Chronic Doses of 11p are Well Tolerated by Mice. The chronic toxicity of 1113 was
addressed following the administration of 6.5 cycles of 1 113 to the LNCaP bearing
xenograft mice. As indicated above, weight loss was limited to 10 % in treated animals.
The hematology report (Table 8.1) indicated that leukopenia was the major toxicological
side effect. Additionally, an alteration in the ratio of neutrophils to lymphocytes was
observed in both the treated and vehicle control groups, indicating the vehicle may play a
role in toxicity. The blood chemistry report did not reveal any significant toxicity (Table
8.2). Creatinine kinase (CK), an indicator of muscle and cardiac toxicity, was elevated
slightly in all mice bearing a tumor. This elevation is likely unrelated to 11 p. Finally,
gamma glutamyl transpeptidase (GGT) was depressed in the mice treated with 11 3,
perhaps indicative of hypothyroidism, hypothalamic malfunction, or low magnesium
level. Overall, the results after a 45 day regimen of 11p at a dose of 30 mg/kg are
extremely encouraging as toxicity seemed to be relatively mild.
Quantification of DNA Adduct Formation in Tissues and Cells. 1 1 has been shown
to be an effective agent in the therapy of LNCaP xenografts with minimal unwanted
toxicity. The efficacy of 1 is likely related to the formation of DNA adducts.
Therefore, we wanted to obtain information regarding the number of DNA adducts
formed in tumor tissue after a therapeutic dose of 11 I as well as in LNCaP cells in vitro.
An understanding of the rate of DNA adduction and the rate of repair of these adducts
when LNCaP cells are exposed to 11 3 in culture could assist us in increasing the efficacy
of 1 p towards xenograft tumors and in the development of new therapeutic regimens.
Furthermore, the work here will establish a groundwork for which future generations of
compounds or vehicles can be assessed.
In an initial effort to gauge the number of DNA adducts formed by a treatment of
1 1 we treated LNCaP and T-47D cells with a 10, 5, or 2.5 CpM dose. (Note: T-47D cells
also express the AR). As shown in Figure 8.11, DNA adduct formation is dose
dependent with roughly a 4:2:1 ratio of adducts at the three dose levels. T-47D cells
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acquired 13,500 DNA adducts after a 4 hour exposure time to 10 gtM 11 P. In LNCaP
cells however, 1 [i only formed 5,400 DNA adducts at the same dose. In fact, at all dose
levels T-47D cells acquired greater than 2-fold more DNA adducts than did LNCaP cells.
Interestingly, work by John Marquis of the Essigmann Laboratory has shown that the two
cell lines are essentially equi-sensitive to exposures of 113 -- a 7.5 to 10 [tM dose of 113
in either cell line is enough to kill essentially 100% of all the cells on a culture dish.
The rate of DNA adduction over time was then assessed in LNCaP cells treated
with a 10 ptM dose of 11 . 11 adducted DNA in these cells in a linear manner for 24
hours at a rate of 1500 adducts/hour (R2 = 0.98). These results, shown in Figure 8.12, are
consistent with those displayed in Figure 8.11, as a 10 [tM dose of 11 p produces 6,000
and 5,400 DNA adducts, respectively, after a 4 hour exposure in both experiments.
In order to monitor the repair of DNA adducts over time, LNCaP cells were
exposed to a sub-lethal dose of 11 P (2.5 jtM) for a brief 2 hour period. The compound
was then removed and the cells were washed several times to remove any drug not
already incorporated within the cells. As seen in Figure 8.13, the rate of DNA adduction
was greater than the rate of repair for the first 9 hours as evident in the increasing number
of DNA adducts to this point (550 adducts/hour). However, subsequent to the 9 hour
time point, DNA repair overwhelmed the rate of DNA adduction and removal of adducts
was seen at a rate of 260 adducts/hour.
Finally, the number of DNA adducts formed in vivo was addressed. Three
LNCaP xenograft mice were administered a 50 mg/kg dose of 11 p. Based on the results
described for the bio-distribution experiment described in the previous chapter, the liver
was harvested due to the high concentrations of compound that accumulated in the liver
at all time points in addition to tumor tissue. The 4 hour time point was chosen since the
bio-distribution results show peak accumulation in the liver and most other organs 4
hours after dosing. Not surprisingly, given the route of administration and the bio-
distribution results, the liver had significantly higher accumulation of 11 p than did the
tumor tissue in all three mice. In fact, the liver accumulated almost 10-fold more adducts
than tumor tissue, an average of 12,500 adducts in liver tissue as compared to only 1,600
in tumor tissue (Fig 8.14). These results may give credence to the repair shielding and
transcription factor hijacking models as 11 inhibited the growth of the LNCaP tumors
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while remaining essentially non-toxic to the mouse. With such a high level of DNA
adducts in the liver, it is rather surprising that more toxicity was not evident. The rate of
repair of these liver adducts may have been greater than in the tumor tissue.
Alternatively, a heretofore unidentified biochemical feature of the tumor cells makes
these cells hyper-sensitive to 11 3.
Discussion
There is accumulating evidence that antihormones, chemotherapeutics, and other
cancer therapies, such as radiation, induce apoptosis in their tumor targets. Disruption of
the apoptotic cell death pathway may therefore lead to drug resistance (El Etreby et al.
1998; El Etreby et al. 2000; McConkey, Greene, and Pettaway 1996). Suppression of
apoptosis may also contribute to tumor progression and metastasis. The possibility that
the disruption of the apoptotic pathway may contribute to androgen-independent
progression and tumor metastasis has been suggested in a recent study using
nonmetastatic and metastatic variants of the LNCaP cell line (McConkey, Greene, and
Pettaway 1996). The emergence of androgen-independent clones of cells that do not
respond to traditional androgen ablation therapy may involve the acquisition of intrinsic
apoptosis resistance (Gingrich et al. 1997; Isaacs and Coffey 1981; Kyprianou 1994;
McConkey, Greene, and Pettaway 1996). A single compound that can induce cell death
by several different mechanisms simultaneously may provide a novel therapeutic
approach to overcome intrinsic apoptosis resistance in androgen-independent cells.
Furthermore, a molecule of this type may also be more effective against primary prostate
cancer than current therapies. Towards this end we have designed a single molecule
capable of covalently modifying DNA and simultaneously attracting tumor specific
proteins to the site of the lesion. A protein-DNA adduct complex could inhibit repair
enzymes from accessing the lesion and, if this protein is a transcription factor as is the
case with the AR, an association with the DNA adduct could disrupt necessary signaling
events. These mechanisms would likely be lethal to a cancerous cell.
In the previous chapters I have reported on the design and features of our lead
compound, 11 j3, that could potentially inhibit tumor growth by the repair shielding and
transcription factor hijacking mechanisms. Several experiments were described that
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illustrate the potential of 11 P to be an effective anticancer agent - it has a high affinity for
the AR, displays differential toxicity in favor of AR-expressing prostate cancers,
favorable pharmacokinetics, and good overall bio-distribution.
Here I assessed the potential of 11 3P as an anticancer chemotherapeutic using
xenograft mouse models. The results illustrated that a 30 mg/kg dose of 11 3
administered IP in a CR-EL based vehicle inhibits the growth of LNCaP xenograft
tumors by an average of 90 % as compared to the vehicle only group after a 45 day
therapy regimen. The toxicity to the mice was relatively modest with a 10% loss in body
weight. In a second experiment the therapeutic benefit of 11 3 was compared directly to
chlorambucil. If one were to look only at the growth inhibition of the two compounds,
chlorambucil would be obviously superior. However, chlorambucil also caused a
reduction in body weight by as much as 30% and also was responsible for the death of all
mice in this treated group. The inhibition of growth seen with the LNCaP xenografts was
in part a result of the toxicity of chlorambucil to the mouse - as the mouse lost weight,
sufficient nourishment was not available for the tumor to grow and therefore the tumor
was not able to grow as rapidly. These results indicate that at equi-mole doses,
chlorambucil is significantly more toxic than 11 p.
Increased therapeutic benefit of chlorambucil as compared to 1 1 may also be
attributed to its aqueous solubility. In Chapter 6, I reported the log P of chlorambucil
(1.44 by HPLC but -0.66 in other literature reports) (Greig et al. 1990) and 11P (5.05).
Even though 1 1P would likely be ionized under physiological conditions, the log P
clearly illustrates that chlorambucil is much more water soluble than 1 13. Therefore, one
of the possible reasons why chlorambucil was more effective in reducing the growth of
the LNCaP xenografts was increased distribution to the tumor as a result of its increased
aqueous solubility.
The results from cell culture work indicated that 11 P was cytotoxic to cell lines in
addition to the AR(+) LNCaP cells. HeLa cells are a cervical cancer derived cell line that
does not express the AR but was found to be sensitive to exposure to 11 p. HeLa cells
grow much more rapidly than LNCaP cells, and we therefore tested this cell line as a
more aggressive cancer in a xenograft mouse model. Mice were treated with a dose of 30
mg/kg and injected 5 days per week for 3 cycles. The rapidly growing HeLa cells formed
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palpable xenograft tumors 5-7 days after inoculation of 3 x 106 cells (LNCaP required 1-2
months before tumors were evident). The growth of the HeLa xenograft tumors were
inhibited by 80% and the toxicity was again limited to only 10% loss in body weight.
These results illustrate the effectiveness of 11 p as an anticancer agent against a more
rapidly growing cell line that does not contain the AR.
DLD-1 cells replicate even more quickly than the HeLa cells, and palpable tumors
grew in the hind flank of mice after only 4-5 days after an inoculation of 3 x 106 cells.
Perhaps as a result of the intensity in proliferation of this cell line, 11 3 did not display a
therapeutic benefit to the xenografts. Although this result was somewhat discouraging,
we reasoned there could be many possibilities as to why 11 3 was ineffective against this
cell line: DLD-1 cells do not express the AR, the cells grow extremely quickly, or the
therapeutic regimen of one injection per day may not have been sufficient as a result of
poor distribution or speed in which the cells divide. In order to address the issue of
distribution to the tumor, we inoculated the DLD-1 cells into the peritoneal cavity of
mice and began a therapeutic course after only 3 days. As shown in Fig 8. 10, 1 13 did
indeed display a therapeutic benefit when compared to the vehicle group.
The results with the HeLa and DLD-1 xenograft experiments indicate that there
may be cytotoxic properties unrelated to repair shielding and transcription factor
hijacking. These properties (discussed in Chapter 6), possibly unrelated to the attraction
of the AR to the sites of DNA damage, may prove 1 13 to have wider applicability in
treating cancers of various origins. We are only now beginning to investigate these
possible additional mechanisms and aspects of 11 3 that may make it a chemotherapeutic
with broader applicability.
The mechanism(s) by which 11 p has proven to be cytotoxic to malignant cells
expressed as xenografts is still not fully understood. However, one aspect of 11 3 that is
clear is its minimal toxicological side effect profile. Overall, 1113 is well tolerated by
mice injected with a 30 mg/kg therapeutic dose. Weight loss was limited to less than 10
% in all mice treated with 6.5 cycles of 11 3. The dose limiting toxicity for tumor
ablation therapy seems to be leukopenia as the white blood cell level dropped from 5-7 (x
mm3) to 1 (x mm3). This fact is not surprising as many anticancer agents, including
chlorambucil, induce myelosuppression (Inoue et al. 1987). The dose limiting toxicity of
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chlorambucil is, in fact, neutropenia, or a decrease in neutrophils (Blumenreich et al.
1988). As in the acute dose of 1 113, the ratio of neutrophils to lymphocytes is altered such
that the percent of neutrophils increases as compared to the percentage of lymphocytes.
Even though these values are still within the normal range provided by Taconic, it is
noted that in both the acute and chronic administrations of 11 p the same result is
observed. The elevation of neutrophils and suppression of lymphocytes could be the
result of an active infection or sensitivity to the vehicle.
Alternatively, the elevation of neutrophils and suppression of lymphocytes may
indicate that 11 fp is interacting with the glucocorticoid receptor (GR). The GR is a
member of the same class of nuclear hormone receptors as the ER and AR.
Corticosteroids, the natural ligands for the GR, have profound effects on lymphocytes
and neutrophils. Corticosteroids actually induce the apoptosis of lymphocytes, (Di et al.
2000; Negoescu et al. 1998) whereas they inhibit the death of neutrophils in vitro (Cox
and Austin 1997; Liles et al. 1996). The mechanisms by which lymphocyte and
neutrophil apoptotic responses to glucocorticoids differ are unknown. However,
glucocorticoid action is mediated through the GR and therefore these apoptotic
differences may arise from downstream targets of the GR (O'Malley 1971; Strickland et
al. 2001; Wenzel et al. 1997). An off-target interaction of 11 with the GR may mediate
the responses seen in the alteration in the ratio of neutrophils to lymphocytes. In fact,
Nicole Dinaut, a former post-doctoral associate in the Essigmann Laboratory, has shown
the RBA of 11 P for the GR to be 2 as compared to dexamethasone. Although this is not a
strong interaction, it may be sufficient in decreasing the lymphocyte count and increasing
the neutrophil count as we have seen here.
The blood chemistry profile after chronic administration of 11 p is relatively mild.
CK is elevated in all tumor bearing mice and therefore the increased levels are unlikely
related to the compound or the vehicle. GGT is involved in the transport of amino acids
and peptides into cells as well as in glutathione metabolism. As a liver enzyme it is
extremely sensitive to ethanol; however, GGT levels typically increase in alcoholics or in
those with liver disease. In mice treated with i1 , GGT decreased. Hepatotoxicity can
be ruled out as the other enzymes typically elevated were found to be normal (AST, ALT,
amylase, and lipase). The decreased level of GGT could be indicative of hypothyroidism,
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hypothalamic function, or low level of magnesium. Further tests would be required to
determine why a low level of GGT was observed.
The minimal toxicity that was observed is likely the result of DNA adduction in
non-target tissues (Bank 1992; Fox and Scott 1980; van Zeeland 1996). Nitrogen
mustards elicit their cytotoxic and anticancer effects through the covalent modification of
DNA. The lone pair electrons of the unprotonated nitrogen in agents such as
chlorambucil and melphalan attack one of the 2-chloroethyl arms in an intramolecular,
rate-determining step to form a positively charged aziridinium ion. The attack of the
aziridinium ion by an external nucleophile, such as guanine or adenine, results in the
formation of a DNA adduct (Chatterji, Yeager, and Gallelli 1982; Kundu, Schullek, and
Wilson 1994; Owen and Stewart 1979). A small portion of these monoadducts go on to
form crosslinks as a result of a second alkylation reaction with the other arm of the
nitrogen mustard. The formation of crosslinks between the 2 strands of DNA, interstrand
crosslinking, is considered to be a critical event, and there is clear evidence that their
formation and subsequent persistence correlates with in vitro cytotoxicity (O'Connor and
Kohn 1990; Sunters et al. 1992). However, the abundance of crosslinks is low because of
the slower rate of alkylation for the second arm of a nitrogen mustard (Gould, Nixon, and
Tilby 2004; Ross, Ewig, and Kohn 1978) and a comparatively quick rate of repair of a
monoadduct. Furthermore, the high water concentration in a cell (55 M) results in a
significant number of monoadducts reacting with water rather than a second DNA base.
The cytotoxicity of nitrogen mustards is thus related to the number of adducts formed. If
a sufficient number of adducts form, the repair capacity of a cell would be saturated and
thus result in lethal effects in a tumor. A potential advantage of 11 p is its ability to attract
the AR. An association between the AR and an 11 P3 monoadduct could provide more
time for the formation of a cross-link and thus render an 113 monoadduct more toxic than
a monoadduct from other nitrogen mustards.
Although we were unable to measure the formation of crosslinks, we were able to
monitor the formation of all DNA adducts after cells or mouse tissues were exposed to
11 p using the highly sensitive technique of AMS. As a proof of concept, the AR(+)
LNCaP and T-47D cell lines were exposed to increasing doses of 1113. As expected, a
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higher dose of 1 3 resulted in a greater number of DNA adducts and in both cell lines the
number of adducts formed was roughly proportional to the dose.
The results in Chapter 6 indicated that a 10 M dose of 11 P was lethal to 98% of
LNCaP cells in a culture dish after a brief 2 hour exposure. Of significance is the number
of DNA adducts that had formed in these cells after a 10 [pM exposure. Therefore, we
treated cells for various lengths of time and monitored the formation of DNA adducts.
DNA adducts accumulated in LNCaP cells at a rate of 1500 adducts/hour. It is somewhat
surprising, however, that 24 hours later 1113 was still forming DNA adducts as efficiently
as it was at earlier time points. One would think that such long durations in aqueous
media would render the compound inactive as a result of the deactivation of the
compound through hydrolysis of the bis-chloroethyl arms of the nitrogen mustard, a
decrease in effective concentration as a result of this deactivation, and also as a result of
the removal of DNA adducts by repair enzymes. Chlorambucil was shown to have a
half-life of only 18 minutes in a non-nucleophilic, chloride-free buffer at 37°C (Haapala
et al. 2001) and 2.4 hours in blood samples where the chloride concentration approaches
100 mM (Newell, Shepherd, and Harrap 1981). Therefore, it is surprising that 11 p was
capable of forming DNA adducts at such a consistent rate for such a long period of time.
Perhaps its lipophilicity results in initial absorption into lipid compartments, in which it is
chemically stable, and from which it is slowly delivered to the aqueous portions of the
cell - including those portions containing DNA.
The rate of repair of 1 1 DNA adducts was also investigated by treating cells for
a brief 2 hour incubation period and then replacing the drug containing media with drug
free media. DNA adducts continued to form for 9 hours after the drug was removed.
This indicates that a substantial fraction of 11 [3 entered the cells and likely was not
excreted (or at least not very quickly). Evidence of DNA repair was seen at time points
later than 9 hours, as the number of DNA adducts eventually diminished. Interestingly,
the number of adducts formed at 24 hours was still greater than that at the earliest time
points. The longevity of the DNA adducts may implicate the repair shielding hypothesis.
The dose of 11 used was sub-lethal, so any disruption in cellular signaling as a result of
transcription factor hijacking was minimal as no toxicity was evident.
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The results from the 11 p DNA adduct repair experiment may also provide insight
as to why the compound is an effective agent in the treatment of LNCaP xenografts. The
level of DNA adducts formed 4 hours after the administration of a 50 mg/kg dose of 1113
was approximately 1600 adducts per cell. Assuming that the LNCaP xenograft tumors
behave as the LNCaP cells in the repair experiment, it is likely that the number of DNA
adducts at 24 hours is close to the number of adducts at 4 hours. With the 5-day
treatment cycle that we used in the therapy of the xenografts, approximately 8,000 DNA
adducts would be present in each LNCaP tumor cell at the end of each cycle. The level
of adducts may increase considerably with each subsequent cycle such that after 4 or 5
cycles each tumor cell may contain 20,000-50,000 adducts, a level likely to be toxic to a
cell.
It is difficult to compare the DNA adduct levels formed after 113 treatments to
mice with other nitrogen mustards like chlorambucil or melphalan, as there is very little
literature that quantifies DNA adduct levels. Many reports used a technique known as
alkaline elution that can only determine relative abundance of DNA adducts (Gould,
Nixon, and Tilby 2004; Rink et al. 1996; Ross, Ewig, and Kohn 1978; Sunters et al.
1992). However, one report indicates that a patient with plasma cell leukemia treated
with high doses of melphalan had 160,000 melphalan-DNA adducts (Tilby et al. 1993).
This is 100-fold higher than what was observed in LNCaP xenografts treated with 11 ,
also at a therapeutically beneficial level. Although it is somewhat difficult to directly
compare two different compounds (with different pharmacokinetics and aqueous
solubility) in two different cell types, such a drastic difference in DNA adduct burden
may imply mechanisms other than saturation of the DNA repair machinery may play a
role in the cytotoxicity of 11 P3. Until such a time as a direct comparison of DNA adduct
levels achieved by doses of melphalan (or chlorambucil) and 11 p in the same cell type
can be made, speculation on additional mechanisms, related or unrelated to DNA
alkylation, is futile at best. Nonetheless, it remains worthwhile to explore the
mechanisms by which 11 P3 was designed to achieve toxicity - repair shielding and
transcription factor hijacking.
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Conclusion
Currently, the most effective therapy against advanced prostate cancer is the
combination of docetaxel with prednisone. This combination results in an improvement
in median survival time of a paltry 3 months (Walsh 2005). We believe a way to increase
the therapeutic effectiveness of an anticancer agent is by designing a single molecule that
can act by several distinct mechanisms simultaneously. We have designed a molecule,
1 p that is not only capable of forming DNA adducts, but can also attract tumor specific
proteins causing the DNA adducts to be shielded from repair enzymes. Furthermore, if
the protein attracted to the site of the DNA damage is a transcription factor, as is the case
for the AR which is expressed at high levels in prostate cancers (Hobisch et al. 1995;
Marcelli and Cunningham 1999), a protein-DNA adduct complex would likely disrupt
necessary signaling events.
In the previous chapters, I have described the results of several experiments
indicating that our lead compound, 1 1B, has many favorable properties of a
chemotherapeutic agent. Here I described the results from several tumor inhibition
studies using 3 different cell lines. 11 p inhibited the growth of AR(+) LNCaP cells
implanted as xenografts most efficiently (90% as compared to the growth of xenografts in
control mice treated with vehicle only) with very little toxic side-effects. 11 was also
found to be effective against two other cell lines, HeLa and DLD-1, implanted as a
xenograft or into the peritoneal cavity, respectively. Neither of these cell lines expresses
the AR and therefore the results with these two cell lines may indicate mechanisms
unrelated to repair shielding and transcription factor hijacking. We are currently
investigating these other possible mechanisms.
I also described the results from several experiments in which we monitored the
number of DNA adducts that had formed after various doses and times of incubation.
These results indicated that the AMS technology is a very sensitive means of monitoring
DNA adduct formation. We will continue to use AMS to gain further insight into the
dynamics of adduct formation and repair in cells treated with 11 P. The results here
suggest that the adducts formed by 11 P persist for long periods of time, and perhaps the
accumulation of these adducts after several days of therapy results in toxicity to the
LNCaP xenografts. The relatively low level of adducts formed in the LNCaP xenografts,
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as compared to what has been reported for a patient with plasma cell leukemia treated
with high doses of melphalan (Tilby et al. 1993), may suggest that 11 P is indeed
disrupting necessary signaling events in the xenograft tumor. This cellular signaling
disruption may be the result of the repair shielding and transcription factor hijacking
mechanisms we originally proposed.
Future Directions
In this chapter, I have discussed the results of several xenograft models - LNCaP,
HeLa and DLD- 1. Of the three, only one is derived from malignant prostatic tissue. In
chapter 2, I discussed the results of a differential toxicity experiment in which LNCaP
cells were more sensitive to 11 p than PC-3 and DU-145 cells, both of which are AR(-)
prostatic malignancies. It would be of considerable interest to inject these cell lines into
mice and compare the efficacy of 11 p against these AR(-) xenografts. If 11 P is indeed
working by our proposed mechanisms, then it should be less effective against the AR(-)
PC-3 and DU-145 cells. Furthermore, quantifying the formation of DNA adducts in
these cells, both in culture and in xenografts, could provide additional insight into the role
of the AR in cellular toxicity. An equal number of DNA adducts in the three cell lines
would imply that the AR may have a role in any differential toxicity observed between
the AR(+) and AR(-) cells. Ideally, isogenic clones that express or are deficient in the
AR would be used; however, I am unaware of any such clones. For the reasons discussed
in the "future work" section of Chapter 4, incorporating the AR into a deficient cell line
may result in altered proliferation of the clone and therefore such an approach is
unwarranted (Hobisch et al. 1995; Jiang and Jordan 1992; Kushner et al. 1990; Maminta,
Molteni, and Rosen 1991; Touitou, Mathieu, and Rochefort 1990; Watts, Parker, and
King 1989).
The CWR22 and CWR22R cell lines may also be very useful in isolating the role
of the AR in the cytotoxic properties of 11. CWR22 cells, like LNCaPs, are a prostate
cancer cell line that expresses the AR and is hormone dependent (Kochera et al. 1999).
The CWR22R cell line was derived from a xenograft that was serially propagated in mice
after castration-induced regression and relapse of the CWR22 xenograft. These cell lines
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represent models of early stage hormone-dependent and late stage hormone-independent
prostate cancer. Both the CWR22 and CWR22R xenografts have responses to antitumor
agents that are representative of patient tumors (Chen et al. 1998), making them excellent
models with which we can further evaluate 11 3.
Additionally, more work with the T47-D cells could also be informative. T47-D,
like LNCaP cells, express the AR. Comparing the rates of DNA adduction and repair of
the cell lines to that of the AR(-) PC-3 and DU-145 cell lines would likely provide further
insight into the repair shielding and transcription factor hijacking hypotheses. Since
these cell lines were derived from actual cancer patients, each cell line has different
mutational spectra in addition to their differences in AR expression. By using several
cell lines, it may be easier to parse out differences related to AR expression rather than to
other mutations that could cause one cell line to be more sensitive than the others for
reasons other than AR expression.
For some time we were limited in our experiments by not having a control
compound by which we could compare DNA adduct levels. We have used chlorambucil
as a control compound in many of our in vitro studies; however, 14C-chlorambucil is
prohibitively expensive. Recently, however, we found a supplier of 14C-melphalan and
we have begun using it in order to assess a toxicological effect with DNA adduct burden.
Our results thus far have been in MCF-7 and MDA-MB231 cells and the comparison has
been with E2-7a (described in Chapter 5). We will begin treating prostate cancer cells
with '4C-melphalan in order to assess toxicity in relation to the number of DNA adducts
that form. If melphalan forms a greater number of DNA adducts at the LD50 than does
1i1 p, it would suggest that mechanisms other than DNA adduction were involved in the
toxicity of 11 3P. Furthermore, if the rates of repair of the two molecules differed
significantly, it may imply the repair shielding and transcription factor hijacking
hypotheses are valid. Other mechanisms unrelated to DNA adduction could not be ruled
out, however. Furthermore, these experiments could also be carried out in xenograft
tissue to compare the number of DNA adducts formed after therapeutic doses of each
compound. Again, these experiments could provide insight into mechanism.
We have received a grant from the National Cancer Institute for the continued
development in transitioning 11 P from the benches at MIT to clinical medical centers
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throughout the country. They are in the process of testing the effects of 11 P in a 60 cell
line screen. These 60 cell lines represent a diverse array of cancers ranging from solid
tumors such as prostate, breast and lung, to hematological cancers. The results from this
screen will indicate certain cell lines that are sensitive to 11 p while also providing us with
cell lines that are resistant (should they exist). Sensitive cell lines will be analyzed for
mechanisms related to or unrelated to AR expression. Using the AMS technology we
would like to assess the contribution of DNA adduction to the cytotoxic properties of
The experiments proposed above will be combined with biochemical studies that
will ascertain the cellular responses after treatment with 11 p. Not only will we be able to
monitor the consequences of DNA adduction by cellular toxicity, but we will also
monitor changes in protein expression. For example, others in the Essigmann Laboratory
have shown that treatment of LNCaP cells with 11 results in increased expression of the
cyclin-dependent kinase (CDK) inhibitors, p27 and p21. Skp2 is reported to be a key
factor in regulating CDK expression levels in many malignancies (Gstaiger et al. 2001)
including prostate cancer (Lu, Schulz, and Wolf 2002) and helps tag p27 for proteolytic
degradation. The induction of p27 led us to investigate the fate of Skp2. 11P rapidly
decreases the expression of Skp2. Therefore, the increased expression of p27 is likely a
result of the decreased expression of Skp2. Although we have only recently begun to
investigate the biochemical changes associated with 11 P treatment of cells, we are
enthusiastic about having a means of directly comparing DNA adduct burden with
biochemical and physiological changes.
Finally, the results obtained with both the acute (Chapter 7) and chronic toxicity
experiments reveal an interesting phenomenon with respect to the ratio of neutrophils to
lymphocytes after a dose of 11 P. In both toxicity experiments, the percent of white blood
cells that were neutrophils increased as compared to the percent that were lymphocytes.
One possible explanation involves the glucocorticoid receptor. Evidence has implicated
corticosteroids, the natural ligands for the GR, actually induce the apoptosis of
lymphocytes, (Di et al. 2000; Negoescu et al. 1998) whereas they inhibit the death of
neutrophils in vitro (Cox and Austin 1997; Liles et al. 1996). Nicole Dinaut has shown
that the GR has a low, but finite, affinity for 11 p (RBA -2, as compared to
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dexamethasone). This may imply that 11 f3 is acting as a corticosteroid and inducing
apoptosis in lymphocyte cells and stimulating neutrophil proliferation. A more direct
way to investigate the effect of 11 3 on lymphocytes and neutrophils would be to expose
both cell types to 11 p in culture. Since 1 3 is a reactive nitrogen mustard and may
actually be toxic to both cell lines for its DNA damaging properties, a "defanged" version
could be made by replacing the chloride atoms with hydroxyl or methoxyl substituents.
These unreactive molecules would not be able to damage DNA and therefore may be
capable of stimulating neutrophil proliferation through interactions with the GR while
leaving genomic DNA unscathed.
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The Hematology Profile of Mice Treated
Chronically with 1 11 Indicates the
Compound is Well Tolerated
IP IP Vehicle Tumor Ave Norm. Ave Taconic
Test N = 3 N = 3 N = 4 N = 4 Nude
WBC (xmm 3)
RBC (x 106 mm 3)
Hgb (g/dL)
HCT (%)
Neutrophils (%)
Lymphs (%)
Monos (%)
Eos (%)
Platelets (1 03/pL)
MCV (fL)
MCH (pg)
MCHC (g/dL)
1 ± 0.3
6.9 ± 2.3
10.8 4
40.6 14
73± 14
24+ 15
2+0
651 340
58.4 + 3.3
15.4 0.6
3.9 + 0.9
7.5 ± 1.3
10.7 ± 1.3
38.7 ± 5.5
64± 21
30 + 20
1.5 ± 0
1111 ± 108
51.8 ± 2.1
14.4 + 1
26.5 2 27.7 0.9
6.9 ± 1.6
8.3 + 2.1
9.3 ± 2.4
45.1 10.3
41.5 + 11.8
58 ±+ 12.1
934 + 542
54.4 3.6
11.2 ± 2
20.6 ± 2.5
5.4 + 0.4
9.3 ± 0.8
11.3 ± 0.3
50.6 ± 3.3
42 ± 8.3
57.8 ± 7.8
1101
54.3
12.2
± 372
± 1.3
± 0.9
22.4 1.1
4.3-13.5
6.9-8.52
7.5-15.2
39.4-43.5
7.0-39
56-92
0-7
0-4
790-1014
51.1-53.4
17.6-19.1
34.3-36.1
Table 8.1 Hematology report for mice injected with 1113.
Values in bold represent abnormally elevated or
suppressed levels. The most notable toxicity is
leukopenia. Additionally the ratio of neutrophils to
lymphocytes is altered in both the treated and vehicle
group.
(Note: Since the test groups contained relatively few mice, the abnormal levels are
deviations from the normal range and do not necessarily reflect statistical
significance.)
The Blood Chemistry Profile of Mice
Treated Chronically with 11 3 Indicates
the Compound is Well Tolerated
IP IP Vehicle Tumor Ave Norm. Ave Taconic
Test N= 3 N = 3 N = 4 N= 4 Nude
Alk. Phosphatase (IU/L)
ALT (SGPT) (IU/L)
AST (SGOT) (IU/L)
CK (IU/L)
GGT (IU/L)
Albumin (g/dL)
Total Protein (g/dL)
Globulin (g/dL)
Total Bilirubin (mg/dL)
Direct Bilirubin (mg/dL)
BUN (mg/dL)
Creatinine (mg/dL)
Cholesterol (mg/dL)
Glucose (mg/dL)
Calcium (mg/dL)
Phosphorous (mg/dL)
Bicarbonate (m Eq/L)
Chloride (mEq/L)
Potassium (mEq/L)
Sodium (mEq/L)
A/G Ratio
B/C Ratio
Indirect Bilirubin (mg/dL)
Na/K Ratio
44 + 11
28 + 13
138 + 56
426 ± 353
0O0
2.8 + 0.2
5.1 0.3
2.3 + 0.1
0.1 + 0.1
0.1 +0
25.3 + 1.5
0.2 + 0.1
104 + 21
240 + 38
9.7 + 0.3
10.5 + 0.8
27.7 + 2.1
111 + 1
6.6 + 0.1
158 + 2
1.2 ± 0.1
0 0
24 + 1
26.7 + 1.2
60 + 5
48 ± 10
119 + 33
367 + 126
1+1
2.5 ± 0.9
4.7 ±+ 0.9
2.2 + 0.2
0.2 ± 0.1
0.1 + 0.1
30.3 + 11.9
0.1 + 0.1
171 ± 131
239 + 40
9.1 + 0.7
9+ 1.2
27.3 + 2.5
111 + 1
6.1 +0.6
156 ±+ 1
1.2 + 0.4
0+0
25.7 +2.3
24.7 + 2.3
Table 8.2 Blood Chemistry report for mice injected with
113. Values in bold represent abnormally elevated or
suppressed levels. The toxicity of 1113 is rather mild.
(Note: Since the test groups contained relatively few mice, the abnormal levels are
deviations from the normal range and do not necessarily reflect statistical
significance.)
65 ±+ 8
26 ± 7
64
184
2
2.9
5.4
2.6
0.1
± 22
+ 146
±_0
± 0.1
+ 0.3
+ 0.2
± 0.1
58 ± 18
36 + 10
112 + 46
722 + 411
1.8 + 0.5
2.8 + 0.7
5 ± 0.6
2.3 + 0.1
0.2 ± 0
0.1 + 0.1
20 ± 34.7
0.3 ± 0.1
215 + 187
238 + 31
10.5 ± 0.4
6.4 + 0.9
28 + 2.4
108 + 2
6.7 + 1
152 + 3
1.3 + 0.3
0 0
23.8 + 4.3
21.3 + 0.5
96-117
61-119
3.4-4.1
4.8-5.6
1.1-1.6
0.3-0.8
30-37
0.5-0.7
116-155
173-288
10.0-12.0
12.3-16.1
118-124
13.8-16.7
157-163
0 ± 0.1
18.8 2.2
0.3 + 0.1
133 ±+ 11
253 + 13
10.5 + 0.5
9.5 1.8
28.3 2.2
108 + 1
7 + 0.7
153 ± 2
1.1 + 0.1
0 0
22.3 2.1
24 ±+ 4.2
1 1 ip Inhibits the Growth of LNCaP
Xenografts.
10 20 30 40
Days of Therapy
Fig 8.1 1 1 therapy of LNCaP xenografts in mice.
Groups of 5 mice were injected with 30 mg/kg of 1113 ()
or vehicle only (). Error bars are the standard deviation
of the mean and a paired t-test provided a P< 0.0001.
The gray bars indicate days of treatment.
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Fig 8.2 11 3 therapy of LNCaP xenografts in mice.
Groups of 5 mice were injected with 30 mg/kg of 11 ()
or vehicle only (). After 3 cycles of therapy the average
mouse in the 11 3 treated group lost 10% of its body
weight.
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Fig 8.4 Therapy of LNCaP xenografts in mice. (
of 5 mice were injected with 30 mg/kg of 1 1 (.),
3roups
12
mg/kg of chlorambucil (A), or vehicle only (). Error bars
are not shown for clarity sake but a paired t-test provided
a P< 0.0001 for both 11 18 and chlorambucil when
compared to the vehicle group. The gray bars indicate
days of treatment.
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Chlorambucil is More Toxic Than 1113
as Assessed
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Therapy of LNCaP xenografts in mice. Groups
mice were injected with 30 mg/kg of 1 1 (e), 12
mg/kg of chlorambucil (A), or vehicle only (o). After 7
cycles of treatment mice dosed with 1 1 lost only 6% of
their body weight. However mice treated with
chlorambucil (at an equi-mole dose) lost up to 30% of
their body weight.
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The Toxicity of Chlorambucil is too
Great to Overcome as All Mice
Eventually Die
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Fig 8.6 Therapy of LNCaP xenografts in mice. Groups
of 5 mice were injected with 30 mg/kg of 11 (e), 12
mg/kg of chlorambucil (), or vehicle only (). All of the
mice treated with chlorambucil were dead 6 days after
the termination of the 7 cycle tumor therapy study.
However, all of the mice treated with 1 1 survived the
therapy.
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11 is also Efficacious Against HeLa
Xenograft Tumors
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Fig 8.7 1113 therapy of HeLa xenografts in mice. Groups
of 5 mice were injected with 30 mg/kg of 1113 () or
vehicle only (O). Error bars are the standard deviation of
the mean and a paired t-test provided a P< 0.0001. The
gray bars indicate days of treatment.
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11 3 is Well Tolerated by Mice after 3
Treatment Cycles as
Weight Loss
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Fig 8.8 1 1 therapy of HeLa xenografts in mice. Groups
of 5 mice were injected with 30 mg/kg of 1 1 (*) or
vehicle only (O). After 3 cycles of therapy the average
mouse in the 11 treated group lost 10% of its body
weight.
Assessed by
a)
Cl0
O
.a
C,
cLc-
C,
15 20
z .x .Ez>bi- N ..... .Ap,,,O :. si8 ......... @iea<aFl | > .. 4v'i...k7,^...z.<n>..o--.7>: vg6.p..vE.'>..,3.7S.g wiirAH
J
tl~,iA- .C1 ge^ 11 I
Mice Treated with 1113 Have Smaller HeLa
Xenografts than Mice Treated with Vehicle
A
B
Fig 8.9 Pictures of HeLa xenograft bearing
Nude mice. A. Mouse treated with 3 cycles
11 . B. Mouse treated with vehicle alone.
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11 3 is Efficacious Against DLD-1 Cells
Implanted Intraperitoneally
A
3
Fig 8.10 1 13 therapy of DLD-1 tumors.
treated with 1 13. B. A mouse treated v
A. A mouse
vith vehicle only.
Tumors are white and nodular and are high-lighted by
encircling.
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11 p Adducts DNA in T-47D and LNCaP
Cells in a Dose-Dependent Manner
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Fig 8.11 Quantification of DNA adduct formation. T-47D
(D) and LNCaP ( ) cells were exposed to 3
concentrations of 11 for 4 hours. The number of
adducts formed is linearly dependent on concentration
for both cell lines. Error bars are standard deviation of
the mean.
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Kinetics of 11 3 DNA Adduction
10 20 30
Hours of Treatment
Fig 8.12 Rate of DNA adduct formation in LNCaP cells.
LNCaP cells were exposed to 10 pM 1113 for 3, 6, 9, 15,
and 24 hours. The rate of adduction was 1500
adducts/hour and the R2 = 0.98.
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Kinetics of Repair of 1113 DNA Adducts
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Fig 8.13 Monitoring DNA repair in LNCaP cells. LNCaP
cells were treated with a sub-lethal dose of 2.5 pM of
11 for 0, 1, 3, 6, 9, 15, and 24 hours after the removal
of the drug. Interestingly, 1 1 3 continued to form DNA
adducts even after it was removed from the media. DNA
repair seems to overwhelm adduct formation at 9 hours,
although a significant portion of the adducts remain 24
hours after the removal of the drug.
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Fig 8.14 Quantitation of DNA adducts in tumor ( ) and
liver (C) tissues. Three Mice were each injected with a
50 mg/kg dose of 11 13 and sacrificed 4 hours later. Liver
tissue forms 5-10 times more adducts than tumor tissue.
Error bars are standard deviation of the mean from
replicate injections on the AMS.
0
(),
z01D~
1D

Biography
The author was born on December 16, 1975 to William and Joyce Hillier in New
Bedford, Massachusetts. He was raised in the neighboring town of Acushnet with his
brother, Adam. After graduating from New Bedford High School, he attended the
College of the Holy Cross in Worcester, Massachusetts where he studied Chemistry. The
author conducted independent research under the advisement of Professor Paul McMaster
on the "Synthesis of novel derivatives of the antiarrythmic agent, apridine- 1". After
graduating in 1997, he worked at Massachusetts General Hospital in the Department of
Radiology Division of Nuclear Medicine in the laboratory of Dr. Alan Fischman and
under the direct supervision of Dr. John Babich. His work focused on the development
of novel diagnostic imaging agents focused on the early detection of Parkinson's disease,
the detection of bacterial infections, and on monitoring cardiac viability. One of the
compounds that he evaluated is currently in clinical trials. In 1997, he pursued a Ph.D. in
Chemistry at Massachusetts Institute of Technology. He joined the laboratory of
Professor John M. Essigmann and wrote his dissertation on "Novel genotoxins that target
estrogen receptor- and androgen receptor- positive cancers: identification of DNA
adducts, pharmacokinetics, and mechanism". During his Ph.D. career he married Kristen
Boudrot, whom he met while working at Massachusetts General Hospital, and they
expanded their family with the birth of their son, Ryan Antonio, on October 1, 2005.
313
Shawn M. Hillier
55Ash St. /Danvers, MA 01923
(617) 253-6207
Email: hillier@mit.edu
EDUCATION
Massachusetts Institute of Technology, Cambridge, MA 1999-2005
Ph.D. in Chemistry, June 2005 Cumulative GPA 4.7 / 5.0
College of the Holy Cross, Worcester, MA 1993-1997
Bachelor of Arts in Chemistry May 1997 Cumulative GPA 3.4 / 4.0
EXPERIENCE
Massachusetts Institute of Technology, Cambridge, MA 1999-2005
Graduate Student, Department of Chemistry
Thesis under John M. Essigmann: "The Rational Design of Genotoxins that Selectively Target Hormone
Receptor-Positive Breast and Prostate Cancers: DNA Adduction, Repair, and Mechanism."
* Quantify the number of DNA adducts formed in vitro and in vivo by accelerator mass spectrometry.
* Monitor repair of DNA adducts using an in vitro whole cell extract system.
* Develop xenograft animal models for tumor ablation therapy.
* Evaluate pharmacokinetic profile after administration of compounds I.P. and I.V.
* Determine the major metabolites of our compounds using human liver microsomes.
* Analyze the toxicity profile by determining the LD50 and monitoring serum chemistries.
* Identify DNA adducts in cell and tissue samples by mass spectrometry.
Massachusetts General Hospital, Boston, MA 1997-present
Consultant, Department of Radiology, Division of Nuclear Medicine 1999-present
Employed part time (3-6 hrs/wk) to diagnose and solve instrumentation problems, interview and train new
laboratory technicians, address interpersonal issues, and assist in daily tasks of research technicians.
Laboratory Supervisor, 1998-1999
Coordinated all research studies (5-10/wk); hired, trained and oversaw 1-2 laboratory technicians; assisted in
submission of grants and manuscripts; developed new protocols; assisted in daily tasks of research technicians.
Laboratory Technician, 1997-1998
* Biological studies including: drug metabolism analysis in human and monkey blood samples, bio-
distributions and pharmacokinetic analysis, toxicity profiles in rats and rabbits.
* Radiochemistry and radiolabeling with frequent handling of 99 mTc, 125I, 11'n, 67 Ga, 11C, 18F.
* Administered: anesthesia, I.V. injections, and I.M. infections.
* Sterile cell culture techniques including the maintenance of cancerous human cell lines (SK-OV, SK-BR).
Massachusetts Institute of Technology, Cambridge, MA 1999-2000
Teaching Assistant, Department of Chemistry, Conducted recitation sections of freshman-level general
chemistry course, graded exams, held office hours.
College of the Holy Cross, Worcester, MA 1996 - 1997
Independent Research, Department of Chemistry, Synthesis of new derivatives of the antiarrythmic agent
aprindine-1.
UMASS Medical Center, Worcester, MA Jan. - May 1997
Academic Internship, Department of Organ Transplantation, Assisted in liver transplant research project
using porcine xenografts; shadowed the renal transplant team during clinic and on rounds; monitored vital
signs (blood pressure, temperature, etc.)
314
ChemDesign Corporation, Fitchburg, MA, summer 1996
Quality Control Laboratory Technician, Accurately analyzed batch chemical samples and troubleshot
instrumentation errors.
College of the Holy Cross, Worcester, MA, 1995-1997
Organic Chemistry Laboratory Teaching Assistant, Aided in supervising chemistry laboratories, graded
lab reports.
INSTRUMENTATION
chromatography (gas, liquid, thin layer), atomic absorption, spectroscopy (UV-VIS, IR, mass,
flourometric, nuclear magnetic), gamma camera, gamma counter, pH meters, electrophoresis.
AWARDS AND PROFESSIONAL MEMBERSHIPS
Aspen Cancer Conference Fellow, Aspen Cancer Conference, Aspen, Colorado, July 20-23, 2003
Edward A Smuckler Award, best abstract, 2003 Pathobiology of Cancer, AACR Workshop in Cancer
Research, Keystone, CO, July 13-20, 2003 Bifunctional Genotoxins that Target Hormone Receptor
Positive Breast and Prostate Cancers: Selectivity, DNA Adduction, and Mechanism.
Best poster award, Toxicology Division, 222nd ACS National Meeting, Chicago, IL, August 26-30, 2001
Synthesis, biochemical properties, and pharmacokinetic profiles of DNA-damaging genotoxins with
selective toxicity towards estrogen receptor-positive breast cancer cells and androgen receptor-positive
prostate cancer cells.
Member, American Association of Cancer Researchers, 2002-2003
Member, American Chemical Society, 2001-2003
Member, International Society for the Study of Xenobiotics, 2003
PUBLICATIONS
Papisov M, Yurkovetskiy A, Hiller A, Yin M, Barzana M, Hillier S, and Fischman AJ. Semi-synthetic
hydrophilic polyals. Under review, J. Biomed. Mater. Res. 2005
Sharma U, Marquis JC, Nicole Dinaut A, Hillier SM, Fedeles B, Rye PT, Essigmann JM, Croy RG. Design,
synthesis, and evaluation of estradiol-linked genotoxicants as anti-cancer agents. Bioorg. Med. Chem. Lett.
2004. Jul 16;14(14):3829-3833.
Mitra K, Marquis JC, Hillier SM, Rye PT, Zayas B, Lee AS, Essigmann JM, Croy RG.
A rationally designed genotoxin that selectively destroys estrogen receptor-positive breast cancer cells.
J Am. Chem. Soc. 2002 Mar 6; 124(9): 1862-3.
Rose D, Zubieta J, Graham W, Hillier S, Babich J. The synthesis and structural characterization of the neutral
.l1In (III) thiolate species In(SCH2CH2) 3N. Inorganic Chemistry Communications May 1998; 1:164-173
SELECTED PRESENTATIONS
Hillier SM, Marquis JC, Mitra KK, Rye PT, Dinaut AN, Sharma U, Rodrigues DC, Liberman RG, Skipper PL,
Wishnok JS, Tannenbaum SR, Essigmann JM, Croy RG. The Rational Design of Genotoxins that Selectively
Destroy Hormone Receptor-Positive Breast and Prostate Cancers. Aspen Cancer Conference, Aspen, Colorado,
July 20-23, 2003
Hillier S, Zayas B, Park H-J, Wishnok J, Wogan G, Essigmann J, Croy RG. Novel genotoxins that target
ER+ breast cancers: identification of DNA adducts, mechanism, and pharmacokinetics. Abstract of Papers,
92nd American Association of Cancer Researchers, New Orleans, Louisiana, March 24-28, 2001
Carter EA, Tompkins RG, Graham W, Barzana M, Hillier S, Babich JW, Fischman AJ. Accumulation of a
Tc-99m Chemotactic Peptide and FDG by Sterile Inflammation in Rats. The Society of Nuclear Medicine
45th Annual Meeting in Toronto, June 7-June 11, 1998
315
